{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1410,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1000,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04125329"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells,one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01221428"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cell will be given to preterm infants with BPD.",
                              "Mesenchymal stem cell will be not given to preterm infants with BPD."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Transplantation of mesenchymal stem cell",
                              "Drug: No transplantation of mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Transplantation of Mesenchymal Stem Cell",
                              "No Transplantation of Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03558334"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The mesenchymal stem cells will be derived from human umbilical cord. After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjects of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg\uff08according to the weight of subject\uff09mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg \uff08according to the weight of subject\uff09mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03765957"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01219465"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.",
                              "The patients who treated with the conventional therapy for urticaria, but not treat with mesenchymal stem cell."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell",
                              "Control patients"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02824393"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury",
                              "Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "mesenchymal cells&platelet lysate"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02118519"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [
                              "IPAAF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells (MSC) into ileal pouch fistula at baseline and possibly again after 3 months if not completely healed."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells (MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04073472"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [
                              "STELLAR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02112500"
                        ]
                  },
                  {
                        "Rank": 10,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intramuscular injection of umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01219452"
                        ]
                  },
                  {
                        "Rank": 11,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cell will be given to participants with moderate and severe bronchopulmonary dysplasia.",
                              "Mesenchymal stem cell will be not given to participants with moderate and severe bronchopulmonary dysplasia."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Transplantation of mesenchymal stem cell",
                              "Drug: No Transplantation of Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Transplantation of Mesenchymal Stem Cell",
                              "No Transplantation of Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03601416"
                        ]
                  },
                  {
                        "Rank": 12,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Drug: cyclophosphamide administration"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell in Haplo-SCT"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03106662"
                        ]
                  },
                  {
                        "Rank": 13,
                        "Acronym": [
                              "UC-MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity",
                              "Patients receive Controlled suspension liquid"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells",
                              "Biological: Controlled suspension liquid"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells",
                              "Controlled suspension liquid"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02302599"
                        ]
                  },
                  {
                        "Rank": 14,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS).\n\nParticipants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02804945"
                        ]
                  },
                  {
                        "Rank": 15,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will be treated with 1 single dose of IV infusion of autologous bone-marrow derived mesenchymal stem cells (1-2 million cells/kg body weight) and their therapeutic response will be followed over 48 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Open label single arm study"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03778333"
                        ]
                  },
                  {
                        "Rank": 16,
                        "Acronym": [
                              "MSC-SCI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01694927"
                        ]
                  },
                  {
                        "Rank": 17,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01068951"
                        ]
                  },
                  {
                        "Rank": 18,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: human amniotic mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "human amniotic mesenchymal stem cell treatment group",
                              "blank control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04318600"
                        ]
                  },
                  {
                        "Rank": 19,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01297972"
                        ]
                  },
                  {
                        "Rank": 20,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.",
                              "Placebo injection in the site of fracture in patients with tibia fracture."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell injection",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell receipients",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02140528"
                        ]
                  },
                  {
                        "Rank": 21,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.",
                              "Patients received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord Mesenchymal Stem Cells",
                              "Drug: Conserved therapy"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord mesenchymal stem cells",
                              "Conserved therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01224327"
                        ]
                  },
                  {
                        "Rank": 22,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells 1\u00d710^6 cells/kg, intravenously"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01763086"
                        ]
                  },
                  {
                        "Rank": 23,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSC co-infusion with either HLA-mismatched PBSC or cord blood"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Mesenchymal stem cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00504803"
                        ]
                  },
                  {
                        "Rank": 24,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin <30 g/L), fresh frozen plasma (200-400 mL/day until the INR was <1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome [HRS]).",
                              "Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Standard Medical Treatment",
                              "Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03863002"
                        ]
                  },
                  {
                        "Rank": 25,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "stem cells drived from iliac bone marrow with centrifuge and ficoll method then inject to non union site 2-3 ml with approximately 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion site of the bone fracture under fluoroscopic gide and general or spinal anesthesia as deemed appropriate by the anesthetist."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: injection the mesenchymal stem cell in non union site"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01788059"
                        ]
                  },
                  {
                        "Rank": 26,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells group refers to treatment with mesenchymal stem cells (1\u00d710^6 cells/kg, intravenously)",
                              "Mesenchymal stem cells and cord blood group refers to treatment with mesenchymal stem cells (at a dose of 1\u00d710^6 cells/kg) and cord blood"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells and cord blood"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Mesenchymal stem cells and cord blood"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01763099"
                        ]
                  },
                  {
                        "Rank": 27,
                        "Acronym": [
                              "CSM/EICH2010"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Allogenic Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01956903"
                        ]
                  },
                  {
                        "Rank": 28,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells",
                              "Patients treated according to current clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Olfactory mucosa-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treated group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03130374"
                        ]
                  },
                  {
                        "Rank": 29,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02285673"
                        ]
                  },
                  {
                        "Rank": 30,
                        "Acronym": [
                              "MSCTXT1DM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with Type 1 Diabetes, who will receive Intravenous injection of autologous bone-marrow derived mesenchymal stem cells",
                              "The patients with Type 1 Diabetes, who will receive intravenous injection of normal saline (sodium chloride 0.9%)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous Injection of autologous mesenchymal stem cells",
                              "Other: Intravenous injection of placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells Transplantation",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04078308"
                        ]
                  },
                  {
                        "Rank": 31,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous injection of mesenchymal stem cell in patients with PKD"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02166489"
                        ]
                  },
                  {
                        "Rank": 32,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.",
                              "Any therapy for diabetic foot which is routinely practiced and accepted in China"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells",
                              "Drug: Standard Therapy"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord mesenchymal stem cells",
                              "Standard Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01216865"
                        ]
                  },
                  {
                        "Rank": 33,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "infusion of Mesenchymal stem cells at dose 1 mln cells per kg",
                              "Without MSC infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "With MSC",
                              "Without MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01941394"
                        ]
                  },
                  {
                        "Rank": 34,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The experimental arm is comprised of GVHD patients receiving allogenic bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02824653"
                        ]
                  },
                  {
                        "Rank": 35,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01946048"
                        ]
                  },
                  {
                        "Rank": 36,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.9% sodium chloride intratracheal instillate on 14 days after birth",
                              "mesenchymal stem cells intratracheal instillate on 14 days after birth ,dose is 25 million cells/kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: 0.9% sodium chloride",
                              "Other: mesenchymal stem cells therapy"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03683953"
                        ]
                  },
                  {
                        "Rank": 37,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture.\n\nMSC will be injected even if the number of available cells is lower than 40 X 10E6.\n\nThe injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist.",
                              "Culture medium used to resuspend the Mesenchymal Stem Cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Other: Culture medium without MSC."
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells",
                              "Culture medium without MSC."
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01429012"
                        ]
                  },
                  {
                        "Rank": 38,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery",
                              "rotator cuff surgery without mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Procedure: without mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "without mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03068988"
                        ]
                  },
                  {
                        "Rank": 39,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 patients with relapsing remitting multiple sclerosis who receive cell free media",
                              "Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: injection of cell free media",
                              "Biological: intravenous injection of mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "cell free media",
                              "mesenchymal stem cell reciepiants"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01377870"
                        ]
                  },
                  {
                        "Rank": 40,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02482194"
                        ]
                  },
                  {
                        "Rank": 41,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 patients with mandibular fractures were managed by open reduction and internal fixation, with application of autologous mesenchymal stem cells on the fracture site.",
                              "10 patients with mandibular fractures were managed by open reduction and internal fixation, without application of autologous mesenchymal stem cells on the fracture site."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Application of autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Fractures with Mesenchymal Stem Cells",
                              "Fractures without Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02755922"
                        ]
                  },
                  {
                        "Rank": 42,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention:\n\nAutologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02945462"
                        ]
                  },
                  {
                        "Rank": 43,
                        "Acronym": [
                              "TERCELOI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Five Mesenchymal Stem Cell infusions"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02172885"
                        ]
                  },
                  {
                        "Rank": 44,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intra spinal injection of 1 \u00d710(8) mesenchymal stem cells +10cc normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02116634"
                        ]
                  },
                  {
                        "Rank": 45,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord mesenchymal stem cells injection is applied for knee OA patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05160831"
                        ]
                  },
                  {
                        "Rank": 46,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02247973"
                        ]
                  },
                  {
                        "Rank": 47,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Four different doses were set, and three subjects in each dose plan received human umbilical cord mesenchymal stem cell injection successively. Each subject received a single dose of 6.0*10^6, 3.0*10^7, 6.0*10^7, and 9.0*10^7 cells / person."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Human umbilical cord mesenchymal stem cell injection"
                        ],
                        "ArmGroupLabel": [
                              "Dose escalation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05468502"
                        ]
                  },
                  {
                        "Rank": 48,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .\n\nMSC a day-case 2\u00b70\u00d7106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v.",
                              "Patients with progressive and refractory NMO treated with regular methods"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02249676"
                        ]
                  },
                  {
                        "Rank": 49,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The volunteers of the experimental group will be given peripheral intravenously a dose of 0.75*10^6/ kg human umbilical cord mesenchymal stem cells at 0,1,5,6 week.",
                              "The control group will be given the same dose of saline containing human albumin."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: saline"
                        ],
                        "ArmGroupLabel": [
                              "experimental group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04441658"
                        ]
                  },
                  {
                        "Rank": 50,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00953485"
                        ]
                  },
                  {
                        "Rank": 51,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of twenty million human umbilical cord mesenchymal stem cells into the degenerative disc"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04414592"
                        ]
                  },
                  {
                        "Rank": 52,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow mesenchymal stem cells 10 cc by intra articular injection once",
                              "Stromal vascular factor from adipose mesenchymal stem cells 10 cc by intra articular injection once",
                              "Bone marrow and Stromal vascular factor from adipose mesenchymal stem cells 5 cc each one, by intra articular injection once."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow mesenchymal stem cells",
                              "Biological: Adipose Mesenchymal stem cells",
                              "Biological: bone marrow & adipose mesenchymal stem cells injection"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow mesenchymal stem cell",
                              "adipose mesenchymal stem cells",
                              "Bone marrow and Adipose mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04351932"
                        ]
                  },
                  {
                        "Rank": 53,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving intra-articular injection of autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous adipose-derived mesenchymal stem cells",
                              "Procedure: abdominal liposuction"
                        ],
                        "ArmGroupLabel": [
                              "Autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03956719"
                        ]
                  },
                  {
                        "Rank": 54,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "To study the safety and efficacy of autologous transplantation of bone marrow mesenchymal stem cells in treatment of newly diagnosed patients with T1DM."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous transplantation"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01157403"
                        ]
                  },
                  {
                        "Rank": 55,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.",
                              "Patients received one dose of normal saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell arm",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01902082"
                        ]
                  },
                  {
                        "Rank": 56,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get no stem cell infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologus Mesenchymal Stem Cells",
                              "Allogeniec Mesenchymal Stem Cells",
                              "Control without Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02409940"
                        ]
                  },
                  {
                        "Rank": 57,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "posterior cervical laminectomy and Mesenchymal stem cells tranplantation. After laminectomy, 1.6X10^7 and 3.2 X10^7 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: cellgram-spine"
                        ],
                        "ArmGroupLabel": [
                              "cellgram-spine"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01676441"
                        ]
                  },
                  {
                        "Rank": 58,
                        "Acronym": [
                              "START"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01775774"
                        ]
                  },
                  {
                        "Rank": 59,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "allogeneic bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04791878"
                        ]
                  },
                  {
                        "Rank": 60,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02344849"
                        ]
                  },
                  {
                        "Rank": 61,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2 weeks",
                              "placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 1, 2"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein",
                              "Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein"
                        ],
                        "ArmGroupLabel": [
                              "MSC group",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03668171"
                        ]
                  },
                  {
                        "Rank": 62,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "standard treatment according to clinical protocols plus mesenchymal stem cells",
                              "standard treatment according to clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Other: standard treatment",
                              "Other: standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04446897"
                        ]
                  },
                  {
                        "Rank": 63,
                        "Acronym": [
                              "MSCSHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients",
                              "Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: adipose-derived mesenchymal stem cells",
                              "Combination Product: adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell Administration for female patients",
                              "Stem cell Administration for male patients"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03346967"
                        ]
                  },
                  {
                        "Rank": 64,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03219801"
                        ]
                  },
                  {
                        "Rank": 65,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplantation of mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00659620"
                        ]
                  },
                  {
                        "Rank": 66,
                        "Acronym": [
                              "IUMTB"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord-derived Mesenchymal stem cell in the saline",
                              "saline without mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Human Umbilical Cord-derived Mesenchymal stem cell",
                              "Drug: placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03645525"
                        ]
                  },
                  {
                        "Rank": 67,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hUMAN MESENCHYMAL STEM CELLS"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01877759"
                        ]
                  },
                  {
                        "Rank": 68,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01962233"
                        ]
                  },
                  {
                        "Rank": 69,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.",
                              "The patients who are in control group and underwent placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01504464"
                        ]
                  },
                  {
                        "Rank": 70,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "To determine hemodynamic and immunologic changes associated with intra-renal delivery of adipose-derived MSC into human subjects with advanced RVD.",
                              "To test adjunctive delivery of MSC to individuals with advanced RVD undergoing renal artery stenting."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cell",
                              "Drug: Mesenchymal stem cell",
                              "Procedure: Mesenchymal stem cell delivery with stent placement"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell delivery",
                              "Mesenchymal stem cell delivery with stent placement"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02266394"
                        ]
                  },
                  {
                        "Rank": 71,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "According to the inclusion and exclusion criteria, selected patients were divided into a cell therapy group and a control group. Umbilical cord derived mesenchymal stem cells at a dose of 100-300 million by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03055078"
                        ]
                  },
                  {
                        "Rank": 72,
                        "Acronym": [
                              "MESAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After bone-marrow aspiration by an authorized person, Mesenchymal Stem Cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of Mesenchymal Stem Cells during Left Ventricular Assist Device surgery"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02460770"
                        ]
                  },
                  {
                        "Rank": 73,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8 plus UDCA.",
                              "placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 4, 8 plus UDCA."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein",
                              "Procedure: mesenchymal stem cell transplantation or placebo infusion via peripheral vein"
                        ],
                        "ArmGroupLabel": [
                              "MSC group",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03668145"
                        ]
                  },
                  {
                        "Rank": 74,
                        "Acronym": [
                              "Measure"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00734396"
                        ]
                  },
                  {
                        "Rank": 75,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01360164"
                        ]
                  },
                  {
                        "Rank": 76,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Inject mesenchymal stem cells from umbilical cord. The patients will be followed up at 1, 2, 3, and 6 months after the injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cells from umbilical cord"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03358654"
                        ]
                  },
                  {
                        "Rank": 77,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1. 3, 7 days to increase the injection of mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Dental pulp mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Pulp mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04302519"
                        ]
                  },
                  {
                        "Rank": 78,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1\u00d710^6 cells/kg, intravenously)each week, four times for a cycle",
                              "Non-mesenchymal stem cell group refers to treatment with other second line drugs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Biological: Non-mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Non-mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01765634"
                        ]
                  },
                  {
                        "Rank": 79,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Non-mesenchymal stem cell group refers to treatment with other second line drugs",
                              "Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1\u00d710^6 cells/kg, intravenously)every two weeks, four times for a cycle"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Non-mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Non-mesenchymal stem cells",
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01765660"
                        ]
                  },
                  {
                        "Rank": 80,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "No intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low dose mesenchymal stem cells",
                              "Procedure: Intraarticular injection",
                              "Biological: High dose mesenchymal stem cells",
                              "Procedure: Intraarticular injection"
                        ],
                        "ArmGroupLabel": [
                              "Low dose mesenchymal stem cells",
                              "High dose mesenchymal stem cells",
                              "Control groups"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03383081"
                        ]
                  },
                  {
                        "Rank": 81,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Stress urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells",
                              "Patients with Stress urinary incontinence receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cells",
                              "Other: Standard treatment according to the Clinical protocols",
                              "Other: Standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04446884"
                        ]
                  },
                  {
                        "Rank": 82,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow Mesenchymal stem cell injection in the testicular tubules and testicular artery"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cell injection"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02414295"
                        ]
                  },
                  {
                        "Rank": 83,
                        "Acronym": [
                              "MSV-DISC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: Autologous bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSV autologous transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02440074"
                        ]
                  },
                  {
                        "Rank": 84,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dose of infused cells is 10e6 cells/Kg",
                              "The dose of infused cells is 4*10e6 cells/Kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous mesenchymal stem cells from adipose tissue.",
                              "Other: Autologous mesenchymal stem cells from adipose tissue."
                        ],
                        "ArmGroupLabel": [
                              "Low dose autologous mesenchymal cells",
                              "High dose",
                              "Placebo Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01056471"
                        ]
                  },
                  {
                        "Rank": 85,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All subjects will receive autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01649700"
                        ]
                  },
                  {
                        "Rank": 86,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects who have never received Mesenchymal Stem Cells",
                              "Subjects who have previously received Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell 0.5",
                              "Biological: Mesenchymal stem cell 1.0",
                              "Biological: Mesenchymal stem cell 1.0"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem cells",
                              "Booster Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02181712"
                        ]
                  },
                  {
                        "Rank": 87,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Other: Saline"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells cohort",
                              "Saline cohort"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04194671"
                        ]
                  },
                  {
                        "Rank": 88,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Wharton Jelly mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02963727"
                        ]
                  },
                  {
                        "Rank": 89,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose tissue derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "adipose tissue mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02966951"
                        ]
                  },
                  {
                        "Rank": 90,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Fistulizing Crohn's disease"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01157650"
                        ]
                  },
                  {
                        "Rank": 91,
                        "Acronym": [
                              "UCMSCDKA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "single- or double-dose intravenous injection of umbilical cord mesenchymal stem cells for the treatment of severe type 1 diabetes patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02763423"
                        ]
                  },
                  {
                        "Rank": 92,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell injection"
                        ],
                        "ArmGroupLabel": [
                              "MSC injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01741090"
                        ]
                  },
                  {
                        "Rank": 93,
                        "Acronym": [
                              "PFCD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04519671"
                        ]
                  },
                  {
                        "Rank": 94,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.",
                              "Basic medication: Decitabine; placebo: saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells",
                              "Drug: Decitabine",
                              "Drug: Decitabine"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03184935"
                        ]
                  },
                  {
                        "Rank": 95,
                        "Acronym": [
                              "RVF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline with a possible repeat injection at 3 months if not completely healed from the first injection. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04519697"
                        ]
                  },
                  {
                        "Rank": 96,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Administration of allogeneic MSCs in the treatment of severe diffuse SSc or rapidly progressive and refractory to conventional treatments by prior cyclophosphamide"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS"
                        ],
                        "ArmGroupLabel": [
                              "INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02213705"
                        ]
                  },
                  {
                        "Rank": 97,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem Cells from adipose will be injected.",
                              "Hyaluronic acid will be injectied."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells from adipose",
                              "Biological: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells from adipose",
                              "hyaluronic acid"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03357575"
                        ]
                  },
                  {
                        "Rank": 98,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).",
                              "Core decompression surgery."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Procedure: core decompression",
                              "Procedure: core decompression"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03180463"
                        ]
                  },
                  {
                        "Rank": 99,
                        "Acronym": [
                              "ASD2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: Expanded autologous bone marrow-derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03343782"
                        ]
                  },
                  {
                        "Rank": 100,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg",
                              "Aspirin Tablet, 100mg/d; Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Drug: Aspirin Tablet",
                              "Drug: Aspirin Tablet"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03186456"
                        ]
                  },
                  {
                        "Rank": 101,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "observe the effectiveness and safety of patients by injecting human umbilical cord mesenchymal stem cells(2*10^7/ml normal saline) and Low temperature plasma vaporization ablation",
                              "observe the effectiveness and safety of patients by injecting normal saline and Low temperature plasma vaporization ablation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "treatment group A \uff08with mesenchymal stem cell intervention\uff09",
                              "control group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04104412"
                        ]
                  },
                  {
                        "Rank": 102,
                        "Acronym": [
                              "CEASE-CF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One time IV Infusion of up to 5 x 10^6 allogeneic hMSCs/kg of body weight. A dose escalation using the \"3+3\" design will be employed. The three doses are 1 x 10^6, 3 x 10^6, and 5 x 10^6 hMSCs/kg. There is no placebo group. All study participants will receive stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Human Allogeneic Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02866721"
                        ]
                  },
                  {
                        "Rank": 103,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Using clinically accepted methods, subjects will undergo bone marrow aspiration (from hip, proximal humerus or tibia) through a small incision prior to arthroscopy in the group undergoing MSC augmentation. They will then undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique with mesenchymal stem cell augmentation.",
                              "Subjects will undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique, without augmentation of mesenchymal stem cells. To maintain patient blinding, all patients will receive a small incision around the site of expected bone marrow aspiration (hip, proximal humerus, or tibia), regardless of whether or not they receive bone marrow."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell augmentation in rotator cuff repair",
                              "Procedure: Standard arthroscopic rotator cuff repair",
                              "Procedure: Standard arthroscopic rotator cuff repair"
                        ],
                        "ArmGroupLabel": [
                              "Rotator cuff repair with stem cells",
                              "Rotator cuff repair without stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02484950"
                        ]
                  },
                  {
                        "Rank": 104,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Human Umbilical Cord Blood-derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "FURESTEM-CD Inj"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04520022"
                        ]
                  },
                  {
                        "Rank": 105,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "no intervention",
                              "mesenchymal stem cell conditioned medium-derived pleiotropic factor"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell conditioned medium-derived pleiotropic factor"
                        ],
                        "ArmGroupLabel": [
                              "control group",
                              "experimental group"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04234750"
                        ]
                  },
                  {
                        "Rank": 106,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Early treatment with mesenchymal stem cells",
                              "Delayed treatment with mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01730547"
                        ]
                  },
                  {
                        "Rank": 107,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(\u03b1MEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02387749"
                        ]
                  },
                  {
                        "Rank": 108,
                        "Acronym": [
                              "LC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "only apply for conventional medical therapy without any cell therapy",
                              "combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Conventional therapy",
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Conventional therapy",
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01573923"
                        ]
                  },
                  {
                        "Rank": 109,
                        "Acronym": [
                              "MESEMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0",
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells",
                              "Suspension media"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01854957"
                        ]
                  },
                  {
                        "Rank": 110,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cell Autologous MSC transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "2"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00659217"
                        ]
                  },
                  {
                        "Rank": 111,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01446614"
                        ]
                  },
                  {
                        "Rank": 112,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal Stem Cells Infusion.",
                              "saline injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: saline"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells",
                              "saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02834858"
                        ]
                  },
                  {
                        "Rank": 113,
                        "Acronym": [
                              "CMM-EM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01228266"
                        ]
                  },
                  {
                        "Rank": 114,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01446640"
                        ]
                  },
                  {
                        "Rank": 115,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "5 Patients with cleft unilateral lip and palate that have already performed the alignment of dental arches through the recommended orthodontic treatment will be selected to be submited to alveolar bone tissue engineering surgery"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: maxillary alveolar graft by tissue engineering",
                              "Procedure: Bone tissue engineering using mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "cleft lip and palate"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01932164"
                        ]
                  },
                  {
                        "Rank": 116,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients with ankle joint osteoarthritis"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "stem cell recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01436058"
                        ]
                  },
                  {
                        "Rank": 117,
                        "Acronym": [
                              "CMM/FPI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Endobronchial infusion of adult mesenchymal stem cells",
                              "Biological: Autologous mesenchymal stem cells derived from bone marrow"
                        ],
                        "ArmGroupLabel": [
                              "MSC endobronchial infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01919827"
                        ]
                  },
                  {
                        "Rank": 118,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "epidermal growth factor",
                              "mesenchymal stem cell conditioned medium-derived pleiotropic factor"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: epidermal growth factor",
                              "Biological: mesenchymal stem cell conditioned medium-derived pleiotropic factor"
                        ],
                        "ArmGroupLabel": [
                              "control group",
                              "experimental group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04235296"
                        ]
                  },
                  {
                        "Rank": 119,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01305694"
                        ]
                  },
                  {
                        "Rank": 120,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the CABG with hUC-MSC treatment group, 1\u00d710^7 human umbilical cord Mesenchymal Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the same time in CABG.",
                              "CABG was performed under general anesthesia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "CABG with hUC-MSC treatment group",
                              "CABG group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04939077"
                        ]
                  },
                  {
                        "Rank": 121,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: intrauterine injection",
                              "Biological: human umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC intrauterine injection group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03386708"
                        ]
                  },
                  {
                        "Rank": 122,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with diagnosis of ALS who receive adipose derived mesenchymal stem cell."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02492516"
                        ]
                  },
                  {
                        "Rank": 123,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Selected patients with Parkinson's disease were randomly divided into a therapy group and a control group. Umbilical Cord Derived Mesenchymal Stem Cells(UC-MSCs) at a dose of 10-20 million by intravenous infusion.Patients in the therapy group treated once a week with UC-MSCs. Each course of treatment Lasted 3 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03550183"
                        ]
                  },
                  {
                        "Rank": 124,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem Cell + NaCl 0,9% 2ml"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: Mesenchymal Stem cell + Nacl 0.9%",
                              "Combination Product: NaCl 0.9%"
                        ],
                        "ArmGroupLabel": [
                              "MSC Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04493918"
                        ]
                  },
                  {
                        "Rank": 125,
                        "Acronym": [
                              "COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.",
                              "The results obtained in the treated group will be compared against the historical controls treated in INCMNSZ, evaluating the same variables."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion IV of Mesenchymal Stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treated group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04416139"
                        ]
                  },
                  {
                        "Rank": 126,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow derived stem cells injected intrathecally to enrolled MS patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01895439"
                        ]
                  },
                  {
                        "Rank": 127,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "control arm with sham transplantation",
                              "Active arm with transplantation of cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: sham transplantation of mesenchymal stem cells",
                              "Biological: autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "sham transplantation of mesenchymal stem cells",
                              "autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02057211"
                        ]
                  },
                  {
                        "Rank": 128,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Genetic: autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01499459"
                        ]
                  },
                  {
                        "Rank": 129,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "standard treatment according to clinical protocols plus mesenchymal stem cells",
                              "standard treatment according to clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Other: standard treatment",
                              "Other: standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04434794"
                        ]
                  },
                  {
                        "Rank": 130,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UCB Mesenchymal Stem Cells treatment of patients with skin injury"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCB Mesenchymal Stem Cells treatment"
                        ],
                        "ArmGroupLabel": [
                              "UCB Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02304562"
                        ]
                  },
                  {
                        "Rank": 131,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols",
                              "Patients with SLE, who receive standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Pooled mesenchymal stem cell",
                              "Other: Standard treatment according to the Clinical protocols",
                              "Other: Standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "SLE patients MSC treatment",
                              "SLE patients standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04184258"
                        ]
                  },
                  {
                        "Rank": 132,
                        "Acronym": [
                              "HULPVAS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight in a dosis"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Intramuscular injection of a suspension of adult mesenchymal stem cells derived"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01824069"
                        ]
                  },
                  {
                        "Rank": 133,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic Mesenchymal Stem Cell from umbilical cord"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "UC-Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04501354"
                        ]
                  },
                  {
                        "Rank": 134,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group wil receive 8 intravenous infusions of mesenchymal stem cells. Four infusions 1 week apart and 4 infusions a month apart"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous Mesenchymal stem cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01322789"
                        ]
                  },
                  {
                        "Rank": 135,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of vertebral bone marrow derived mesenchymal stem cells at a dose of 100 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of vertebral allogeneic bone marrow derived mesenchymal stem cells at a dose of 100 million cells into ileal pouch fistula(s)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Ossium vBM-MSC",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05075811"
                        ]
                  },
                  {
                        "Rank": 136,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02287831"
                        ]
                  },
                  {
                        "Rank": 137,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02235844"
                        ]
                  },
                  {
                        "Rank": 138,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01378182"
                        ]
                  },
                  {
                        "Rank": 139,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with tracheal/laryngeal stenosis receiving standard surgical treatment and mesenchymal stem cells",
                              "Patients with tracheal/laryngeal stenosis receiving standard surgical treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Olfactory mucosa-derived mesenchymal stem cells",
                              "Other: Patients treated according to current clinical protocols",
                              "Other: Patients treated according to current clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "Patients with tracheal/laryngeal stenosis receiving standard treatment and stem cells",
                              "Patients with tracheal/laryngeal stenosis receiving standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05535803"
                        ]
                  },
                  {
                        "Rank": 140,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with trophic ulcers received standard treatment and MSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04457037"
                        ]
                  },
                  {
                        "Rank": 141,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 patients will be given mesenchymal stem cells at dose 2x10^6 cells/kg MSCs on days 1 and day 7 (if needed) in addition to standard care",
                              "Only supportive care will be given to 10 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04444271"
                        ]
                  },
                  {
                        "Rank": 142,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cells only"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "stem cells group"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02705742"
                        ]
                  },
                  {
                        "Rank": 143,
                        "Acronym": [
                              "MSC&IMPLANTS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Evaluation of Osseointegration of Dental Implants to be done using Allogenic Mesenchymal Stem Cells.Primary and Secondary stability are measured using RFA."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogenic Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "osseointegration using Allogenic MSC's"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02731586"
                        ]
                  },
                  {
                        "Rank": 144,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment and mesenchymal stem cells",
                              "Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Other: standard treatment",
                              "Other: standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04432467"
                        ]
                  },
                  {
                        "Rank": 145,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03505034"
                        ]
                  },
                  {
                        "Rank": 146,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three groups of patients were enrolled in this study. Every group includes three patients. The three groups of patients were treated with high, medium and low dose of cytokine.The low-dose is 1 \u00d7 10^7cells / 3mL",
                              "the medium-dose is 5 \u00d7 10^7cells / 3mL",
                              "the high dose is 1 \u00d7 10^8cells / 3mL"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cells",
                              "Drug: mesenchymal stem cells",
                              "Drug: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "low dose of mesenchymal stem cells",
                              "medium dose of mesenchymal stem cells",
                              "high dose of mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03357770"
                        ]
                  },
                  {
                        "Rank": 147,
                        "Acronym": [
                              "SEED-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cell",
                              "Drug: Control group"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01392105"
                        ]
                  },
                  {
                        "Rank": 148,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects diagnosed with severe or very severe COPD will be infused intravenously with Mesenchymal Stem Cells (MSC)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Subjects with Advanced Chronic Obstructive Pulmonary Disease"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04047810"
                        ]
                  },
                  {
                        "Rank": 149,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Standard of care (SOC) plus a dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 5, 10 and 15 \u00d710E7 cells. Proceed from lower dose to next higher dose if no safety concerns for each cohort."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord-derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord-derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05227846"
                        ]
                  },
                  {
                        "Rank": 150,
                        "Acronym": [
                              "AMSCDRSE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs [AEDs]) and receiving autologous mesenchymal stem cells",
                              "Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "study group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02497443"
                        ]
                  },
                  {
                        "Rank": 151,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02283879"
                        ]
                  },
                  {
                        "Rank": 152,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous transplantation of Mesenchymal Stem Cell (Dose A - 1 million cells per kg, Dose B - 5 million cells per kg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: transplantation of hUC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03873506"
                        ]
                  },
                  {
                        "Rank": 153,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSC-INF\u03b2 administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10^5 MSC/kg once a week for 4 treatments. Up to 4 dose levels of MSC-INF\u03b2 tested. Symptom questionnaire completed once a week for 4 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: MSC-INF\u03b2",
                              "Behavioral: Questionnaires"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells + Interferon Beta (MSC-INF\u03b2)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02530047"
                        ]
                  },
                  {
                        "Rank": 154,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intubated without comorbidity",
                              "Intubated with comorbidity",
                              "No intubated"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stem cells",
                              "Other: Mesenchymal stem cells",
                              "Other: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2",
                              "Group 3"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04713878"
                        ]
                  },
                  {
                        "Rank": 155,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients who underwent mesenchymal stem cell transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intraventricular injection"
                        ],
                        "ArmGroupLabel": [
                              "stem cell recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01759784"
                        ]
                  },
                  {
                        "Rank": 156,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular injection",
                              "Intramuscular injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cells",
                              "Drug: Plasmalyte A"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00883870"
                        ]
                  },
                  {
                        "Rank": 157,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "High dose (8 million cells per kg of body weight)",
                              "Low dose: 2 million cells per kg body weight"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Prochymal\u2122 adult human mesenchymal stem cells",
                              "Drug: adult human mesenchymal stem cells",
                              "Drug: Prochymal\u2122 adult human mesenchymal stem cells",
                              "Drug: adult human mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "High dose",
                              "Low dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00294112"
                        ]
                  },
                  {
                        "Rank": 158,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00850187"
                        ]
                  },
                  {
                        "Rank": 159,
                        "Acronym": [
                              "IPAAF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into ileal pouch fistula(s)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04519684"
                        ]
                  },
                  {
                        "Rank": 160,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).",
                              "Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).",
                              "Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC",
                              "Biological: UC-MSC",
                              "Biological: UC-MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC group 1",
                              "MSC group 2",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03529136"
                        ]
                  },
                  {
                        "Rank": 161,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02291926"
                        ]
                  },
                  {
                        "Rank": 162,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone marrow aspiration"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01895413"
                        ]
                  },
                  {
                        "Rank": 163,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Hyaluronic Acid",
                              "Biological: Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Hyaluronic acid",
                              "Bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01459640"
                        ]
                  },
                  {
                        "Rank": 164,
                        "Acronym": [
                              "MESADDE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Approximately 11 million ASCs in a 0.5 ml suspension"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Adipose tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03878628"
                        ]
                  },
                  {
                        "Rank": 165,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cell infusion and bone marrow mononuclear cell infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell infusion",
                              "Biological: bone marrow mononuclear cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00813267"
                        ]
                  },
                  {
                        "Rank": 166,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04366323"
                        ]
                  },
                  {
                        "Rank": 167,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dosage of the intravenous route is 100 million MSCs for each subject."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "intravenous injection of UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04357600"
                        ]
                  },
                  {
                        "Rank": 168,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "bone marrow-derived mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow-derived mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01849887"
                        ]
                  },
                  {
                        "Rank": 169,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Two escalated intrathecal infusions of autologous mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal stem cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02987413"
                        ]
                  },
                  {
                        "Rank": 170,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.",
                              "Conventional treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Drug: conventional treatment",
                              "Drug: conventional treatment"
                        ],
                        "ArmGroupLabel": [
                              "Treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03180450"
                        ]
                  },
                  {
                        "Rank": 171,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "25 million mesenchymal stem cells administered intrathecally every 3 months for 4 injections",
                              "25 million mesenchymal stem cells administered intrathecally every 6 months for 2 injections (placebo injections at 3 month and 9 month timepoints)",
                              "Placebo (lactated Ringer's) administered intrathecally every 3 months for 4 injections"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Other: Placebo",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1",
                              "Arm 2",
                              "Arm 3"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05167721"
                        ]
                  },
                  {
                        "Rank": 172,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.",
                              "The control group will be given the same dose of saline containing human albumin."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Other: saline"
                        ],
                        "ArmGroupLabel": [
                              "experimental group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04216849"
                        ]
                  },
                  {
                        "Rank": 173,
                        "Acronym": [
                              "BMAC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in this group will receive between 1-4 ml of bone marrow aspirate concentrate (BMAC) containing mesenchymal stem cells (MSCs) obtained from their iliac crest. A small incision will be made on the anterior superior iliac spine in order to withdraw the aspirate. The aspirate will be ran through a centrifuge in order to isolate the BMAC containing MSCs. The BMAC will be injected into the ACL allograft prior to implanting into the patient.",
                              "Patients will receive a sham incision on the anterior superior iliac spine where the bone marrow aspirate is obtained in the the experimental group. This ensures proper blinding. The patient will receive the normal standard of care."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Autologous Bone Marrow Derived Mesenchymal Stem Cells",
                              "Other: Sham incision"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell Recipient",
                              "Control Sham Incision"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04650568"
                        ]
                  },
                  {
                        "Rank": 174,
                        "Acronym": [
                              "MESCAMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.",
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells",
                              "Suspension media"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02239393"
                        ]
                  },
                  {
                        "Rank": 175,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "No intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Intravenous infusion",
                              "Biological: umbilical cord mesenchymal stem cell",
                              "Procedure: Intrathecal injection",
                              "Biological: umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous infusion group",
                              "Intrathecal injection group",
                              "Control groups"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03378414"
                        ]
                  },
                  {
                        "Rank": 176,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adult adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells(MSC) treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01649687"
                        ]
                  },
                  {
                        "Rank": 177,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "rotator cuff repair stem cells",
                              "rotator cuff repair"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell",
                              "Procedure: Rotator cuff repair",
                              "Procedure: Rotator cuff repair"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03362424"
                        ]
                  },
                  {
                        "Rank": 178,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "cotransplantation of islet and mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: cotransplantation of islet and mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00646724"
                        ]
                  },
                  {
                        "Rank": 179,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)",
                              "Control Group: Using basic contrast ."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Peripheral iv"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03826433"
                        ]
                  },
                  {
                        "Rank": 180,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Basic medication\uff1aAspirin Enteric-coated Tablets & Atorvastatin Calcium\uff1b Allogeneic umbilical cord mesenchymal stem cells",
                              "Basic medication\uff1aAspirin Enteric-coated Tablets & Atorvastatin Calcium; Placebo\uff1asaline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cell",
                              "Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium",
                              "Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03176498"
                        ]
                  },
                  {
                        "Rank": 181,
                        "Acronym": [
                              "ALLO-ASC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.",
                              "10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection",
                              "Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection"
                        ],
                        "ArmGroupLabel": [
                              "1 million cells/ml of ALLO-ASC",
                              "10 million cells/ml of ALLO-ASC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01856140"
                        ]
                  },
                  {
                        "Rank": 182,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 enrolled refractory ITP patients will be picked up to infuse hUC-MSCs at the indicated dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "15 refractory ITP patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04014166"
                        ]
                  },
                  {
                        "Rank": 183,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells",
                              "Patients with Urinary incontinence receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cells",
                              "Other: Standard treatment according to the Clinical protocols",
                              "Other: Standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04426643"
                        ]
                  },
                  {
                        "Rank": 184,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00962923"
                        ]
                  },
                  {
                        "Rank": 185,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment consistsof Mesenchymal Stem Cells administered as a one-time, single-dose therapy via IV infusion at a dose of 1 X 10 8 cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords"
                        ],
                        "ArmGroupLabel": [
                              "COVID-19 patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 186,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03299413"
                        ]
                  },
                  {
                        "Rank": 187,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, which is divided into 1 cc pre-filled syringes and administered in 20 divided doses to 15-20 parts of the muscle in divided doses along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia so that the entire diluted solution is administered.",
                              "- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, then administered to 15-20 parts of the muscle along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)",
                              "Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)"
                        ],
                        "ArmGroupLabel": [
                              "Test Group 1 (Low Dose)",
                              "Test Group 2 (High Dose)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04661644"
                        ]
                  },
                  {
                        "Rank": 188,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells",
                              "Patients with Covid-19 associated pneumonia receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells",
                              "Other: Standard treatment according to the Clinical protocols",
                              "Other: Standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04382547"
                        ]
                  },
                  {
                        "Rank": 189,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure.",
                              "Treatment of chronic renal failure patients with conventional methods."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Treatment group",
                              "Drug: Control group"
                        ],
                        "ArmGroupLabel": [
                              "Treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03321942"
                        ]
                  },
                  {
                        "Rank": 190,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells (hUC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000"
                        ],
                        "NCTId": [
                              "NCT02481440"
                        ]
                  },
                  {
                        "Rank": 191,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection",
                              "The patients who are in control group and underwent placebo injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03164083"
                        ]
                  },
                  {
                        "Rank": 192,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02790762"
                        ]
                  },
                  {
                        "Rank": 193,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.\n\nPatients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)",
                              "Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.\n\nPatients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Prednisone and cyclosporine or primary therapies",
                              "Biological: Mesenchymal stem cell (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Mesenchymal stem cell (MSC)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00972660"
                        ]
                  },
                  {
                        "Rank": 194,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving intraarticular injection of low dose of mesenchymal stem cells.",
                              "Patients receiving intraarticular injection of high dose of mesenchymal stem cells.",
                              "Patients receiving intraarticular injection of Sodium Hyaluronate"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low Dose of Mesenchymal stem cell",
                              "Biological: High Dose of Mesenchymal stem cell",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose of Mesenchymal stem cell",
                              "High Dose of Mesenchymal stem cell",
                              "Sodium Hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04130100"
                        ]
                  },
                  {
                        "Rank": 195,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02652351"
                        ]
                  },
                  {
                        "Rank": 196,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 0, and Study Month 3.\n\n- Each treatment period was separated by a 4 - week washout to allow the effective systemic elimination of the UC MSCs before subsequent treatment initiation",
                              "Cohort 2 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 7, and Study Month 10"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency",
                              "Biological: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord-Derived Mesenchymal Stem Cell, then Placebo (group A)",
                              "Placebo, then Umbilical Cord-Derived Mesenchymal Stem Cell (group B)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05345418"
                        ]
                  },
                  {
                        "Rank": 197,
                        "Acronym": [
                              "PRIME-HFrEF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The volunteers of the experimental group will be given peripheral intravenously a dose of 1.0*10^6/kg human umbilical cord mesenchymal stem cells at 0,6,12 week.",
                              "The control group will be given the same dose of saline containing human albumin."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Other: human serum albumin"
                        ],
                        "ArmGroupLabel": [
                              "experimental group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04992832"
                        ]
                  },
                  {
                        "Rank": 198,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: Single dose experiments",
                              "Other: Multi-dose experiments"
                        ],
                        "ArmGroupLabel": [
                              "Single dose experiments",
                              "Multi-dose experiments"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04464213"
                        ]
                  },
                  {
                        "Rank": 199,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The MSCs treatment group patients will receive an intra-articular injection of a mesenchymal stem cell (MSCs) suspension in the affected knee.\n\nThe treatment will be carried out after the patient has received a blood test and clinically evaluated at T0.\n\nT0: Beginning of the study, blood test and bone marrow aspiration. T30: Intra-articular injection of MSCs T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)",
                              "The patient will be given a single intra-articular injection of hyaluronic acid sodium salt, Synvisc-One (TRB Chemedica Ltd.) The hyaluronic acid will be purchased for the patient from the manufacturer or from the pharmacy of the hospital.The intra-articular injection will be carried out after the patient has received a clinical evaluation at T0.\n\nT0: Beginning of the study T30: Intra-articular injection of Synvisc-One (HA) T44: Adverse events follow up 2 weeks after intra-articular injection (by phone)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells Treatment (MSCs)",
                              "Drug: Hyaluronic acid (HA)"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells Treatment (MSCs)",
                              "Hyaluronic acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04326985"
                        ]
                  },
                  {
                        "Rank": 200,
                        "Acronym": [
                              "MSCPRPOAK"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle",
                              "About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell suspension",
                              "Biological: PRP",
                              "Biological: PRP"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell, PRP",
                              "platelet rich plasma"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01985633"
                        ]
                  },
                  {
                        "Rank": 201,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ MSC 50*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.",
                              "Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Wharton's jelly derived Mesenchymal stem cells.",
                              "Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 202,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells, Intramuscular injection",
                              "Normal saline, Intramuscular injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Biological: Normal saline"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Normal saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03239535"
                        ]
                  },
                  {
                        "Rank": 203,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.",
                              "In the MSCs injection group, 1\u00d710^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: saline",
                              "Biological: human umbilical cord-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "control",
                              "MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04996966"
                        ]
                  },
                  {
                        "Rank": 204,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "No intervention",
                              "The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: The pleiotropic factor derived from mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "control group",
                              "experimental group"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04538885"
                        ]
                  },
                  {
                        "Rank": 205,
                        "Acronym": [
                              "CP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ASTROSTEM"
                        ],
                        "ArmGroupLabel": [
                              "Astrostem"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03979898"
                        ]
                  },
                  {
                        "Rank": 206,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stem cell transplantation via peripheral vein: 1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8.",
                              "Standard medication for viral hepatitis and cirrhosis"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: mesenchymal stem cell transplantation via peripheral vein",
                              "Other: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "MSC group",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03209986"
                        ]
                  },
                  {
                        "Rank": 207,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution",
                              "Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution",
                              "Placebo Infusion (Plasma-Lyte A solution only)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Low Dose Mesenchymal Stem Cells (MSCs)",
                              "Drug: High Dose Mesenchymal Stem Cells (MSCs)",
                              "Drug: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose Mesenchymal Stem Cells (MSCs)",
                              "High Dose Mesenchymal Stem Cells (MSCs)",
                              "Plasma Lyte A Solution"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02633163"
                        ]
                  },
                  {
                        "Rank": 208,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cords from healthy donor are processed with 24 hours after vaginal delivery.\n\nThe cords are delivered in a sterilized jar the laboratory to process. After washing in PBS to remove any contaminating blood, the cord is cut into small pieces. The pieces are minced and digested by enzyme. The UC-MSCs is cultured and expanded using commercially available serum-free and xeno-free medium at 37\u00b0C in a humidified atmosphere with 5% CO2. The UC-MSCs is suspended in 15 ml of saline buffer"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord-derived mesenchymal stem cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "human umbilical cord-derived mesenchymal stem cell transplantation for patients with liver cirrhosis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05331872"
                        ]
                  },
                  {
                        "Rank": 209,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients to receive allogeneic UC-MSCs via intralesional injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells (UC-MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05039411"
                        ]
                  },
                  {
                        "Rank": 210,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles",
                              "Patients with bone defects receiving standard surgical treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells enriched by extracellular vesicles",
                              "Other: Standard treatment of bone defects",
                              "Other: Standard treatment of bone defects"
                        ],
                        "ArmGroupLabel": [
                              "Patients with bone defects receiving standard treatment and MSC enriched with extracellular vesicles",
                              "Patients with bone defects receiving standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05520125"
                        ]
                  },
                  {
                        "Rank": 211,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC",
                              "Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction",
                              "Other: Standard treatment according to the clinical protocols",
                              "Other: Standard treatment according to the clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "Patients with Recurrent Pregnancy Loss receiving standard treatment and autologous MSC",
                              "Standard treatment according to the clinical protocols"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05520112"
                        ]
                  },
                  {
                        "Rank": 212,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Refractory rheumatoid arthritis patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03333681"
                        ]
                  },
                  {
                        "Rank": 213,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention group"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01364246"
                        ]
                  },
                  {
                        "Rank": 214,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD) will receive a new treatment called Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Interstitial Lung Disease with Connective Tissue Disorder"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03929120"
                        ]
                  },
                  {
                        "Rank": 215,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.",
                              "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.",
                              "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells low-dose group",
                              "Biological: Mesenchymal stem cells mid-dose group",
                              "Biological: Mesenchymal stem cells high-dose group"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells low-dose group",
                              "Mesenchymal stem cells mid-dose group",
                              "Mesenchymal stem cells high-dose group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01809769"
                        ]
                  },
                  {
                        "Rank": 216,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10^6/kg body weight are suspended in 100ml saline and infused intravenously.\n\nDexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.\nA sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort.",
                              "The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. ."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stem cells",
                              "Drug: Placebo of Mycophenolate Mofetil",
                              "Drug: Mycophenolate Mofetil",
                              "Other: Placebo of Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Mycophenolate Mofetil"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03580291"
                        ]
                  },
                  {
                        "Rank": 217,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "There will only be one treatment arm to evaluate the security of the treatment with MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cell (MSC) therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell (MSC) therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02443961"
                        ]
                  },
                  {
                        "Rank": 218,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Large volume whole-lung lavage (WLL) only",
                              "Combined large volume WLL with clinical grade umbilical cord mesenchymal stem cells transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: large volume whole-lung lavage (WLL)",
                              "Procedure: large volume whole-lung lavage (WLL)",
                              "Biological: clinical grade umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Control Group",
                              "Experimental Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02668068"
                        ]
                  },
                  {
                        "Rank": 219,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells",
                              "Autologous bone marrow-derived mononuclear cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mononuclear and mesenchymal stem cells",
                              "Biological: Mononuclear cells"
                        ],
                        "ArmGroupLabel": [
                              "Mononuclear and mesenchymal stem cells",
                              "Mononuclear cells only"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01456819"
                        ]
                  },
                  {
                        "Rank": 220,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02749448"
                        ]
                  },
                  {
                        "Rank": 221,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight.",
                              "- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight.",
                              "Conventional treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stem cells from adipose tissue",
                              "Other: Mesenchymal stem cells from adipose tissue"
                        ],
                        "ArmGroupLabel": [
                              "Low dose",
                              "High dose",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01745744"
                        ]
                  },
                  {
                        "Rank": 222,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Within 30 days after extracting bone marrow, autologous bone marrow-derived mesenchymal stem cells is directly injected into the lesion. Then the second cell is injected within 30 days after the first cell injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Cellgram-CLI"
                        ],
                        "ArmGroupLabel": [
                              "2-time injection group : Cellgram-CLI"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02477540"
                        ]
                  },
                  {
                        "Rank": 223,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke",
                              "Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Standard medical care",
                              "Other: Standard medical care",
                              "Biological: Autologous bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Standard medical care",
                              "BM-MSCs"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01461720"
                        ]
                  },
                  {
                        "Rank": 224,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: normal saline",
                              "Biological: autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "normal saline",
                              "autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00911365"
                        ]
                  },
                  {
                        "Rank": 225,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02152657"
                        ]
                  },
                  {
                        "Rank": 226,
                        "Acronym": [
                              "UCMSCBA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "17 patients with BA underwent Kasai operation and then will received two doses of UC-MSCs at 1x106 cells/kg (body weight) administered via hepatic artery",
                              "17 patients with BA will be conducted Kasai operation only"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord blood - derived mesenchymal stem cells",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04522869"
                        ]
                  },
                  {
                        "Rank": 227,
                        "Acronym": [
                              "EXPAND"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05522569"
                        ]
                  },
                  {
                        "Rank": 228,
                        "Acronym": [
                              "EXIT-ARDS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Saline",
                              "ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)",
                              "ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Saline",
                              "Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles",
                              "Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles"
                        ],
                        "ArmGroupLabel": [
                              "Placebo Saline",
                              "10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles",
                              "15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05127122"
                        ]
                  },
                  {
                        "Rank": 229,
                        "Acronym": [
                              "Cellgram-ED"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intracavernous injection of Placebo Oral PDE5-inhibitor can take daily and on demand.",
                              "Single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take daily and on demand."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cellgram-ED"
                        ],
                        "ArmGroupLabel": [
                              "Placebo-Control group",
                              "Injection group: Cellgram-ED"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04594850"
                        ]
                  },
                  {
                        "Rank": 230,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01609283"
                        ]
                  },
                  {
                        "Rank": 231,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Wharton Jelly Mesenchymal stem cells Site: Renal parenchyma Route of administration: ultrasound guided- intra-parenchymal total of 3 sites in each kidney.\n\nNumber of doses: 3 doses 2 weeks apart for each kidney. Time interval between each dose: 2 weeks Total volume of cell suspension infused: 3 ml/kidney; each site will receive a 1 ml cell suspension with a total volume of 3 ml in each kidney."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03288571"
                        ]
                  },
                  {
                        "Rank": 232,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The MSCs of 1\u00d710*6/kg will be given in Central venous catheterization for injection at a total 100 ml . Once every week#a total of two times. The Conventional drug therapy\uff08expectorant\uff0cbronchodilator\uff09 is used.",
                              "The Conventional drug therapy\uff08expectorant\uff0cbronchodilator\uff09 is used with the control group"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: adipose derived mesenchymal stem cells",
                              "Drug: Conventional drug therapy\uff08expectorant\uff0cbronchodilator\uff09",
                              "Drug: Conventional drug therapy\uff08expectorant\uff0cbronchodilator\uff09"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04055415"
                        ]
                  },
                  {
                        "Rank": 233,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose I"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02945449"
                        ]
                  },
                  {
                        "Rank": 234,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "For patients who have an operation of total knee replacement, two removed tissues (synovial membrane and infrapatellar fat pad) will be collected for mesenchymal stem cell isolation."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: 103024-F"
                        ],
                        "ArmGroupLabel": [
                              "103024-F"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02375568"
                        ]
                  },
                  {
                        "Rank": 235,
                        "Acronym": [
                              "MSC-SLE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Phase I-II, Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:\n\n1.10^6 CSM / kg\n2.10^6 CSM / kg\n4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03562065"
                        ]
                  },
                  {
                        "Rank": 236,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will be given secretome - mesenchymal stem cell and COVID-19 standard therapy",
                              "This group will be given placebo and COVID-19 standard therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection of secretome - mesenchymal stem cell",
                              "Drug: Standard treatment of Covid-19",
                              "Other: Placebo",
                              "Drug: Standard treatment of Covid-19"
                        ],
                        "ArmGroupLabel": [
                              "Secretome - mesenchymal stem cell group (n = 20)",
                              "Control ( n= 20)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05122234"
                        ]
                  },
                  {
                        "Rank": 237,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group I disease 0-7. days,",
                              "In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group II; 8-14 days of the disease. days",
                              "In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group III; It will be divided into 3 groups as those applied on the 15th day and after."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cell Antigen-1, Human",
                              "Drug: Mesenchymal Stem Cell Antigen-1, Human",
                              "Drug: Mesenchymal Stem Cell Antigen-1, Human"
                        ],
                        "ArmGroupLabel": [
                              "stem cell application; Group I disease 0-7. days,",
                              "stem cell application; Group II; 8-14 days of the disease. days",
                              "stem cell application; Group III; those applied on the 15th day and after."
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05240430"
                        ]
                  },
                  {
                        "Rank": 238,
                        "Acronym": [
                              "ISIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Control group without intervention nor placebo",
                              "First dose of stem cells",
                              "Second dose of stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Autologous mesenchymal stem cells",
                              "Genetic: Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2",
                              "3"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00875654"
                        ]
                  },
                  {
                        "Rank": 239,
                        "Acronym": [
                              "Liveradvance"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18",
                              "Solution without cells on days 1, 4, 11 and 18"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic Mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02857010"
                        ]
                  },
                  {
                        "Rank": 240,
                        "Acronym": [
                              "MSCsTcGVHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.",
                              "patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Biological: mesenchymal stem cell",
                              "Drug: Cyclosporine and Glucocorticoid"
                        ],
                        "ArmGroupLabel": [
                              "allogenic mesenchymal stem cells (MSCs)",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01526850"
                        ]
                  },
                  {
                        "Rank": 241,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem cell + Nacl 0.9%"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cell + NaCl 0,9% 2ml"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04499105"
                        ]
                  },
                  {
                        "Rank": 242,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for 3 participants.",
                              "Intravenous infusion of MSC (mesenchymal stem cell) dose 1 x 10^6/kg for next 3 participants.",
                              "Intravenous infusion of MSC (mesenchymal stem cell) dose 2 x 10^6/kg for next 3 participants.",
                              "Intraventricular infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for final 3 participants."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC",
                              "Biological: MSC",
                              "Biological: MSC",
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "Group 1 MSC dose .5 x 10^6/kg IV",
                              "Group 2 MSC dose 1 x 10^6/kg IV",
                              "Group 3 MSC dose 2 x 10^6/kg IV",
                              "Group 4 MSC dose 0.5 x 10^6/kg I"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03371329"
                        ]
                  },
                  {
                        "Rank": 243,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04432545"
                        ]
                  },
                  {
                        "Rank": 244,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14. Dose escalation will be guided by a fast track design. One patient is entered per dose level until a DLT is experienced. At that point, two additional patients will be enrolled at the same dose level. Dose levels will be 2.5 x 10e6 MSC/kg per dose, 5 x 10e6 MSC/kg per dose or 7.5 x 10e6 MSC/kg per dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02410239"
                        ]
                  },
                  {
                        "Rank": 245,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia",
                              "2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem/stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose-derived mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03876197"
                        ]
                  },
                  {
                        "Rank": 246,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal and intravenous treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously in patients with active multiple sclerosis, failures to respond to other treatments"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection of autologous bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00781872"
                        ]
                  },
                  {
                        "Rank": 247,
                        "Acronym": [
                              "MSCsTreatPBC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients who have primary biliary cirrhosis.",
                              "Patients who have primary biliary cirrhosis."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Biological: mesenchymal stem cell",
                              "Drug: ursodeoxycholic acid"
                        ],
                        "ArmGroupLabel": [
                              "allogenic mesenchymal stem cells (MSCs)",
                              "ursodeoxycholic acid (UDCA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01440309"
                        ]
                  },
                  {
                        "Rank": 248,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-UT)",
                              "Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife\u00ae-UT)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cell complex collagen",
                              "Biological: human umbilical cord mesenchymal stem cell complex collagen",
                              "Procedure: intrauterine injection"
                        ],
                        "ArmGroupLabel": [
                              "stem cell and collagen transplantation group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05495711"
                        ]
                  },
                  {
                        "Rank": 249,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV.\n\nThe remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01983709"
                        ]
                  },
                  {
                        "Rank": 250,
                        "Acronym": [
                              "VALIANT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1 - Five (5) subjects will be treated with a single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection. These subjects will be part of the control (Standard care) group.",
                              "Group 2 - Five (5) subjects will be treated with a single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml. These subjects will be part of the experimental group.",
                              "Group A will consist of 15 subjects that will receive 20 million Allogeneic hMSCs delivered via lumbar level injection based on pain originator.",
                              "Group B will consist of 15 subjects who will receive 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution via lumbar level injection based on pain originator."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebo",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (hMSCs)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group 1 - Placebo",
                              "Group 2 - Allogeneic Human Mesenchymal Stem Cells (hMSCs)",
                              "Group A - Allogeneic Human Mesenchymal Stem Cells (hMSCs)",
                              "Group B - Placebo"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03487731"
                        ]
                  },
                  {
                        "Rank": 251,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group of low dose of Mesenchymal stem cells.",
                              "Group of mid dose of mesenchymal stem cells",
                              "Controlled group with no intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous adipose derived mesenchymal stem cells",
                              "Drug: Autologous adipose derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells 0,5 million * weight (kg)",
                              "Mesenchymal stem cells 1 million * weight (kg)",
                              "Controlled group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01257776"
                        ]
                  },
                  {
                        "Rank": 252,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous mesenchymal stem cells from the adipose tissue in an unique intralesional infusion with a dose of 40 million cells.",
                              "Ringer lactate solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Infusion of mesenchymal stem cells from adipose tissue",
                              "Other: Infusion of placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Ringer lactate solution"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02292628"
                        ]
                  },
                  {
                        "Rank": 253,
                        "Acronym": [
                              "UMSIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous umbilical cord derived mesenchymal stem cells",
                              "intravenous placebo solution with the same appearance as the treatment group."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-derived Mesenchymal Stem Cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment group",
                              "Placebo Comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04811651"
                        ]
                  },
                  {
                        "Rank": 254,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 million umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 1 week after the first transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04062136"
                        ]
                  },
                  {
                        "Rank": 255,
                        "Acronym": [
                              "MSC-pMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with intrathecal and intravenous injection of autologous MSC (1 million cells per Kg of body weight)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Repeated MSCs treatment in MS patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04823000"
                        ]
                  },
                  {
                        "Rank": 256,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.",
                              "Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous, Adipose Derived Mesenchymal Stem Cells",
                              "Other: Best Medical Management: Occupational and Physical Therapy",
                              "Biological: Autologous, Adipose Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group 1: AD-MSC Injection",
                              "Treatment Group 2: Best Medical Management"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04520373"
                        ]
                  },
                  {
                        "Rank": 257,
                        "Acronym": [
                              "Recruiting"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Control group without intervention, whereas they receive conventional stroke treatment that including rehabilitation",
                              "Patients will receive human umbilical cord mesenchymal stem cells transplantation accompanied with conventional treatment including rehabilitation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "conventional stroke treatment",
                              "hUC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02580019"
                        ]
                  },
                  {
                        "Rank": 258,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Maximal medical therapy which comprises of optimal pharmacological therapy",
                              "Autologous Bone marrrow-derived mesenchymal stem cells implantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BM-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Maximal medical therapy",
                              "Maximal medical therapy and BM-MSCs"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01720888"
                        ]
                  },
                  {
                        "Rank": 259,
                        "Acronym": [
                              "ALSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "It is planned that IMP administration will be performed three times for each enrolled patient. IMP administration could be performed only if the patients does not have any contraindications for lumbar puncture."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells isolated from Wharton's jelly"
                        ],
                        "ArmGroupLabel": [
                              "Treatment arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04651855"
                        ]
                  },
                  {
                        "Rank": 260,
                        "Acronym": [
                              "GALENE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Twenty (20) subjects will be treated with 20 million (2 x 10^7) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Pilot"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02677350"
                        ]
                  },
                  {
                        "Rank": 261,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Every patient is given 1x106 MSCs per kg infused via liver artery",
                              "autologous bone marrow mesenchymal stem cells transplantation",
                              "autologous bone marrow mesenchymal stem cells transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous bone marrow mesenchymal stem cells transplantation",
                              "Biological: autologous bone marrow msenchymal stem cells transplantation",
                              "Biological: autologous bone marrow mesenchymal stem cells transplantation",
                              "Biological: autologous bone marrow msenchymal stem cells transplantation",
                              "Biological: autologous bone marrow mesenchymal stem cells transplantation",
                              "Biological: autologous bone marrow msenchymal stem cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "autologous bone marrow mesenchymal stem cells transplantation",
                              "mesenchymal stem cells transplantation",
                              "stem cells transplantation"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01854125"
                        ]
                  },
                  {
                        "Rank": 262,
                        "Acronym": [
                              "CHOCMSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients hospitalized in recovery unit and having a very severe septic shock with community origin (\u2265 2 organ failures other than hemodynamic) since less than 12 hours, will receive 10^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in central venous line.",
                              "Patients hospitalized in recovery unit and having a very severe septic shock with community origin (\u2265 2 organ failures other than hemodynamic) since less than 12 hours, will receive 250 ml albumin 4%, infused for 30 minutes in central venous line."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection of mesenchymal stem cells",
                              "Biological: Injection of albumin alone"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02883803"
                        ]
                  },
                  {
                        "Rank": 263,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018871"
                        ]
                  },
                  {
                        "Rank": 264,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.",
                              "Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: placebo",
                              "Biological: mesenchymal cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "placebo",
                              "mesencymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01873625"
                        ]
                  },
                  {
                        "Rank": 265,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intrathecal injection of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018793"
                        ]
                  },
                  {
                        "Rank": 266,
                        "Acronym": [
                              "CMM/EICH/2008"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.",
                              "Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.",
                              "Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue."
                        ],
                        "ArmGroupLabel": [
                              "Conventional treatment plus high dose: 3x10e6 cells / Kg.",
                              "Conventional treatment plus low dose: 1x10e6 cells / Kg"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01222039"
                        ]
                  },
                  {
                        "Rank": 267,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Four intrathecal (IT) administrations of autologous MSC cells administered every 3 months in ALS patients. the IT treatment will be administered through a regular lumbar puncture at a dose of 1x10^6 MSCs per kg body weight in 3 ml saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Repeated MSCs treatment in ALS patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04821479"
                        ]
                  },
                  {
                        "Rank": 268,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Low Dose Mesenchymal Stem Cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Drug: Low Dose Mesenchymal Stem Cells ( MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03171194"
                        ]
                  },
                  {
                        "Rank": 269,
                        "Acronym": [
                              "AMASS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One transconjunctival injection of allogeneic ASCs into the LG in one eye.",
                              "One transconjunctival injection of Cryostor CS10 into the LG in one eye."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ASCs",
                              "Drug: Cryostor CS10"
                        ],
                        "ArmGroupLabel": [
                              "Adipose tissue-derived mesenchymal stem cells (ASCs)",
                              "Placebo (vehicle, Cryostor CS10)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04615455"
                        ]
                  },
                  {
                        "Rank": 270,
                        "Acronym": [
                              "ARDS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord derived mesenchymal stem cells (UCMSCs) suspension",
                              "Biological: normal saline"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03608592"
                        ]
                  },
                  {
                        "Rank": 271,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal Stem Cell Therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cell Therapy"
                        ],
                        "ArmGroupLabel": [
                              "Treatment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152160"
                        ]
                  },
                  {
                        "Rank": 272,
                        "Acronym": [
                              "UCMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg at week 0,week 2,week 4,week 6,week 8 with a duration for treatment for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03745417"
                        ]
                  },
                  {
                        "Rank": 273,
                        "Acronym": [
                              "ANU"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Forty (40) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.",
                              "Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.",
                              "Eight (8) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allo-hMSCs",
                              "Drug: Placebo",
                              "Drug: Allo-hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic hMSCs",
                              "Placebo",
                              "Pilot - Allogeneic hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02675556"
                        ]
                  },
                  {
                        "Rank": 274,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton Jelly Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose 1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03751735"
                        ]
                  },
                  {
                        "Rank": 275,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will receive the implantation of autologous mesenchymal stem cell origin of adipose tissue with a dose of 2 x 50 million cells given with a distance of 1 month",
                              "This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord with a dose of 2 x 50 million cells given a distance of 1 month.",
                              "This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord as much as 2 x 50 million followed by 2 x 10cc mesenchymal stem cell secretions from adipose tissue intravenously given at a distance of 1 month."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose Mesenchymal Stem Cell Implantation",
                              "Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation",
                              "Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose MSC Group",
                              "Allogeneic Umbilical Cord MSC Group",
                              "Allogeneic Umbilical Cord MSC and Adipose Secretome Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04876326"
                        ]
                  },
                  {
                        "Rank": 276,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intervention Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01610440"
                        ]
                  },
                  {
                        "Rank": 277,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "5 subjects will receive AMSCs via direct injection into the kidney parenchyma only",
                              "5 subjects will receive AMSCs via intra-arterial infusion only",
                              "5 subjects will receive AMSCs via direct injection into the kidney parenchyma and intra-arterial infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic adipose derived mesenchymal stem cells",
                              "Drug: Allogeneic adipose derived mesenchymal stem cells",
                              "Drug: Allogeneic adipose derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra parenchymal injection",
                              "Intra-arterial infusion",
                              "Intra parenchymal injection & Intra-arterial infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04388761"
                        ]
                  },
                  {
                        "Rank": 278,
                        "Acronym": [
                              "MESEMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0",
                              "At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Drug: Suspension media"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Suspension media"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02403947"
                        ]
                  },
                  {
                        "Rank": 279,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "drug name and ingredients : RNL-Vascostem[Autologous adipose tissue derived mesenchymal stem cells] dosage : Intramuscular infusion, 5 x 10e6 cells/kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: RNL-Vascostem\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "RNL-Vascostem\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01302015"
                        ]
                  },
                  {
                        "Rank": 280,
                        "Acronym": [
                              "MESSAGE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00836732"
                        ]
                  },
                  {
                        "Rank": 281,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSC transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00813969"
                        ]
                  },
                  {
                        "Rank": 282,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months",
                              "Sham operation and 10ml saline as placebos, once a month for 4 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Mesenchymal Stem Cells",
                              "Drug: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03521323"
                        ]
                  },
                  {
                        "Rank": 283,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months",
                              "Placebo: Sham operation, 10ml saline, once a month for 4 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Mesenchymal Stem Cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03521336"
                        ]
                  },
                  {
                        "Rank": 284,
                        "Acronym": [
                              "STARTING-2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: Mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treatment",
                              "Standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01716481"
                        ]
                  },
                  {
                        "Rank": 285,
                        "Acronym": [
                              "ALOASCU"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic adipose tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic ASCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01914887"
                        ]
                  },
                  {
                        "Rank": 286,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "standard frailty treatment and supplementary medication"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells transplantation",
                              "Drug: standard frailty treatment and supplementary medication",
                              "Drug: standard frailty treatment and supplementary medication"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (UC-MSC trasnplatation)",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04919135"
                        ]
                  },
                  {
                        "Rank": 287,
                        "Acronym": [
                              "MSC-SAA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first agent MSC injection, began two weeks after ATG application; Each patient was injected three times, one time per week; Study on single dose tolerance and efficacy index; Each subjects received three dose groups of treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC+ATG"
                        ],
                        "ArmGroupLabel": [
                              "MSC+ATG"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02218437"
                        ]
                  },
                  {
                        "Rank": 288,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00314483"
                        ]
                  },
                  {
                        "Rank": 289,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1: Patients with allergic rhinitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells",
                              "Group 2: Patients with chronic polypous rhinosinusitis receiving standard treatment and olfactory mucosa-derived mesenchymal stem cells",
                              "Group 3: Patients with allergic rhinitis receiving standard treatment",
                              "Group 4: Patients with chronic polypous rhinosinusitis receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Olfactory mucosa-derived mesenchymal stem cells",
                              "Other: Standard treatment of type Allergic Rhinitis according to the clinical protocols",
                              "Biological: Olfactory mucosa-derived mesenchymal stem cells",
                              "Other: Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols",
                              "Other: Standard treatment of type Allergic Rhinitis according to the clinical protocols",
                              "Other: Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "Patients with allergic rhinitis receiving standard treatment and mesenchymal stem cells",
                              "Patients with chronic rhinosinusitis receiving standard treatment and mesenchymal stem cells",
                              "Patients with allergic rhinitis receiving standard treatment",
                              "Patients with chronic polypous rhinosinusitis receiving standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05167552"
                        ]
                  },
                  {
                        "Rank": 290,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will be treated in combination with hUC-MSC and DMARDs with a 12 months follow-up.",
                              "Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) with a 12 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hUC-MSC + DMARDs",
                              "Drug: DMARDs"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC + DMARDs",
                              "DMARDs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02643823"
                        ]
                  },
                  {
                        "Rank": 291,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Clinical case series"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Bone Marrow Aspiration",
                              "Procedure: Bone marrow mesenchymal stem cell implantation"
                        ],
                        "ArmGroupLabel": [
                              "Single"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00891501"
                        ]
                  },
                  {
                        "Rank": 292,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Intravitreal transplantation of mesenchymal stem cell",
                              "Biological: Culture and isolation of autologous bone-marrow mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC transplantion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02330978"
                        ]
                  },
                  {
                        "Rank": 293,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)",
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)",
                              "Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intra-articular injection of ADMSC",
                              "Biological: Intra-articular injection of ADMSC",
                              "Biological: Intra-articular injection of ADMSC"
                        ],
                        "ArmGroupLabel": [
                              "osteoarthritis of the knee",
                              "osteoarthritis of the hip",
                              "osteoarthritis of the glenohumeral joint"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03869229"
                        ]
                  },
                  {
                        "Rank": 294,
                        "Acronym": [
                              "MANT3_ASC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05011474"
                        ]
                  },
                  {
                        "Rank": 295,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: BCP with autologous mesenchymal stem cells (MSC)."
                        ],
                        "ArmGroupLabel": [
                              "Augmentation of new alveolar bone"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02751125"
                        ]
                  },
                  {
                        "Rank": 296,
                        "Acronym": [
                              "CSM/ON/2011"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.\n\nThey employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.\n\nPharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: bone marrow aspirate"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01700920"
                        ]
                  },
                  {
                        "Rank": 297,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.",
                              "MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.",
                              "MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2",
                              "3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00603330"
                        ]
                  },
                  {
                        "Rank": 298,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade umbilical cord mesenchymal stem cells (MSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: clinical grade umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "treatment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02277145"
                        ]
                  },
                  {
                        "Rank": 299,
                        "Acronym": [
                              "RA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.",
                              "Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).",
                              "Patients will be treated in combination with UC-MSC and DMARDS."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)",
                              "Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)",
                              "Biological: UC-MSC+DMARDS"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs Treatment",
                              "DMARDS",
                              "UC-MSC+DMARDS"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01547091"
                        ]
                  },
                  {
                        "Rank": 300,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of cycle 1 and MV-NIS infected MSC (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Laboratory Biomarker Analysis",
                              "Procedure: Mesenchymal Stem Cell Transplantation",
                              "Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (MV-NIS infected mesenchymal stem cells)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02068794"
                        ]
                  },
                  {
                        "Rank": 301,
                        "Acronym": [
                              "CELMA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Usual tratment for COVID-19 plus MSC",
                              "Usual treatment for COVID-19"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord derived mesenchymal stem cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04429763"
                        ]
                  },
                  {
                        "Rank": 302,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous mesenchymal stem cell transplantation",
                              "Procedure: Autologous mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "A",
                              "B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00476060"
                        ]
                  },
                  {
                        "Rank": 303,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis)",
                              "Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories)",
                              "Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis)",
                              "Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Hyaluronic Acid",
                              "Drug: Hyaluronic Acid",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell",
                              "Biological: Recombinant Human Somatropin",
                              "Drug: Hyaluronic Acid",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell",
                              "Drug: Hyaluronic Acid",
                              "Biological: Recombinant Human Somatropin"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Intervention 1",
                              "Intervention 2",
                              "Intervention 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03800810"
                        ]
                  },
                  {
                        "Rank": 304,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intranasal of 3 cc of conditioned medium each, for 3 days in a row and Intra-parenchymal transplantation of 20x10^6 UC-MSCs",
                              "Intra-parenchymal transplantation of 20x10^6 UC-MSCs",
                              "Neurologic and Neutrophic Drugs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Conditioned Medium",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Procedure: Neurologic and Neutrophic Drugs"
                        ],
                        "ArmGroupLabel": [
                              "Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment",
                              "Umbilical cord mesenchymal stem cells treatment",
                              "Standard treatment (control)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05008588"
                        ]
                  },
                  {
                        "Rank": 305,
                        "Acronym": [
                              "NEUROSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic mesenchymal stem cells from bone marrow"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: intravitreal injection of MSV"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem from valladolid (MSV)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03173638"
                        ]
                  },
                  {
                        "Rank": 306,
                        "Acronym": [
                              "CELEB"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion",
                              "3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hMSCs",
                              "Biological: hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02625246"
                        ]
                  },
                  {
                        "Rank": 307,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01540292"
                        ]
                  },
                  {
                        "Rank": 308,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00420134"
                        ]
                  },
                  {
                        "Rank": 309,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in group A will receive two autologous AD-MSC administrations on day 0 and day 90 \u00b1 7",
                              "Patients in group B will receive two autologous AD-MSC administrations on day 180 \u00b1 14 and day 270 \u00b1 14"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency",
                              "Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs infusions, then Placebo",
                              "Placebo, then AD-MSCs infusions"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05329662"
                        ]
                  },
                  {
                        "Rank": 310,
                        "Acronym": [
                              "Bmmsct"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Receive the best medication, percutaneous coronary intervention, and bone marrow mesenchymal stem cells transfer(Intracoronary artery )",
                              "Receive the best medication, percutaneous coronary intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow mesenchymal stem cells transfer",
                              "Drug: Best medical treatment",
                              "Procedure: Percutaneous coronary intervention",
                              "Drug: Best medical treatment",
                              "Procedure: Percutaneous coronary intervention"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04421274"
                        ]
                  },
                  {
                        "Rank": 311,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Instrumented posterolateral arthrodesis"
                        ],
                        "ArmGroupLabel": [
                              "MSC seeded onto a phosphate ceramic"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01513694"
                        ]
                  },
                  {
                        "Rank": 312,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.",
                              "1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.",
                              "1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC",
                              "Biological: MSC",
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC and the oral hypoglycemic drugs",
                              "MSC and insulins",
                              "MSC and the combination of drugs and insulins"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01413035"
                        ]
                  },
                  {
                        "Rank": 313,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) in two intravenous infusions of 100x10^6 cells at time zero and three months",
                              "Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) single intravenous infusion of 200x10^6 cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)",
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Dose Arm 1",
                              "Dose Arm 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05362786"
                        ]
                  },
                  {
                        "Rank": 314,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous transplantation of autologous bone marrow mesenchymal stem cell plus conventional treatment include rehabilitation",
                              "Control group receive conventional stroke treatment that include rehabilitation"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Intravenous stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous stem cell transplantation",
                              "Conventional treatment"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02564328"
                        ]
                  },
                  {
                        "Rank": 315,
                        "Acronym": [
                              "BIOMAX"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSV treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSV treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01389661"
                        ]
                  },
                  {
                        "Rank": 316,
                        "Acronym": [
                              "MESCAFY"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Peripheral IV Infusion of 100 million MSCs at baseline and repeated at three months",
                              "Peripheral IV Infusion of 100 million MSCs at baseline and peripheral IV infusion of placebo at three months",
                              "Peripheral IV infusion of placebo at baseline and repeated at three months"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cells (MSCs)",
                              "Drug: Mesenchymal Stem Cells (MSCs)",
                              "Drug: Mesenchymal Stem Cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2",
                              "Group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05284604"
                        ]
                  },
                  {
                        "Rank": 317,
                        "Acronym": [
                              "MSV_allo"
                        ],
                        "AgreementOtherDetails": [
                              "The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.",
                              "Intraarticular injection of hyaluronic acid (60 mg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Allogenic mesenchymal stromal cells injection",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic mesenchymal stromal cells injection",
                              "Hyaluronic acid (Durolane)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01586312"
                        ]
                  },
                  {
                        "Rank": 318,
                        "Acronym": [
                              "MESAMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Genetic: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intervention arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01076920"
                        ]
                  },
                  {
                        "Rank": 319,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intra bronchial injection, Autologous MSCs transplantation derived bone marrow, 60millions cells, once"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous MSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSCs transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01758055"
                        ]
                  },
                  {
                        "Rank": 320,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects who receive a radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC)",
                              "Patients receive standard of care.",
                              "Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at time of first stage of BBF",
                              "Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at first and second stage of BBF",
                              "Subjects will receive placebo at first and second stage of BBF"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)",
                              "Biological: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)",
                              "Biological: Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Single dose AMSC treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula",
                              "No Treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula",
                              "Single dose AMSC treatment at first stage of brachiobasilic arteriovenous fistula",
                              "AMSC treatment at first and second stage of brachiobasilic arteriovenous fistula",
                              "Placebo treatment in brachiobasilic arteriovenous fistula"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02808208"
                        ]
                  },
                  {
                        "Rank": 321,
                        "Acronym": [
                              "MESAMI2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "injection of human albumin 4%",
                              "intramyocardial injection of 6.10e7 stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebo comparator",
                              "Drug: Autologous MSC from bone marrow"
                        ],
                        "ArmGroupLabel": [
                              "Placebo comparator",
                              "Autologous MSC from bone marrow"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02462330"
                        ]
                  },
                  {
                        "Rank": 322,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical mesenchymal stem cell (UC-MSCs) infusion",
                              "Drug: traditional therapy"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cell Infusion",
                              "traditional therapy control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01374854"
                        ]
                  },
                  {
                        "Rank": 323,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive MSCs as in the Pilot study.",
                              "Patients receive standard of care.",
                              "Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cell",
                              "Other: Best Practice",
                              "Biological: Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Phase II Arm I (mesenchymal stem cells)",
                              "Phase II Arm II (standard of care)",
                              "Pilot study (mesenchymal stem cells)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04565665"
                        ]
                  },
                  {
                        "Rank": 324,
                        "Acronym": [
                              "HOPE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A dose of 2x10^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.",
                              "Matching placebo will be administered IV on days 1, 3, 5 and 7 in all subjects."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NestaCell\u00ae",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "NestaCell\u00ae",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04315987"
                        ]
                  },
                  {
                        "Rank": 325,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit",
                              "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conventional plus MSC treatment",
                              "Drug: Conventional plus pacebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus MSC treatment",
                              "Conventional plus pacebo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01218464"
                        ]
                  },
                  {
                        "Rank": 326,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Adipose Tissue derived MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "AdMSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01643681"
                        ]
                  },
                  {
                        "Rank": 327,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1\u00d7106 huc-MSCs/kg body weight.",
                              "Received conventional treatment and 50 ml saline once per week for the first month and once per month for 6 months(9 times in total)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: huc-MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Conventional treatment, huc-MSCs",
                              "Conventional plus placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02223897"
                        ]
                  },
                  {
                        "Rank": 328,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01142856"
                        ]
                  },
                  {
                        "Rank": 329,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10^8 total HB-adMSC cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04228666"
                        ]
                  },
                  {
                        "Rank": 330,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Intravenousling (IV) AD-MSC in 10 patients with type 1 diabetes mellitus."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: adipose-derived messenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Adipose-derived messenchymal stem cell (AD-MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05308836"
                        ]
                  },
                  {
                        "Rank": 331,
                        "Acronym": [
                              "AMASCIS-02"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 patients will receive intravenous alogenic adipose tissue-derived stem cells in a single dose of one million cells per kg.",
                              "15 patients will receive a single intravenous placebo solution with the same appearance as the treatment group."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Alogenic adipose tissue-derived stem cells",
                              "Drug: Placebo solution"
                        ],
                        "ArmGroupLabel": [
                              "Treatment group",
                              "Placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04280003"
                        ]
                  },
                  {
                        "Rank": 332,
                        "Acronym": [
                              "OA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.",
                              "After arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.",
                              "Without arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.",
                              "Without arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome",
                              "Biological: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome",
                              "Biological: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome",
                              "Biological: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome"
                        ],
                        "ArmGroupLabel": [
                              "Arthroscopy + Booster",
                              "Arthroscopy + Pre-Conditioning",
                              "Non Arthroscopy + Booster",
                              "Non Arthroscopy + Pre-Conditioning"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314661"
                        ]
                  },
                  {
                        "Rank": 333,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The people in this group will receive intravenous MSCs 2 x 10^6/kg as a single dose and standardized treatment of acute ischemic stroke.",
                              "The people in this group will receive placebo and standardized treatment of acute ischemic stroke."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Other: standardized treatment",
                              "Biological: Placebo",
                              "Other: standardized treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04093336"
                        ]
                  },
                  {
                        "Rank": 334,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 treatment doses + 1 placebo 3 months apart",
                              "3 treatment doses 3 months apart",
                              "3 placebo doses 3 months apart"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC+placebo",
                              "Drug: MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC+placebo",
                              "MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04506073"
                        ]
                  },
                  {
                        "Rank": 335,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: fibroblast growth factor",
                              "Biological: Stem cell-derived derived pleiotropic factor"
                        ],
                        "ArmGroupLabel": [
                              "control group",
                              "experimental group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04235868"
                        ]
                  },
                  {
                        "Rank": 336,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "the patients with ALS who underwent intravenous injection of mesenchymal stem cell."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: intra venous injection of stem cell"
                        ],
                        "ArmGroupLabel": [
                              "stem cell reciepient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01759797"
                        ]
                  },
                  {
                        "Rank": 337,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation",
                              "Control group receive conventional stroke treatment that include rehabilitation"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: intracerebral stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "intracerebral stem cell transplantation",
                              "conventional treatment"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01714167"
                        ]
                  },
                  {
                        "Rank": 338,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02192749"
                        ]
                  },
                  {
                        "Rank": 339,
                        "Acronym": [
                              "MSCIMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: MSC Treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSC Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00395200"
                        ]
                  },
                  {
                        "Rank": 340,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose-Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "ADMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02544802"
                        ]
                  },
                  {
                        "Rank": 341,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with post collapse osteonecrosis.",
                              "This group will consist of patients who have concentrations of Mesenchymal Stem Cells in with pre-collapse osteonecrosis.",
                              "This control group will be selected in patients undergoing hip arthroscopy for femoral/acetabular impingement."
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Collapse ON group",
                              "Pre-collapse group",
                              "FAI group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02941666"
                        ]
                  },
                  {
                        "Rank": 342,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with ALS that underwent mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: intrathecal injection"
                        ],
                        "ArmGroupLabel": [
                              "stem cell reciepient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01771640"
                        ]
                  },
                  {
                        "Rank": 343,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01985464"
                        ]
                  },
                  {
                        "Rank": 344,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients undergoing a first liver transplantation. Beside receiving standard liver tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2",
                              "Patients undergoing a first kidney transplantation. Beside receiving standard kidney tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids associated with ant-IL-2 antibodies), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC Liver Transplantation",
                              "MSC Kidney Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01429038"
                        ]
                  },
                  {
                        "Rank": 345,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure",
                              "drug therapy according to Vietnamese MOHS procedure"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells transplantation",
                              "Drug: drug therapy according to Vietnamese MOHS procedure",
                              "Drug: drug therapy according to Vietnamese MOHS procedure"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (UC-MSC trasnplatation)",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04433104"
                        ]
                  },
                  {
                        "Rank": 346,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02034188"
                        ]
                  },
                  {
                        "Rank": 347,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Administration of autologous adipose derived SVF"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: AD-SVF"
                        ],
                        "ArmGroupLabel": [
                              "Deployment of AD-SVF"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04064879"
                        ]
                  },
                  {
                        "Rank": 348,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 \u00d7 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.",
                              "1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived MSCs",
                              "Drug: Compound betamethasone"
                        ],
                        "ArmGroupLabel": [
                              "Autologous adipose-derived MSCs",
                              "Compound betamethasone"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03279796"
                        ]
                  },
                  {
                        "Rank": 349,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive the treatment according to the treatment principle of severe and critical cases in \"Influenza diagnosis and treatment plan (2019 version)\"",
                              "Participants will receive intravenous infusion of definitive HUC-MSCs (1\u00d710^6 cells/Kg \u00d7 body weight(kg), which was selected by immunomodulatory assay through coculture with BV2 cell) on the basis of the routine treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Routine treatment",
                              "Biological: Human umbilical cord mesenchymal stem cells",
                              "Procedure: Routine treatment"
                        ],
                        "ArmGroupLabel": [
                              "Routine treatment group",
                              "HUC-MSCs adjuvant Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04282928"
                        ]
                  },
                  {
                        "Rank": 350,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00250302"
                        ]
                  },
                  {
                        "Rank": 351,
                        "Acronym": [
                              "MYSTEP1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Two doses of 1 x 10^6 MSCs/kg body weight:\n\nfirst administration intraoperatively via intraportal infusion\nsecond infusion via intravenous infusion on postoperative day 2 (+/- 1 day)\n\nStandard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment with Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02957552"
                        ]
                  },
                  {
                        "Rank": 352,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "stem cell transplant"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Stem Cell Product"
                        ],
                        "ArmGroupLabel": [
                              "stem cell product"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03259217"
                        ]
                  },
                  {
                        "Rank": 353,
                        "Acronym": [
                              "PROMETHEUS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells",
                              "Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells",
                              "Participants will receive placebo injections"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Lower dose mesenchymal stem cell (MSC) injection",
                              "Biological: Higher dose MSC injection",
                              "Genetic: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Lower dose mesenchymal stem cell (MSC) injection",
                              "Higher dose MSC injection",
                              "(3) Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00587990"
                        ]
                  },
                  {
                        "Rank": 354,
                        "Acronym": [
                              "PERISCOPE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.\n\nIn addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.\n\nPeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton\u00b4s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix .",
                              "The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton\u00b4s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.",
                              "Procedure: Surgery by sternotomy"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03798353"
                        ]
                  },
                  {
                        "Rank": 355,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects diagnosed with End Stage Renal Disease (ESRD) and are currently on hemodialysis therapy with planned creation of a new upper extremity arteriovenous fistula will receive Adipose Derived Mesenchymal Stem Cells treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Adipose Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04392206"
                        ]
                  },
                  {
                        "Rank": 356,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "at a dose of 1x1,000,000 hMSC/kg",
                              "at a dose of 5x1,000,000 hMSC/kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord blood-derived mesenchymal stem cells",
                              "Biological: Human umbilical cord blood-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00823316"
                        ]
                  },
                  {
                        "Rank": 357,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord-derived mesenchymal stem cell",
                              "Other: Comprehensive treatment"
                        ],
                        "ArmGroupLabel": [
                              "Comprehensive treatment plus UC-MSC treatment",
                              "Comprehensive treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03945487"
                        ]
                  },
                  {
                        "Rank": 358,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose derived, autologous mesenchymal stem cells (AD-MSCs) at a dose of 15 million or 30 million cells will be administered via intra-arterial delivery with interventional radiology to the inferior mesenteric artery in subjects with medically refractory ulcerative colitis."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose derived, autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04312113"
                        ]
                  },
                  {
                        "Rank": 359,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.",
                              "The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Osteoarthritis",
                              "Cartilage"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03477942"
                        ]
                  },
                  {
                        "Rank": 360,
                        "Acronym": [
                              "WJ-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "RP patients with progressive visual acuity and visual field loss: before stem cell application.",
                              "RP patients, after stem cell applications."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton's jelly derived mesenchymal stem cell",
                              "Biological: Wharton's jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Before application",
                              "After application"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04224207"
                        ]
                  },
                  {
                        "Rank": 361,
                        "Acronym": [
                              "KDD&MSV"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous bone marrow mesenchymal stem cells (MSV)"
                        ],
                        "ArmGroupLabel": [
                              "MSV autologous transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01183728"
                        ]
                  },
                  {
                        "Rank": 362,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10^6 cells at day 0 and month 3.",
                              "Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10^6 cells at day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions",
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Dose Arm 1",
                              "Dose Arm 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04869761"
                        ]
                  },
                  {
                        "Rank": 363,
                        "Acronym": [
                              "Keloid"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.",
                              "A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.",
                              "A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium",
                              "Biological: Conditioned Medium",
                              "Biological: Conditioned Medium",
                              "Biological: Triamcinolone Acetonide"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs + CM",
                              "CM + CM",
                              "Triamcinolon acetonide"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04326959"
                        ]
                  },
                  {
                        "Rank": 364,
                        "Acronym": [
                              "REPAIR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells Transplantation",
                              "Biological: Mesenchymal Stem Cells Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Conventional Therapy",
                              "Conventional Therapy with Add-On MSC therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04898088"
                        ]
                  },
                  {
                        "Rank": 365,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.",
                              "Received fibrin glue and normal saline.",
                              "Received only normal saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allogenic adipose stem cell injection",
                              "Biological: fibrin glue/normal saline injection",
                              "Biological: normal saline injection"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell group",
                              "Active control (fibrin glue) group",
                              "Control (normal saline )group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02298023"
                        ]
                  },
                  {
                        "Rank": 366,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion",
                              "Instrumented spinal fusion together with patient's bone iliac crest."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA",
                              "Standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01552707"
                        ]
                  },
                  {
                        "Rank": 367,
                        "Acronym": [
                              "MSV_LE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid",
                              "Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells (MSC)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells (MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03673748"
                        ]
                  },
                  {
                        "Rank": 368,
                        "Acronym": [
                              "UwmBmmscALS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Biological: Cell-based therapy of autologous bone marrow-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Biological: Cell-based therapy"
                        ],
                        "ArmGroupLabel": [
                              "Autologous BM-MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02881489"
                        ]
                  },
                  {
                        "Rank": 369,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients who will receive Autologous Mesenchymal Stem Cells from AdiposeTissue by Intrathecal injection of stem cells that will be performed 3 times.",
                              "Patients who will receive Autologous Mesenchymal Stem Cells from Bone marrow by Intrathecal injection of stem cells that will be performed 3 times."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Recipient of AT-MSC",
                              "Recipient of BM-MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02981576"
                        ]
                  },
                  {
                        "Rank": 370,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00447460"
                        ]
                  },
                  {
                        "Rank": 371,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells derived from bone marrow (BM-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Haploidentical MSCs derived from bone marrow"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04153630"
                        ]
                  },
                  {
                        "Rank": 372,
                        "Acronym": [
                              "GVHD-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01549665"
                        ]
                  },
                  {
                        "Rank": 373,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the local treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day. In the combined treatment group, 60 million umbilical cord MSCs were injected into the diseased intestinal mucosa on the first day; on the second day, 1 million cells/kg of body weight were administered intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "MSCs local treatment group/combined treatment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05262829"
                        ]
                  },
                  {
                        "Rank": 374,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01668576"
                        ]
                  },
                  {
                        "Rank": 375,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "a single-group, open, investigator-initiated clinical study\n\n: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: autologous adipose derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "a single, open clinical trial"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02338271"
                        ]
                  },
                  {
                        "Rank": 376,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Harvested tissue from the back (molar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.",
                              "Harvested tissue from the front (premolar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage."
                        ],
                        "ArmGroupInterventionName": [
                              "Diagnostic Test: progenitor potential of Gingival Mesenchymal cells",
                              "Diagnostic Test: progenitor potential of Gingival Mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "Progenitor Potential at Molar site",
                              "Progenitor Potential at Premolar site"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03570333"
                        ]
                  },
                  {
                        "Rank": 377,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eiligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: cord blood transplantation"
                        ],
                        "ArmGroupLabel": [
                              "cord blood transplant"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01092026"
                        ]
                  },
                  {
                        "Rank": 378,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on day 0 and placebo on month 6.",
                              "A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on month 6 and placebo on day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow autologous mesenchymal stem cells transplantation",
                              "Biological: Bone marrow autologous mesenchymal stem cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1",
                              "Arm 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02035514"
                        ]
                  },
                  {
                        "Rank": 379,
                        "Acronym": [
                              "THSW-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100mL human umbilical cord mesenchymal stem cell preparation, containing 2.5\u00d710^7 cells.",
                              "100mL human umbilical cord mesenchymal stem cell preparation, containing 5.0\u00d710^7 cells.",
                              "100mL human umbilical cord mesenchymal stem cell preparation, containing 1.0\u00d710^8 cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hUCMSCs",
                              "Biological: hUCMSCs",
                              "Biological: hUCMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Low-dose group",
                              "medium-dose group",
                              "High-dose group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05442437"
                        ]
                  },
                  {
                        "Rank": 380,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with hip joint osteoarthritis who underwent cell injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: stem cell injection"
                        ],
                        "ArmGroupLabel": [
                              "hip osteoarthritis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01499056"
                        ]
                  },
                  {
                        "Rank": 381,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1*10^7 Umbilical cord Mesenchymal Stem Cells (MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Umbilical cord MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord MSCs Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03181087"
                        ]
                  },
                  {
                        "Rank": 382,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord mesenchymal stem cells (1*10^6/kg cells): delivered via peripheral intravenous infusion.",
                              "Placebo:normal saline delivered via peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells\uff08HUC-MSCs\uff09",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "HUC-MSCs Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314011"
                        ]
                  },
                  {
                        "Rank": 383,
                        "Acronym": [
                              "CELLTOP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive a single dose of 100 million autologous, adipose derived mesenchymal stem cells. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous, Adipose derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Phase I"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03308565"
                        ]
                  },
                  {
                        "Rank": 384,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Routine rehabilitation treatments",
                              "Injection of UC-MSCs via the peripheral vein.",
                              "Injection of UC-MSCs via the intrathecal route.",
                              "Injection of UC-MSCs via the nasal route."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Control group",
                              "Procedure: UC-MSCs",
                              "Procedure: UC-MSCs",
                              "Procedure: UC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Intravenous UC-MSCs group",
                              "Intrathecal UC-MSCs group",
                              "Intranasal UC-MSCs group"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03414697"
                        ]
                  },
                  {
                        "Rank": 385,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01958502"
                        ]
                  },
                  {
                        "Rank": 386,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive NeuroRegen scaffold with mesenchymal stem cells transplantation after spinal cord injury.",
                              "Patients receive NeuroRegen scaffold with neural stem cells transplantation after spinal cord injury."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NeuroRegen scaffold/mesenchymal stem cells transplantation",
                              "Biological: NeuroRegen scaffold/neural stem cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "NeuroRegen scaffold/mesenchymal stem cells transplantation",
                              "NeuroRegen scaffold/neural stem cells transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02688049"
                        ]
                  },
                  {
                        "Rank": 387,
                        "Acronym": [
                              "UC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Targeted endoscopic delivery of remestemcel-L at a dose of 150 million cells into the submucosal layer of the colon wall at baseline.\n\nIf at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial).",
                              "Targeted endoscopic delivery of remestemcel-L at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.\n\nIf at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial).",
                              "Direct injection of normal saline into the submucosal layer of the colon wall.\n\nIf not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.\n\nIf at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Remestemcel-L",
                              "Drug: Remestemcel-L",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Remestemcel-L (150 million cells)",
                              "Remestemcel-L (300 million cells)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04543994"
                        ]
                  },
                  {
                        "Rank": 388,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients",
                              "Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients along with a supervised physical therapy program",
                              "Supervised physical therapy program without stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord derived Mesenchymal Stem Cells",
                              "Biological: Umbilical cord derived Mesenchymal Stem Cells",
                              "Other: Supervised physical therapy",
                              "Other: Supervised physical therapy"
                        ],
                        "ArmGroupLabel": [
                              "Injection of Umbilical cord derived UC- MSCs",
                              "injection of UC- MSCs and SPT",
                              "Supervised Physical Therapy (SPT)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03326505"
                        ]
                  },
                  {
                        "Rank": 389,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once",
                              "Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord tissue-derived mesenchymal stem cells",
                              "Biological: Human umbilical cord tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular knee injection of UC-MSC",
                              "IV injection of UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02237846"
                        ]
                  },
                  {
                        "Rank": 390,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients received Bone marrow mesenchymal stem cells (BMSC) plus standard treatment",
                              "Patients received standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis",
                              "Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis"
                        ],
                        "ArmGroupLabel": [
                              "BMSC group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02985346"
                        ]
                  },
                  {
                        "Rank": 391,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.",
                              "Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Treated group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02574585"
                        ]
                  },
                  {
                        "Rank": 392,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A group of 10 patients only will be subjected to electro-myogram test every 3 month and then follow up for their survival time without any cell therapy intervention.",
                              "A group of 10 patients will be take stem cells intra-thecally Dose: 1 million cells/kg for three times Intervals: Every 3 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Adipose derived Mesenchymal Stem cell"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02855112"
                        ]
                  },
                  {
                        "Rank": 393,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants who receive standard of care plus treatment with ex vivo cultured adult human mesenchymal stem cells.",
                              "Participants who receive standard of care and do not receive treatment with ex vivo cultured adult human mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Prochymal\u00ae",
                              "Drug: Standard of Care for GVHD",
                              "Drug: Placebo",
                              "Drug: Standard of Care for GVHD"
                        ],
                        "ArmGroupLabel": [
                              "Prochymal\u00ae",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00366145"
                        ]
                  },
                  {
                        "Rank": 394,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Maximal amount of MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02304588"
                        ]
                  },
                  {
                        "Rank": 395,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04657458"
                        ]
                  },
                  {
                        "Rank": 396,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion with hucMSCs, 9*10^7 cells, 30ml",
                              "Intravenous infusion with hucMSCs, 6*10^7 cells, 30ml",
                              "Intravenous infusion with hucMSCs, 3*10^7 cells, 30ml"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hucMSCs",
                              "Biological: hucMSCs",
                              "Biological: hucMSCs"
                        ],
                        "ArmGroupLabel": [
                              "High dose group",
                              "Medium dose group",
                              "Low dose group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03816852"
                        ]
                  },
                  {
                        "Rank": 397,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After randomization, patients will be allocated to receive conventional treatment:\n\nBasiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.\nIf after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR.",
                              "Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme). Dosage: 2x10E6/Kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: conventional treatment",
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "conventional treatment",
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02770430"
                        ]
                  },
                  {
                        "Rank": 398,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "conventional symptomatic treatments such as antiviral (oseltamivir), hormones, oxygen therapy, mechanical ventilation and other supportive therapies",
                              "On the basis of the above-mentioned conventional symptomatic treatment and supportive therapy, umbilical cord mesenchymal stem cells were given at 106/Kg body weight / time, once every 4 days for a total of 4 times. Peripheral intravenous infusion was given within 3 days of first admission"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Oseltamivir",
                              "Drug: hormones",
                              "Device: oxygen therapy",
                              "Drug: Oseltamivir",
                              "Drug: hormones",
                              "Device: oxygen therapy",
                              "Procedure: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04371601"
                        ]
                  },
                  {
                        "Rank": 399,
                        "Acronym": [
                              "MESERIC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Type 1 diabetic man\nAged from 18 to 50 years\nHaving a diabetes evolving for at least 10 years\nPresenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot\nPresenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)\nIIEF-5 score less than or equal to 10"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous Bone Marrow derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "arm treated with MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03361631"
                        ]
                  },
                  {
                        "Rank": 400,
                        "Acronym": [
                              "Disc_allo"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline",
                              "Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic Mesenchymal Stromal Cells",
                              "Drug: Mepivacaine"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic Mesenchymal Stromal Cells",
                              "Mepivacaine"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01860417"
                        ]
                  },
                  {
                        "Rank": 401,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic bone marrow-derived MSCs will be delivered intravenously.",
                              "Allogeneic bone marrow-derived MSCs will be delivered intravenously.",
                              "Allogeneic bone marrow-derived MSCs will be delivered intravenously.",
                              "Allogeneic bone marrow-derived MSCs will be delivered intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)",
                              "Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)",
                              "Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)",
                              "Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow-derived MSC transplantation (1 x 10 6 MSC/kg)",
                              "Bone marrow-derived MSC transplantation (3 x 10 6 MSC/kg)",
                              "Bone marrow-derived MSC transplantation (6 x 10 6 MSC/kg)",
                              "Bone marrow-derived MSC transplantation (10 x 10 6 MSC/kg)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02611167"
                        ]
                  },
                  {
                        "Rank": 402,
                        "Acronym": [
                              "MESRIX-SAFETY"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with intra-glandular Injections of allogeneic adipose derived stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adipose derived stem/stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic mesenchymal stem/stromal cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03874572"
                        ]
                  },
                  {
                        "Rank": 403,
                        "Acronym": [
                              "ADMSP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4\uff0cweek 8 with a duration for treatment for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03265613"
                        ]
                  },
                  {
                        "Rank": 404,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single subtenon injection of Wharton jelly-derived mesenchymal stem cells will be performed on a single eye after randomization",
                              "Single subtenon injection of mesenchymal stem cell exosomes (Wharton jelly-derived)will be performed on a single eye after randomization.",
                              "A single subtenon injection of saline will be performed on a single eye after randomization."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cells",
                              "Biological: Subtenon injection of Wharton jelly derived mesenchymal stem cell exosomes",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Wharton jelly-derived mesenchymal stem cell",
                              "Mesenchymal stem cell exosome (Wharton jelly-derived)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05413148"
                        ]
                  },
                  {
                        "Rank": 405,
                        "Acronym": [
                              "LipAge"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose tissue collection and Transdermal injection of the filler agent, composed of mesenchymal stem cells derived from the autologous adipose tissue, associated with hyaluronic acid.",
                              "Transdermal injection of hyaluronic acid only."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Adipose tissue collection",
                              "Biological: Transdermal injection",
                              "Procedure: Transdermal injection"
                        ],
                        "ArmGroupLabel": [
                              "Test",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02034786"
                        ]
                  },
                  {
                        "Rank": 406,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "the ucMSCs suspension(3\u00d7 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube",
                              "Normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ucMSCs",
                              "Other: Normal saline"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01207869"
                        ]
                  },
                  {
                        "Rank": 407,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UCMSCs + CM is administered via intrathecal injection",
                              "UCMSCs is administered via intrathecal injection",
                              "Physiotherapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: Conditioned Medium",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Other: Standard Therapy"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs + CM",
                              "UCMSCs",
                              "Standard Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314687"
                        ]
                  },
                  {
                        "Rank": 408,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cellular therapy : injection of mesenchymal stem cells subjected to hepatogenic induction"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cellular therapy"
                        ],
                        "ArmGroupLabel": [
                              "Cellular therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02108132"
                        ]
                  },
                  {
                        "Rank": 409,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Targeted endoscopic delivery of remestemcel-L, at a dose of 150 million cells into the submucosal layer of the colon wall at baseline\n\nIf at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)",
                              "Targeted endoscopic delivery of remestemcel-L, at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.\n\nIf at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial).",
                              "Direct injection of normal saline into the submucosal layer of the colon wall. If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L, at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.\n\nIf at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Remestemcel-L",
                              "Drug: Remestemcel-L",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "remestemcel-L (150 million cells)",
                              "remestemcel-L (300 million cells)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04548583"
                        ]
                  },
                  {
                        "Rank": 410,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of autologous bone marrow-derived mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous bone marrow-derived mesenchymal stem cells."
                        ],
                        "ArmGroupLabel": [
                              "Safety"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01162915"
                        ]
                  },
                  {
                        "Rank": 411,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 intravenous infusions of suspension of 200 000 000 MSCs each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.",
                              "2 intravenous infusions of 400 mL saline each at interval of 7 days. Infusions will be repeated every 3 months for 1 year."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone marrow mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSCs",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02594839"
                        ]
                  },
                  {
                        "Rank": 412,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.",
                              "The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.",
                              "The patients will be assigned to the control group."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SLE group",
                              "Biological: LN group",
                              "Other: the control group"
                        ],
                        "ArmGroupLabel": [
                              "SLE group",
                              "LN group",
                              "the control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03458156"
                        ]
                  },
                  {
                        "Rank": 413,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human amniotic mesenchymal stem cells (hAMSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Human amniotic mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Uremic Calciphylaxis Patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04592640"
                        ]
                  },
                  {
                        "Rank": 414,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hMSC-Exos low-dose group",
                              "hMSC-Exos medium-dose group",
                              "hMSC-Exos high-dose group",
                              "basic treatment+hMSC-Exos (a quarter of MTD/day)",
                              "basic treatment+hMSC-Exos (MTD/day)",
                              "basic treatment+normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: low dose hMSC-Exos",
                              "Biological: medium dose hMSC-Exos",
                              "Biological: high dose hMSC-Exos",
                              "Biological: Dosage 1of hMSC-Exos",
                              "Biological: Dosage 2 of hMSC-Exos",
                              "Biological: No hMSC-derived exosomes"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1: hMSC-Exos low dose",
                              "Phase 1: hMSC-Exos medium dose",
                              "Phase 1: hMSC-Exos high dose",
                              "Phase 2: hMSC-Exos dosage 1",
                              "Phase 2: hMSC-Exos dosage 2",
                              "Phase 2: control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04602104"
                        ]
                  },
                  {
                        "Rank": 415,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1: Participants will receive a single intrathecal dose of 1 \u00d7 10(7) mesenchymal stem cells (MSCs)",
                              "Group 2: Participants will receive one intrathecal dose of 5 \u00d7 10(7) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 5 \u00d7 10(7) MSCs approximately one month later",
                              "Group 3: Participants will receive one intrathecal dose of 1 \u00d7 10(8) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 1 \u00d7 10(8) MSCs approximately one month later",
                              "Group 4: Participants will receive up to 10 doses of 5 x 10(7) (\u00b120%) mesenchymal stem cells (MSCs) approximately 6 months apart.",
                              "Group 5: Participants will receive up to 10 doses of 2.5 x 10(7) (\u00b120%) mesenchymal stem cells (MSCs) approximately 6 months apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells",
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "1 dose of 1 \u00d7 10(7) MSCs",
                              "2 doses of 5 \u00d7 10(7) MSCs",
                              "2 doses of 1 \u00d7 10(8) MSCs",
                              "10 doses of 5 x 10(7) (\u00b120%) MSCs",
                              "10 doses of 2.5 x 10(7) (\u00b120%) MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02315027"
                        ]
                  },
                  {
                        "Rank": 416,
                        "Acronym": [
                              "AMSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "implantation group will receive MSC and HA-CaSo4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "implantation group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02307435"
                        ]
                  },
                  {
                        "Rank": 417,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive 25 x 10^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.",
                              "Patients will undergo marrow cellution surgical procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Procedure: Marrow cellution"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Marrow cellution (standard treatment)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05016011"
                        ]
                  },
                  {
                        "Rank": 418,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stem cells",
                              "Lactated Ringer's Solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02833792"
                        ]
                  },
                  {
                        "Rank": 419,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Biological: placebo"
                        ],
                        "ArmGroupLabel": [
                              "group 1",
                              "group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03237442"
                        ]
                  },
                  {
                        "Rank": 420,
                        "Acronym": [
                              "DMT1-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "DMT1+MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02893306"
                        ]
                  },
                  {
                        "Rank": 421,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 2 x 106/ml concentrated solution",
                              "High dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 4 x 106/ml concentrated solution",
                              "Comparative analysis of psychometric and morphometric based data"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC Treatment group 1 (low dose)",
                              "Drug: MSC Treatment group 2 (high dose)",
                              "Other: Healthy Control (no treatment)"
                        ],
                        "ArmGroupLabel": [
                              "MSC treatment group 1",
                              "MSC treatment group 2",
                              "Healthy Control (no treatment)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03692221"
                        ]
                  },
                  {
                        "Rank": 422,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "ex vivo cultured adult mesenchymal stem cells",
                              "ex vivo cultured adult mesenchymal stem cells",
                              "ex vivo cultured adult mesenchymal stem cells",
                              "ex vivo cultured adult mesenchymal stem cells",
                              "ex vivo cultured adult mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Provacel",
                              "Biological: Provacel",
                              "Biological: Provacel",
                              "Biological: Provacel",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Provacel: Cohort 1",
                              "Provacel: Cohort 2",
                              "Provacel: Cohort 3",
                              "Provacel: Cohort 4",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00114452"
                        ]
                  },
                  {
                        "Rank": 423,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment and then be followed until the week 48 study visit.",
                              "Participants will receive conventional treatment plus a dose of UC-MSC and then be followed until the week 48 study visit.",
                              "Participants will receive conventional treatment plus plasma exchange and then be followed until the week 48 study visit.",
                              "Participants will receive conventional treatment plus umbilical cord mesenchymal stem cells transplantation combined with plasma exchange. Participants will then be followed until the week 48 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Conventional treatment",
                              "Other: Conventional plus UC-MSC treatment",
                              "Other: Conventional plus PE treatment",
                              "Other: Conventional plus UC-MSC and PE therapy"
                        ],
                        "ArmGroupLabel": [
                              "Conventional treatment",
                              "Conventional plus UC-MSC treatment",
                              "Conventional plus PE treatment",
                              "Conventional plus UC-MSC and PE therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01724398"
                        ]
                  },
                  {
                        "Rank": 424,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention in the form of Dental Implants placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix a biological material procured from patient's peripheral blood",
                              "Intervention in the form of Dental Implant placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix and peripheral blood mesenchymal stem cells which are the biological materials procured from patient's peripheral blood"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Dental Implant with PRFM",
                              "Biological: Dental Implant with PRFM and PBMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Dental Implant with PRFM",
                              "Dental Implant with PRFM and PBMSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03044119"
                        ]
                  },
                  {
                        "Rank": 425,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Group 1",
                              "Other: Group 2",
                              "Other: Group 3"
                        ],
                        "ArmGroupLabel": [
                              "Group A"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01322906"
                        ]
                  },
                  {
                        "Rank": 426,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Local transplantation stem cell preparation combined with silver ion dressing",
                              "Local trantment with silver ion dressing"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: silver ion dressing",
                              "Other: stem cell preparation combined with silver ion dressing"
                        ],
                        "ArmGroupLabel": [
                              "experimental group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05319106"
                        ]
                  },
                  {
                        "Rank": 427,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous MMSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Study group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04146519"
                        ]
                  },
                  {
                        "Rank": 428,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01213953"
                        ]
                  },
                  {
                        "Rank": 429,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01323894"
                        ]
                  },
                  {
                        "Rank": 430,
                        "Acronym": [
                              "BPI+MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient will receive nerve transfer procedure without augmentation",
                              "Following nerve transfer procedure, the end-to-end anastomosis will be wrapped with HAM-AdMSC composite as augmentation"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Nerve transfer procedure",
                              "Procedure: Nerve transfer with HAM-AdMSC composite wrapping"
                        ],
                        "ArmGroupLabel": [
                              "Control group (Nerve transfer procedure)",
                              "Experimental group (Nerve transfer with HAM-AdMSC composite wrapping)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04654286"
                        ]
                  },
                  {
                        "Rank": 431,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in group A will receive GMSCs seeded into collagen scaffolds at the local periodontal defects immediately after open flap debridement.",
                              "Patients in group B will receive collagen scaffolds implantation at the local periodontal defects immediately after open flap debridement.",
                              "Patients in comparator group will only undergo an open flap debridement."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: GMSCs and collagen scaffolds",
                              "Biological: Collagen scaffolds",
                              "Procedure: Open flap debridement"
                        ],
                        "ArmGroupLabel": [
                              "Group A: GMSCs and collagen scaffolds",
                              "Group B: collagen scaffolds",
                              "Group C: comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03137979"
                        ]
                  },
                  {
                        "Rank": 432,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05187936"
                        ]
                  },
                  {
                        "Rank": 433,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs group refers to treatment with mesenchymal stem cells (1\u00d710^6 cells/kg, intravenously) weekly for 8 doses. Besides, glucocorticoids and cyclosporine (CsA) will be used for treatment concurrently.",
                              "Glucocorticoids and CsA will be used for treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Drug: Glucocorticoids",
                              "Drug: cyclosporine",
                              "Drug: Glucocorticoids",
                              "Drug: cyclosporine"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04692376"
                        ]
                  },
                  {
                        "Rank": 434,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive allogeneic hMSCs IV over 10-20 minutes once weekly for 4 weeks and standard of care drugs for heart failure.",
                              "Patients receive only standard of care drugs for heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Laboratory Biomarker Analysis",
                              "Other: Standard of Care",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Laboratory Biomarker Analysis",
                              "Other: Standard of Care",
                              "Drug: Mesenchymal Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Arm I (hMSCs)",
                              "Arm II (standard of care drugs)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02408432"
                        ]
                  },
                  {
                        "Rank": 435,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.",
                              "This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection",
                              "Procedure: arthroscopy of the affected knee/ Bone Marrow Concentrate Injection"
                        ],
                        "ArmGroupLabel": [
                              "arthroscopy with removal of calcified cartilage",
                              "arthroscopy without removal of calcified cartilage"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03648463"
                        ]
                  },
                  {
                        "Rank": 436,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "placenta-MSCs derived exosomes Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. These vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti-inflammatory properties by using paracrine effects. Exosomes, as a vehicle for signaling, are responsible for a significant part of cell-to-cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC-derived exosome treatment on various fistulas and inflammatory bowel disease. In this study, we aimed to evaluate the safety and effectiveness of PlacentaMSCs derived exosomes in the treatment of patients with complex preanal fistula (Crohn's) in phases I and II of the clinical trial",
                              "placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: placenal MSC derived exosomes",
                              "Other: placenal MSC derived exosomes"
                        ],
                        "ArmGroupLabel": [
                              "exosome therapy",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05499156"
                        ]
                  },
                  {
                        "Rank": 437,
                        "Acronym": [
                              "MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Our intervention is to add treatment of exosomes derived from mesenchymal stem cells (MSC-Exo) after pars plana vitrectomy(PPV) and ILM peeling.",
                              "Control group that receives treatment of only pars plana vitrectomy(PPV) and ILM peeling."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: exosomes derived from mesenchymal stem cells (MSC-Exo)"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03437759"
                        ]
                  },
                  {
                        "Rank": 438,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.",
                              "The control group received intra-articular injection of sodium hyaluronate one month after operation."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous Adipose-derived Mesenchymal Stem Cell Gel",
                              "Procedure: Extraction of abdominal fat",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose-derived Mesenchymal Stem Cell Gel",
                              "sodium hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03955497"
                        ]
                  },
                  {
                        "Rank": 439,
                        "Acronym": [
                              "Alaunus"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.",
                              "Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: allogeneic human mesenchymal stem cells (allo-hMSCs)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic human mesenchymal stem cells (allo-hMSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03265808"
                        ]
                  },
                  {
                        "Rank": 440,
                        "Acronym": [
                              "RanoKure"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.",
                              "Conventional endodontic procedure"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Regenerative Endodontic Procedure",
                              "Procedure: Conventional Root Canal Treatment"
                        ],
                        "ArmGroupLabel": [
                              "Regenerative Endodontic Procedure (REP)",
                              "Conventional Root Canal Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT03102879"
                        ]
                  },
                  {
                        "Rank": 441,
                        "Acronym": [
                              "CRATUS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
                              "Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
                              "Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
                              "Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.",
                              "Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.",
                              "Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.",
                              "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Placebo",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Pilot phase - Group 1",
                              "Pilot Phase - Group 2",
                              "Pilot Phase - Group 3",
                              "Randomized Phase - Group A",
                              "Randomized phase - Group B",
                              "Randomized Phase - Group C",
                              "Addendum B - Antibiotic free cell Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02065245"
                        ]
                  },
                  {
                        "Rank": 442,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive Prochymal\u00ae consisting of 2 million hMSCs/kg actual body weight, intravenously (IV) on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 milligrams (mg)/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.",
                              "Participants will receive Prochymal\u00ae consisting of 8 million hMSCs/kg actual body weight IV on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 mg/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Prochymal\u00ae - 2 Million cells/kg",
                              "Drug: Methylprednisolone",
                              "Drug: Prednisone",
                              "Drug: Cyclosporine",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil",
                              "Drug: Prochymal\u00ae- 8 Million cells/kg",
                              "Drug: Methylprednisolone",
                              "Drug: Prednisone",
                              "Drug: Cyclosporine",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil"
                        ],
                        "ArmGroupLabel": [
                              "Prochymal\u00ae - 2 Million cells/kg",
                              "Prochymal\u00ae - 8 Million cells/kg"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00136903"
                        ]
                  },
                  {
                        "Rank": 443,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal stem cells (UCMSC) expanded and treated for 1-2 weeks. Then administer 5x10^6 of UCMSC per cm^2 of the cartilage defect.",
                              "Administer hyaluronic acid (30 mg) in a single injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells",
                              "Device: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treatment",
                              "Hyaluronic acid treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02776943"
                        ]
                  },
                  {
                        "Rank": 444,
                        "Acronym": [
                              "CHAMP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Amputation performed at 7 days post allogeneic bone marrow derived mesenchymal stem cell injections.",
                              "Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.",
                              "Tissue Collection Group:\n\nAmputation performed with no MSC administration. Subjects will not be followed after amputation is performed. Tissue collection will occur at time of amputation.",
                              "Patients undergoing lower extremity bypass grafting procedure. Skeletal muscle samples of the sartorius and anterior tibial muscle will be collected for comparison to treatment group. No study testing, nor follow up visits will occur.",
                              "Patients undergoing a standard of care surgical procedure under anesthesia. Core needle biopsies will be collected from the anterior tibial muscle at the time of surgical procedure. No study testing, nor follow up visits will occur."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Active/Treatment Group",
                              "Observation Group 1",
                              "Observation Group 2",
                              "Observation Group 3",
                              "Control Group 4"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention",
                              "No Intervention",
                              "No Intervention",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02685098"
                        ]
                  },
                  {
                        "Rank": 445,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cell, HA-CaSO4, \u00acBMP-2, and Implant"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cell, HA-CaSO4, \u00acBMP-2, and Implant"
                        ],
                        "ArmGroupLabel": [
                              "Stemcell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01725698"
                        ]
                  },
                  {
                        "Rank": 446,
                        "Acronym": [
                              "MSC in IPF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placental MSC",
                              "Placental MSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Placental MSC",
                              "Other: Placental MSC"
                        ],
                        "ArmGroupLabel": [
                              "1*10^6 MSC / kg",
                              "2*10^6 MSC / kg"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01385644"
                        ]
                  },
                  {
                        "Rank": 447,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three doses of Neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy",
                              "Three doses of concentrated paracrine factors of human mesenchymal stem cell \uff080.5ml\uff09 intrathecally at 12h,24h,48h after birth.+routine therapy",
                              "Three doses of concentrated paracrine factors 0.5ml intrathecally at 12h,24h,48h after birth.And three doses of neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy",
                              "neonates only receive routine therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: neural progenitor cell",
                              "Biological: Paracrine factors",
                              "Biological: progenitor cell and paracrine factors"
                        ],
                        "ArmGroupLabel": [
                              "Neural progenitor cell",
                              "Paracrine factors",
                              "Progenitor cell and paracrine factors",
                              "Routine therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02854579"
                        ]
                  },
                  {
                        "Rank": 448,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in the MSC arm will be given MSC, i.v., 1000000 cells per kilogram of body weight.",
                              "Patients in the control arm will not be given MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03552848"
                        ]
                  },
                  {
                        "Rank": 449,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.",
                              "This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose",
                              "Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose"
                        ],
                        "ArmGroupLabel": [
                              "Lower Dose MSC",
                              "Higher Dose MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03840343"
                        ]
                  },
                  {
                        "Rank": 450,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "High concentration of Allo-ASC 0.5cc (Total: 10 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection",
                              "Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection",
                              "Normal saline 0.5cc & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: High concentration of Allo-ASC",
                              "Drug: Fibrin glue",
                              "Biological: Low concentration of Allo-ASC",
                              "Drug: Fibrin glue",
                              "Drug: Fibrin glue",
                              "Drug: Normal saline"
                        ],
                        "ArmGroupLabel": [
                              "High concentration of Allo-ASC group",
                              "Low concentration of Allo-ASC group",
                              "Placebo Comparator (Fibrin) group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03449082"
                        ]
                  },
                  {
                        "Rank": 451,
                        "Acronym": [
                              "Implant_bone"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.",
                              "In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Biocomplex: aBM-MSCs/fibrin glue/collagen fleece",
                              "Procedure: Two-stage surgical implant placement"
                        ],
                        "ArmGroupLabel": [
                              "Group-A",
                              "Control Group-B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03070275"
                        ]
                  },
                  {
                        "Rank": 452,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC and PRP"
                        ],
                        "ArmGroupLabel": [
                              "MSC and PRP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03484741"
                        ]
                  },
                  {
                        "Rank": 453,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1: Low-dose BC-U001 Cohort 2: Medium-dose BC-U001 Cohort 3: High-dose BC-U001"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: hUC-MSC infusion (BC-U001)"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC infusion (BC-U001)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04971980"
                        ]
                  },
                  {
                        "Rank": 454,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra Articular injection in Patients with osteoarthritis of knee joint"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Injection"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01207661"
                        ]
                  },
                  {
                        "Rank": 455,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional standard therapy and control saline spray",
                              "Conventional standard therapy and fibrin spray",
                              "Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Stem Cell",
                              "Genetic: Stem Cell",
                              "Genetic: Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Standard therapy and control saline spray",
                              "standard therapy and fibrin spray",
                              "Conventional standard therapy and MSCs"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Sham Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01751282"
                        ]
                  },
                  {
                        "Rank": 456,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of 2\u00d710~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)",
                              "Intraarticular injection of hyaluronic acid"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical-cord mesenchymal stromal cells (UC-MSCs)",
                              "Other: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03166865"
                        ]
                  },
                  {
                        "Rank": 457,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Adipose Tissue derived MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue Derived MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01643655"
                        ]
                  },
                  {
                        "Rank": 458,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Adipose Tissue derived MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue derived MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01769872"
                        ]
                  },
                  {
                        "Rank": 459,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with crohn's disease who underwent mesenchymal cell and fibroblast injection.",
                              "The patients with Crohn's disease who underwent mesenchymal cell transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal cell and fibroblast injection",
                              "Biological: mesenchymal cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal cell and fibroblast transplantaion",
                              "mesenchymal cell transplantaion"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01874015"
                        ]
                  },
                  {
                        "Rank": 460,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Symptoms and Objective Examination"
                        ],
                        "ArmGroupLabel": [
                              "Symptoms and Objective Examination"
                        ],
                        "ArmGroupType": [
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00955669"
                        ]
                  },
                  {
                        "Rank": 461,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intramuscular injection"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02208713"
                        ]
                  },
                  {
                        "Rank": 462,
                        "Acronym": [
                              "AMSC_UC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "interventions: The MSCs of 5\u00d710*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week\uff0ca total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used",
                              "interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose-cord mesenchymal stromal cells (A-MSCs)",
                              "Other: Conventional drugs",
                              "Other: Conventional drugs"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03609905"
                        ]
                  },
                  {
                        "Rank": 463,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2.5 x 10^6 MSC per kg will be infused intravenously on Day 1",
                              "Plasmalyte with 0.5% Human Serum Albumin will be infused intravenously on Day 1"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSCs)",
                              "Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)"
                        ],
                        "ArmGroupLabel": [
                              "Group A Treatment",
                              "Group B Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04061746"
                        ]
                  },
                  {
                        "Rank": 464,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.",
                              "Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Auotologous BMSCs plus autologous PRP",
                              "Biological: Auotologous PRP"
                        ],
                        "ArmGroupLabel": [
                              "BMSCs plus PRP group",
                              "PRP group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03969680"
                        ]
                  },
                  {
                        "Rank": 465,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous infusion and intrathecal injection (total of 100 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152290"
                        ]
                  },
                  {
                        "Rank": 466,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: conventional therapy plus low dose hUC-MSCs treatment",
                              "Biological: conventional therapy plus medium dose hUC-MSCs treatment",
                              "Biological: conventional therapy plus high dose hUC-MSCs treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus hUC-MSCs treatment (low dose)",
                              "conventional therapy plus hUC-MSCs treatment \uff08medium dose\uff09",
                              "conventional therapy plus hUC-MSCs treatment \uff08high dose\uff09"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01342250"
                        ]
                  },
                  {
                        "Rank": 467,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) with fibrin glue injection to the anal sphincter",
                              "0.9% normal saline with fibrin glue injection to the anal sphincter"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC injection",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC group",
                              "Normal saline group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02384499"
                        ]
                  },
                  {
                        "Rank": 468,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous infusion and intralesional injection of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158127"
                        ]
                  },
                  {
                        "Rank": 469,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The study is designed to examine the safety of administering EVs derived from allogeneic MSCs to 2nd degree burn wounds of less than 20% TBSA. The study will consist of a single dose level which will evaluate the safety of administering allogeneic Extracellular Vesicles-with a total of 10 patients. The chosen dosage will correlate to a dose of MSCs administered under another protocol (IND 14810). The dose level delivered will be EVs derived from approximately 1 X 104 MSCs for each cm2 treated area not to exceed 20% TBSA in total (cumulative, if more than one area is treated). The limitation in wound sizes to be treated will not change throughout the study. Up to 2 additional administrations of EVs will be given over a period of no more than 8 weeks. The first treatment will be administered within 48 hours of the burn injury. The subsequent treatments will be administered no less than 7 days and no more than 6 weeks apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AGLE-102"
                        ],
                        "ArmGroupLabel": [
                              "AGLE-102"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05078385"
                        ]
                  },
                  {
                        "Rank": 470,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion and intraarticular injection (total dose of 100 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147675"
                        ]
                  },
                  {
                        "Rank": 471,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "CVA patients who have disability, will receive total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis/Intraparanchymal"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: exosome"
                        ],
                        "ArmGroupLabel": [
                              "exosome or vesicle"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03384433"
                        ]
                  },
                  {
                        "Rank": 472,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous and sub-tenon delivery (total dose of 100 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147701"
                        ]
                  },
                  {
                        "Rank": 473,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head",
                              "Isolated core decompression"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA",
                              "Standard Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01605383"
                        ]
                  },
                  {
                        "Rank": 474,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158933"
                        ]
                  },
                  {
                        "Rank": 475,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158101"
                        ]
                  },
                  {
                        "Rank": 476,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003960"
                        ]
                  },
                  {
                        "Rank": 477,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158439"
                        ]
                  },
                  {
                        "Rank": 478,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived mesenchymal stem cells",
                              "Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment plus adipose-derived limbal stem cells",
                              "Patients with inflammatory-dystrophic diseases of the cornea receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Other: standard treatment",
                              "Biological: limbal stem cells",
                              "Other: standard treatment",
                              "Other: standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "limbal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04484402"
                        ]
                  },
                  {
                        "Rank": 479,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018858"
                        ]
                  },
                  {
                        "Rank": 480,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003908"
                        ]
                  },
                  {
                        "Rank": 481,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147766"
                        ]
                  },
                  {
                        "Rank": 482,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152394"
                        ]
                  },
                  {
                        "Rank": 483,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018819"
                        ]
                  },
                  {
                        "Rank": 484,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04855955"
                        ]
                  },
                  {
                        "Rank": 485,
                        "Acronym": [
                              "AUB001"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04642911"
                        ]
                  },
                  {
                        "Rank": 486,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152381"
                        ]
                  },
                  {
                        "Rank": 487,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003388"
                        ]
                  },
                  {
                        "Rank": 488,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147688"
                        ]
                  },
                  {
                        "Rank": 489,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018832"
                        ]
                  },
                  {
                        "Rank": 490,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018767"
                        ]
                  },
                  {
                        "Rank": 491,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05016804"
                        ]
                  },
                  {
                        "Rank": 492,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018845"
                        ]
                  },
                  {
                        "Rank": 493,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003947"
                        ]
                  },
                  {
                        "Rank": 494,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05016817"
                        ]
                  },
                  {
                        "Rank": 495,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "three intrathecal injections of 50 million cells at two-month intervals."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003921"
                        ]
                  },
                  {
                        "Rank": 496,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003934"
                        ]
                  },
                  {
                        "Rank": 497,
                        "Acronym": [
                              "WJ-MSC-AMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton's jelly- Derived Mesenchymal Stem Cells Transfer"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: intracoronary human umbilical WJ-MSC transfer"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01291329"
                        ]
                  },
                  {
                        "Rank": 498,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158114"
                        ]
                  },
                  {
                        "Rank": 499,
                        "Acronym": [
                              "MSC-COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ex vivo expanded Wharton's Jelly derived mesenchymal stem cells will be infused at day 0, day 3 and day 5 (+/- 1 day), in patients with moderate to severe ARDS with a mechanical ventilation.\n\nday 0: 1.10^6 MSC/kg day 3: 0.5. 10^6 MSC/kg day 5: 0.5 . 10^6 MSC/kg",
                              "Only the vehicle solution, without MSCs, containing albumin 4% , NaCl 0,9% and ACD will be injected to patients at day 0, 3 and 5 (+/-1 day)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC Arm",
                              "Placebo Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04625738"
                        ]
                  },
                  {
                        "Rank": 500,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05093725"
                        ]
                  },
                  {
                        "Rank": 501,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01274975"
                        ]
                  },
                  {
                        "Rank": 502,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment plus BM-MSCs",
                              "Conventional treatment plus placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MSCs",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04346368"
                        ]
                  },
                  {
                        "Rank": 503,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "91 patients will be involved in this group",
                              "91 patients will be involved in this group"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: hUC-MSCs",
                              "Other: glucocorticoids"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSCs combined with glucocorticoids group.",
                              "glucocorticoids group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05531266"
                        ]
                  },
                  {
                        "Rank": 504,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01300598"
                        ]
                  },
                  {
                        "Rank": 505,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic stem cells implantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01759212"
                        ]
                  },
                  {
                        "Rank": 506,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Calcipotriol ointment",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs plus Calcipotriol ointment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03392311"
                        ]
                  },
                  {
                        "Rank": 507,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive low-dose cell administration",
                              "Participants will receive medium-dose cell administration",
                              "Participants will receive high-dose cell administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCTC-0010",
                              "Biological: MSCTC-0010",
                              "Biological: MSCTC-0010"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose MSCTC-0010",
                              "Medium Dose MSCTC-0010",
                              "High Dose MSCTC-0010"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04385056"
                        ]
                  },
                  {
                        "Rank": 508,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)",
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)",
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)",
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)",
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: 1X level of MSCs-Exo",
                              "Biological: 2X level of MSCs-Exo",
                              "Biological: 4X level of MSCs-Exo",
                              "Biological: 6X level of MSCs-Exo",
                              "Biological: 8X level of MSCs-Exo"
                        ],
                        "ArmGroupLabel": [
                              "1X level",
                              "2X level",
                              "4X level",
                              "6X level",
                              "8X level"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04313647"
                        ]
                  },
                  {
                        "Rank": 509,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Corlicyte",
                              "Drug: Corlicyte",
                              "Drug: Corlicyte"
                        ],
                        "ArmGroupLabel": [
                              "Dose 1",
                              "Dose 2",
                              "Dose 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04104451"
                        ]
                  },
                  {
                        "Rank": 510,
                        "Acronym": [
                              "RIMECARD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord derived mesenchymal are injected intravenously to Patients.",
                              "Intravenous placebo solution are administrated to Patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ucMSC",
                              "Other: Controls"
                        ],
                        "ArmGroupLabel": [
                              "ucMSC",
                              "Controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01739777"
                        ]
                  },
                  {
                        "Rank": 511,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive standard of care plus 3 does of UC-MSCs",
                              "Participants will receive standard of care plus 3 does of placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Saline containing 1% Human serum albumin\uff08solution without UC-MSCs\uff09"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04288102"
                        ]
                  },
                  {
                        "Rank": 512,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "conventional treatment & antiviral treatment",
                              "Participants will receive umbilical cord derived mesenchymal stem cell treatment at day 1 and conventional treatment and antiviral treatment through the one year study visit. Participants will then be followed until one years study visit"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: conventional treatment",
                              "Other: UC-MSC transplantation"
                        ],
                        "ArmGroupLabel": [
                              "conventional",
                              "UC-MSC transplantation"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01728727"
                        ]
                  },
                  {
                        "Rank": 513,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC iv(2*10^6cell/kg, 48h before op)",
                              "Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)",
                              "Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC (iv 2*10^6cell/kg + ia 5*10^6cell, 48h before op)",
                              "Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)",
                              "Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)+MSC( iv 2*10^6cell/kg at d1,d7)",
                              "Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)",
                              "Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)+MSC( iv 2*10^6cell/kg at d1,d7)",
                              "Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell",
                              "Biological: mesenchymal stem cell",
                              "Biological: mesenchymal stem cell",
                              "Biological: mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "iv of BMSC to prevent rejection",
                              "routine treatment protocol to prevent rejection",
                              "ia and iv of MSC to prevent rejection",
                              "routine treatment to prevent rejection",
                              "Routine CMR treatment plus MSC to prevent CMR",
                              "Routine CMR treatment to prevent CMR",
                              "Routine AMR treatment plus MSC to prevent AMR",
                              "Routine AMR treatment to prevent AMR"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention",
                              "Experimental",
                              "No Intervention",
                              "Experimental",
                              "No Intervention",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02490020"
                        ]
                  },
                  {
                        "Rank": 514,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01624779"
                        ]
                  },
                  {
                        "Rank": 515,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1*10^7 Umbilical cord MSCs",
                              "1ml of 0.9% saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Umbilical cord MSCs",
                              "Other: 0.9% Saline"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord MSCs Group",
                              "Placebo-Controlled Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02968459"
                        ]
                  },
                  {
                        "Rank": 516,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects receive a safety evaluation at 1 month, 3 months, 6 months, 9 months and 12 months after intravenous infusion of Cellgram-CKD 10mL at intervals of 2 weeks (14 days) 3 times.\n\nIn the case of Cellgram-CKD, a milky white cell suspension solution is filled in a colorless and transparent plastic syringe, and the syringe tip is fixed with an obturator."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cellgram-CKD"
                        ],
                        "ArmGroupLabel": [
                              "Cellgram-CKD"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05042206"
                        ]
                  },
                  {
                        "Rank": 517,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conserved Therapy",
                              "Patients with liver cirrhosis will be randomly divided into three groups.\n\n1. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group.2. Umbilical cord MSCs will be infused to patients intravenously for another group. The control group will receive conserved therapy. The efficacy of different interventional therapies will be compared."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conserved Therapy",
                              "Procedure: Hepatic artery infusion or Intravenous infusion"
                        ],
                        "ArmGroupLabel": [
                              "Conserved Therapy",
                              "Interventional Therapy"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01233102"
                        ]
                  },
                  {
                        "Rank": 518,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after the onset of heart attack."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04056819"
                        ]
                  },
                  {
                        "Rank": 519,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide",
                              "Umbilical Cord Mesenchymal Stem Cell Infusion",
                              "Liraglutide",
                              "Standard Medical Treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: GLP-1",
                              "Biological: SC",
                              "Other: Standard Medical Treatment",
                              "Biological: SC",
                              "Other: Standard Medical Treatment",
                              "Drug: GLP-1",
                              "Other: Standard Medical Treatment",
                              "Other: Standard Medical Treatment"
                        ],
                        "ArmGroupLabel": [
                              "SC-GLP-1",
                              "SC",
                              "GLP-1",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01954147"
                        ]
                  },
                  {
                        "Rank": 520,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stempeucel - CLI will be administered at the lowest dose",
                              "Stempeucel - CLI will be administered at intermediate dose",
                              "Standard protocol of care alone"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Mesenchymal Stem Cells",
                              "Biological: Allogeneic Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Low dose",
                              "Intermediate dose",
                              "Control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01484574"
                        ]
                  },
                  {
                        "Rank": 521,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All the cases in this group are managed with skin grafting only. Every odd case are kept in skin grafting only group.",
                              "All the cases in this group are managed with skin grafting and application of stem cells. every even cases are kept in skin grafting and stem cells group."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cell application",
                              "Biological: mesenchymal stem cell application"
                        ],
                        "ArmGroupLabel": [
                              "skin grafting only",
                              "skin grafting and stem cell group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04219657"
                        ]
                  },
                  {
                        "Rank": 522,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This arm will receive standard protocol of care alone",
                              "This arm will receive high dose of Allogeneic Mesenchymal Stem Cells",
                              "This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells",
                              "This arm will receive low dose of Allogeneic Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Mesenchymal Stem Cells",
                              "Biological: Allogeneic Mesenchymal Stem Cells",
                              "Biological: Allogeneic Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Stem cells high dose",
                              "Stem cells intermediate dose",
                              "Stem cells low dose"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01591200"
                        ]
                  },
                  {
                        "Rank": 523,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Study Group A",
                              "Study Group B",
                              "Study Group C",
                              "Study Group D",
                              "Study Group E"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03169231"
                        ]
                  },
                  {
                        "Rank": 524,
                        "Acronym": [
                              "AMASCIS-01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.",
                              "The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebo",
                              "Drug: Allogenic mesenchymal stem cells from adipose tissue"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "Allogeneic stem cells from adipose tissue"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01678534"
                        ]
                  },
                  {
                        "Rank": 525,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSC",
                              "Drug: Control"
                        ],
                        "ArmGroupLabel": [
                              "MSC transfusion",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04611256"
                        ]
                  },
                  {
                        "Rank": 526,
                        "Acronym": [
                              "PerioRegen"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue",
                              "in Group B (Fibrin glue/collagen fleece), a collagen fleece enriched with autologous fibrin glue devoid of stem cells will fill the osseous defect",
                              "Group C will receive open flap debridement retaining the soft tissue wall of the pocket"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MSCs/fibrin glue/collagen fleece",
                              "Other: Fibrin glue/collagen fleece",
                              "Procedure: Open flap debridement"
                        ],
                        "ArmGroupLabel": [
                              "Group A",
                              "Group B",
                              "Group C"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02449005"
                        ]
                  },
                  {
                        "Rank": 527,
                        "Acronym": [
                              "RESCeCUF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)",
                              "9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)",
                              "12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Mesenchymal Stem Cell injection",
                              "Procedure: Mesenchymal Stem Cell injection",
                              "Procedure: Mesenchymal Stem Cell injection"
                        ],
                        "ArmGroupLabel": [
                              "Stromal Vascular fraction",
                              "Autologous mesenchymal stem cells",
                              "Allogenic mesenchymal stem cells"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03726255"
                        ]
                  },
                  {
                        "Rank": 528,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSCs plus standard of care (SOC).",
                              "Placebo plus SOC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Placebo(solution without UC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05224960"
                        ]
                  },
                  {
                        "Rank": 529,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04064957"
                        ]
                  },
                  {
                        "Rank": 530,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hUC-MSCs 4*10^5/kg/each time",
                              "hUC-MSCs 8*10^5/kg/each time",
                              "hUC-MSCs 12*10^5/kg/each time"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Genetic: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "low dose",
                              "middle dose",
                              "high dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04822922"
                        ]
                  },
                  {
                        "Rank": 531,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three intra-articular injections in total and autologous adipose-derived mesenchymal stem cells (AMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.",
                              "Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Auotologous AMSCs plus autologous PRP",
                              "Biological: Auotologous PRP"
                        ],
                        "ArmGroupLabel": [
                              "AMSCs plus PRP group",
                              "PRP group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04212728"
                        ]
                  },
                  {
                        "Rank": 532,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "standard of care (SOC) plus UC-MSCs",
                              "SOC plus placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Saline containing 1% Human serum albumin\uff08solution without UC-MSCs\uff09"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05121870"
                        ]
                  },
                  {
                        "Rank": 533,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Biological: Bone marrow-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe"
                        ],
                        "ArmGroupLabel": [
                              "Hyaluronic Acid (HA) + P-MMSCs",
                              "Hyaluronic Acid (HA) + BM-MMSCs",
                              "Hyaluronic Acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04453111"
                        ]
                  },
                  {
                        "Rank": 534,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low dose allogenic mesenchymal stem cells with IM injection",
                              "High dose allogenic mesenchymal stem cells with IM injection",
                              "normal saline with Intramuscular injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogenic MSC",
                              "Drug: Allogenic MSC",
                              "Drug: Normal saline"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose Allogenic MSC",
                              "High Dose Allogenic MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02336646"
                        ]
                  },
                  {
                        "Rank": 535,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional therapy plus MenSCs treatment",
                              "Conventional therapy plus placebo treatment:\n\nOral or intravenous administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: conventional therapy plus MenSC transplantation",
                              "Drug: Conventional therapy plus placebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "Intervention",
                              "No intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01483248"
                        ]
                  },
                  {
                        "Rank": 536,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients whose fistula is treated by exosome (40 patients).",
                              "The patients whose fistula is treated with conventional treatment plan (40 patients)."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: placenta-MSCs derived exosomes",
                              "Other: placenta-MSCs derived exosomes"
                        ],
                        "ArmGroupLabel": [
                              "exosome cases",
                              "Controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05402748"
                        ]
                  },
                  {
                        "Rank": 537,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan",
                              "Single intraarticular dose of 2ml Plasmalyte"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Ex- vivo cultured adult allogeneic MSCs",
                              "Biological: Plasmalyte-A"
                        ],
                        "ArmGroupLabel": [
                              "Ex- vivo cultured adult allogeneic MSCs",
                              "Plasmalyte-A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01453738"
                        ]
                  },
                  {
                        "Rank": 538,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04087889"
                        ]
                  },
                  {
                        "Rank": 539,
                        "Acronym": [
                              "WANICHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to have standard of care plus placebo. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.\n\nAssigned Interventions:\n\nBiological/Vaccine: Biological/Vaccine: WJMSCs Vs.placebo",
                              "The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to standard of care plus one time or three times in doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.\n\nBiological/Vaccine:\n\nWJMSCs Vs.placebo",
                              "The investigators performed a double-blind, placebocontrolled trial, randomly assigning 100 patients with coronary artery disease to compare standard of care plus placebo to one time or three times at 30-day intervals for equal doses of 1x106 /kg of WJMSCs. Participants allocated to each study arm in a 1:1:1 ratio, to investigate the therapeutic efficacy and safety of WJMSCs in patients with coronary artery disease.\n\nBiological/Vaccine:\n\nWJMSCs Vs.placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS",
                              "Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS",
                              "Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS"
                        ],
                        "ArmGroupLabel": [
                              "Placebo Infusion PBS",
                              "Single dose Infusion WJMSCs",
                              "Infusion WJMSCs multiple doses"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04551456"
                        ]
                  },
                  {
                        "Rank": 540,
                        "Acronym": [
                              "CKD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.",
                              "Intervention of Rituximab combined with mesenchymal stem cells group: as follows, Rituximab, 100mg/time every one week, the infusion should be a total of 4 times; and then after at least 4 days interval after the first and the third infusion of the Rituximab , the dosage of mesenchymal stem cells tends to be 10^6/kg/time every 2 weeks, while the infusion should be a total of 2 times."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: conventional therapy",
                              "Drug: Rituximab",
                              "Drug: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "parallel control of conventional therapy",
                              "experimental group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02966717"
                        ]
                  },
                  {
                        "Rank": 541,
                        "Acronym": [
                              "SYMBOLpreclini"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03967275"
                        ]
                  },
                  {
                        "Rank": 542,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Age-matched non-diabetic subjects",
                              "Type 2 diabetes with metformin monotherapy failure"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Non-diabetic controls",
                              "Type 2 diabetes"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02286128"
                        ]
                  },
                  {
                        "Rank": 543,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit",
                              "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conventional plus UC-MSC",
                              "Drug: Conventional plus placebo"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus UC-MSC",
                              "Conventional plus placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01690247"
                        ]
                  },
                  {
                        "Rank": 544,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "To characterize and evaluate functional and anatomical changes of nerve fiber injuries after umbilical cord mesenchymal stem cells transplantation with BOLD drived-DTI",
                              "To determine the therapeutic efficiency of umbilical cord mesenchymal stem cells and also the utility of the integration of BOLD-fMRI and DTI.",
                              "To correlate the imaging results with the electrophysiology outcomes"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: BOLD-fMRI drived DTI scanning",
                              "Biological: stem cell transplantation",
                              "Procedure: BOLD-fMRI drived DTI scanning"
                        ],
                        "ArmGroupLabel": [
                              "evaluation",
                              "BOLD-fMRI and DTI",
                              "correlate the imaging results"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03336996"
                        ]
                  },
                  {
                        "Rank": 545,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment and then be followed until the week 72 study visit.",
                              "Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.",
                              "Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conventional treatment",
                              "Genetic: Conventional plus BM-MSC treatment",
                              "Genetic: Conventional plus UC-MSC treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional treatment",
                              "Conventional plus BM-MSC treatment",
                              "Conventional plus UC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01844063"
                        ]
                  },
                  {
                        "Rank": 546,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Thirty of the enrolled patients were randomly assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.",
                              "Thirty of the enrolled patients were randomly assigned to Group B were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as Bone Mesenchymal Stem Cells(BMSC) transplantation via portal vein."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conserved therapy",
                              "Procedure: Autologous BMSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Group A(conserved therapy )",
                              "Group B (BMSC Transplantion)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00993941"
                        ]
                  },
                  {
                        "Rank": 547,
                        "Acronym": [
                              "RP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "a total 2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell will be injected by peribulbar",
                              "1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected by peribulbar",
                              "1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension will be injected by peribulbar"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Conditioned Medium (CM)",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)",
                              "Biological: Conditioned Medium (CM)"
                        ],
                        "ArmGroupLabel": [
                              "Conditioned Medium (CM)",
                              "UC-MSC + NaCl",
                              "UC-MSC+CM"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04315025"
                        ]
                  },
                  {
                        "Rank": 548,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: hUC-MSCs+Injectable collagen scaffold+CABG",
                              "Biological: hUC-MSCs+CABG",
                              "Procedure: CABG"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSCs+Injectable collagen scaffold+CABG",
                              "hUC-MSCs+CABG",
                              "CABG"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02635464"
                        ]
                  },
                  {
                        "Rank": 549,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will be given Covid-19 standard therapy with intramuscular Hypoxic S-MSC secretome",
                              "This group will receive standard Covid-19 therapy with the best supportive care"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection of Secretome-MSCs",
                              "Drug: Standard treatment of Covid-19",
                              "Drug: Standard treatment of Covid-19"
                        ],
                        "ArmGroupLabel": [
                              "Secretome-MSCs (n=24)",
                              "Control (n=24)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04753476"
                        ]
                  },
                  {
                        "Rank": 550,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)",
                              "Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-UMC-BETA",
                              "Drug: Placebo",
                              "Drug: XCEL-UMC-BETA",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-UMC-BETA/placebo",
                              "Placebo/XCEL-UMC-BETA"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03003364"
                        ]
                  },
                  {
                        "Rank": 551,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil",
                              "Drug: Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00752479"
                        ]
                  },
                  {
                        "Rank": 552,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group A was the hormone replacement combined with transplantation of umbilical cord mesenchymal stem cells group(test group).",
                              "Group B was the hormone replacement group (control group)."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: transplantation of human UC-MSCs into ovaries of POI patients",
                              "Drug: hormone replacement treatment",
                              "Drug: hormone replacement treatment"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs+hormone replacement group",
                              "hormone replacement group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05308342"
                        ]
                  },
                  {
                        "Rank": 553,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET",
                              "standard endometrial preparation for frozen/thawed ET"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow-derived MSC and HRT",
                              "Other: hormonal replacement therapy"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow-derived MSC and HRT",
                              "hormonal replacement therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03166189"
                        ]
                  },
                  {
                        "Rank": 554,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cartilage defect are treated surgical either with chondrocytes or stem cells",
                              "Active rehabilitation program"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: stem cells",
                              "Procedure: Chondrocytes",
                              "Other: Rehabilitation program"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells",
                              "Rehabilitation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00885729"
                        ]
                  },
                  {
                        "Rank": 555,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 8 weeks.",
                              "Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 4 weeks.",
                              "Patients in Group Control received standard medical treatment, including bed rest, nutritional supplementation, administration of human serum albumin (10g per day until serum albumin was 35g/L) and plasma (200 ml to 400 ml per day until the international normalized ratio was less than 1.5), anti-viral therapy, glycyrrhizin,S-adenosylmethionine and appropriate treatment for complications (such as infection, encephalopathy, hepatorenal syndrome and intestinal paralysis)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: umbilical cord blood mesenchymal stem cells",
                              "Drug: umbilical cord blood mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Group MSC-1",
                              "Group MSC-2",
                              "Group Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02812121"
                        ]
                  },
                  {
                        "Rank": 556,
                        "Acronym": [
                              "COSMIC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection",
                              "Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection",
                              "Intestinal biopsies during colonoscopy or biopsies taken on surgical specimen after intestinal resection"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Intestinal biopsies during colonoscopy",
                              "Other: Biopsies taken on surgical specimen",
                              "Other: Intestinal biopsies during colonoscopy",
                              "Other: Biopsies taken on surgical specimen",
                              "Other: Intestinal biopsies during colonoscopy",
                              "Other: Biopsies taken on surgical specimen"
                        ],
                        "ArmGroupLabel": [
                              "Crohn's disease patient group",
                              "Ulcerative colitis patient group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03115749"
                        ]
                  },
                  {
                        "Rank": 557,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BM-MSC"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01531348"
                        ]
                  },
                  {
                        "Rank": 558,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs Participants will receive HUC-MSCs",
                              "Comparator participants will receive saline solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC",
                              "Biological: Saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05512988"
                        ]
                  },
                  {
                        "Rank": 559,
                        "Acronym": [
                              "PMD-MSC-PD-01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Injection of PMD-MSCs into the penis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02395029"
                        ]
                  },
                  {
                        "Rank": 560,
                        "Acronym": [
                              "PMD-MSC-ED-01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based patient reported treatment satisfaction."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Injection of PMD-MSCs into the penis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02398370"
                        ]
                  },
                  {
                        "Rank": 561,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PBSC will be intravenously infused at a dose of 2\u00d710^8/kg. MSCs will be intravenously infused at a dose of 1\u00d710^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PBSC",
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "PBSC & MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02083718"
                        ]
                  },
                  {
                        "Rank": 562,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.",
                              "10x10^6 MSC",
                              "30x10^6 MSC",
                              "90x10^6 MSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.",
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.",
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.",
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection."
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01144962"
                        ]
                  },
                  {
                        "Rank": 563,
                        "Acronym": [
                              "AdMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each subject receives three separate doses of 200 million allogeneic adipose-derived mesenchymal stem cells via intravenously infusion on days 0, 3, and 6 with a total of 600 million AdMSCs during 7 days in addition to their standard of care.",
                              "The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adipose-derived stem cells",
                              "Biological: Allogeneic adipose-derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Study Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05017298"
                        ]
                  },
                  {
                        "Rank": 564,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs Participants will receive antiviral drug, anti-fibrotic drugs and UC-MSCs",
                              "Comparator participants will receive antiviral drug, anti-fibrotic drugs and saline solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05507762"
                        ]
                  },
                  {
                        "Rank": 565,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.",
                              "Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.",
                              "Participants will be given conventional therapy only with a 6 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells",
                              "Drug: Conventional therapy"
                        ],
                        "ArmGroupLabel": [
                              "Group1 :Conventional plus hUCMSCs treatment",
                              "Group 2: Conventional plus hCBMNCs and hUCMSCs therapy",
                              "Group 3:Conventional therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01443689"
                        ]
                  },
                  {
                        "Rank": 566,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment plus MSCs Participants will receive conventional treatment plus 3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6).",
                              "Without MSCs Therapy but conventional treatment should be received."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSCs Treatment Group",
                              "Conventional Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04252118"
                        ]
                  },
                  {
                        "Rank": 567,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The control group will undergo tendon repair procedure only (without augmentation)",
                              "The experimental group will undergo tendon repair procedure augmented with AAdMSC-HAM composite"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Tendon repair procedure",
                              "Procedure: Tendon repair augmented with AAdMSC-HAM composite"
                        ],
                        "ArmGroupLabel": [
                              "Control group (Tendon repair)",
                              "Experimental group (Tendon repair augmented with AAdMSC-HAM composite)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04670302"
                        ]
                  },
                  {
                        "Rank": 568,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs.",
                              "Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Transplantation of hUC-MSCs",
                              "Drug: No transplantation of hUC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Transplantation of hUC-MSCs",
                              "No transplantation of hUC-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03774537"
                        ]
                  },
                  {
                        "Rank": 569,
                        "Acronym": [
                              "UCMSC-Heart"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in this arm received umbilical cord MSCs by intracoronary injection",
                              "Patients in this arm did not receive any intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC group"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02439541"
                        ]
                  },
                  {
                        "Rank": 570,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity",
                              "Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MNC",
                              "Biological: MSC",
                              "Procedure: Control",
                              "Biological: MNC",
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MNC & MSC with Control",
                              "MNC & MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03795974"
                        ]
                  },
                  {
                        "Rank": 571,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic MSC (AlloMSC)"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00698191"
                        ]
                  },
                  {
                        "Rank": 572,
                        "Acronym": [
                              "UCMSC-UC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord MSCs are administrated to patients by three intravenous infusion",
                              "Patients will receive normal saline at the same time points as that in experimental group."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC group",
                              "Other: Control group(Normal saline)"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC group",
                              "Control group(Normal saline)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02442037"
                        ]
                  },
                  {
                        "Rank": 573,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Fat graft will be enriched with ex vivo expanded stem cells",
                              "Fat graft will not be enriched with ex vivo expanded stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Fat graft enriched with ex vivo expanded stem cells",
                              "Procedure: Fat graft not enriched with ex vivo expanded stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell enriched",
                              "Non stem cell enriched"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02494752"
                        ]
                  },
                  {
                        "Rank": 574,
                        "Acronym": [
                              "REGEN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100 million human MSCs in 200mls of normal saline, intravenously, once-off, over 1-2hours"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human Mesenchymal Stem Cell (MSC) infusion therapy"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Population"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04174898"
                        ]
                  },
                  {
                        "Rank": 575,
                        "Acronym": [
                              "UCMSC-ALI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord MSCs are administrated to patients by intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC group"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02444455"
                        ]
                  },
                  {
                        "Rank": 576,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02529566"
                        ]
                  },
                  {
                        "Rank": 577,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "infusion of aUCMSC and conventional therapy",
                              "conventional therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UCMSCC",
                              "Drug: conventional treatment",
                              "Drug: conventional treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "conventional"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03291366"
                        ]
                  },
                  {
                        "Rank": 578,
                        "Acronym": [
                              "WJ-ICMP Tria"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intracoronary infusion WJMSCs or placebo in patients with ischemic heart failure",
                              "Intravenous infusion WJMSCs or placebo in patients with ischemic heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: WJMSCs Vs. placebo",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Intracoronary infusion WJMSCs",
                              "Intravenous infusion WJMSCs"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02368587"
                        ]
                  },
                  {
                        "Rank": 579,
                        "Acronym": [
                              "UCMSC-PQLI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord MSCs are administrated to patients by intravenous injection",
                              "Patients will receive normal saline at the same time points as that in experimental group."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC group",
                              "Other: Control group(Normal saline)"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC group",
                              "Control group(Normal saline)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02444858"
                        ]
                  },
                  {
                        "Rank": 580,
                        "Acronym": [
                              "UMSC01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after COVID-19 infection.",
                              "Normal saline will be administered to patients after COVID-19 infection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells",
                              "Biological: Controlled normal saline"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05501418"
                        ]
                  },
                  {
                        "Rank": 581,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of autologous bone marrow-derived mesenchymal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: MSCs injection"
                        ],
                        "ArmGroupLabel": [
                              "MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01913886"
                        ]
                  },
                  {
                        "Rank": 582,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Multipoint of Transdermal injection into the wrinkles. Injectable filler agent composed of umbilical cord mesenchymal stem cells (UCMSCs) and hyaluronic acid (HA).",
                              "Procedure: Transdermal injection of hyaluronic acid only."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells and hyaluronic acid",
                              "Drug: hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs-HA",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02698813"
                        ]
                  },
                  {
                        "Rank": 583,
                        "Acronym": [
                              "STREAMS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1-2 x106 MSCs/kg administered at Week 0",
                              "Suspension media administered at Week 0"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01606215"
                        ]
                  },
                  {
                        "Rank": 584,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive six autologous stem cell injections through spinal taps every 2 months over a year.",
                              "Patients will receive six placebo injections through spinal taps every 2 months over a year."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intrathecal MSC-NP injection",
                              "Other: Intrathecal saline injection"
                        ],
                        "ArmGroupLabel": [
                              "Intrathecal MSC-NP injection",
                              "Intrathecal saline injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03355365"
                        ]
                  },
                  {
                        "Rank": 585,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intrathecal administration of autologous MSC-NP in three doses at three month intervals"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: intrathecal administration of autologous MSC-NP"
                        ],
                        "ArmGroupLabel": [
                              "autologous MSC-NP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01933802"
                        ]
                  },
                  {
                        "Rank": 586,
                        "Acronym": [
                              "UMSC01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis.",
                              "For IV administration, normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis. For IT administration, sham puncture procedure will partially penetrate without reaching subarachnoid space, and no spinal fluid will be drawn."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells",
                              "Biological: Control group"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05532943"
                        ]
                  },
                  {
                        "Rank": 587,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Trinity multipotent stem cells",
                              "Demineralized bone matrix"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Trinity multipotent stem cells",
                              "Biological: Demineralized bone matrix(DBM)"
                        ],
                        "ArmGroupLabel": [
                              "Trinity",
                              "Demineralized bone matrix"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00851162"
                        ]
                  },
                  {
                        "Rank": 588,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01142050"
                        ]
                  },
                  {
                        "Rank": 589,
                        "Acronym": [
                              "AETHER"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10^6 (20 million) cells delivered via peripheral intravenous infusion",
                              "Patients will receive a matched placebo delivered via peripheral intravenous infusion",
                              "Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10^6 (20 million) cells delivered via peripheral intravenous infusion",
                              "Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10^6 (200 million) cells delivered via peripheral intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)",
                              "Biological: matched placebo",
                              "Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)",
                              "Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)"
                        ],
                        "ArmGroupLabel": [
                              "20 million hMSCs",
                              "Placebo",
                              "100 million hMSCs",
                              "200 million hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02013700"
                        ]
                  },
                  {
                        "Rank": 590,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of freshly collected autologous adipose tissue"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Injection of autologous adipose tissue in anal fistula"
                        ],
                        "ArmGroupLabel": [
                              "Injection with adipose tissue"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04834609"
                        ]
                  },
                  {
                        "Rank": 591,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue (sacffold)",
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with ligament derived conditioned medium",
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition",
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition and ligament derived conditioned medium"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium",
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium",
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium",
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium"
                        ],
                        "ArmGroupLabel": [
                              "control group",
                              "conditioned medium group",
                              "stem cells group",
                              "composite group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04889963"
                        ]
                  },
                  {
                        "Rank": 592,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "5 blood samples at time points as described in protocol",
                              "3 blood samples at time points described in protocol"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: blood samples",
                              "Procedure: blood samples"
                        ],
                        "ArmGroupLabel": [
                              "liver transplant patients",
                              "Liver resection patients"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02557724"
                        ]
                  },
                  {
                        "Rank": 593,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Long-term follow up of Mesenchymal stem cell group"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: no Intervention"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03933995"
                        ]
                  },
                  {
                        "Rank": 594,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00361049"
                        ]
                  },
                  {
                        "Rank": 595,
                        "Acronym": [
                              "SMART-MS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Receives mesenchymal stem cells at baseline and placebo at 6 months",
                              "Receives placebo at baseline and mesenchymal stem cells at 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: MSCs",
                              "Drug: Saline",
                              "Other: MSCs",
                              "Drug: Saline"
                        ],
                        "ArmGroupLabel": [
                              "Arm A - Crossover with MSCs at baseline and placebo at 6 months",
                              "Arm B - Crossover with placebo at baseline and MSCs at 6 months"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04749667"
                        ]
                  },
                  {
                        "Rank": 596,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intraarticular dose of allogeneic MSCs",
                              "Single intraarticular dose of 2ml Plasmalyte"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Ex- vivo cultured adult allogeneic MSCs",
                              "Biological: Plasmalyte-A"
                        ],
                        "ArmGroupLabel": [
                              "Ex- vivo cultured adult allogeneic MSCs",
                              "Plasmalyte-A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01448434"
                        ]
                  },
                  {
                        "Rank": 597,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Interstitial cystitis patients who receive submucosal injection of hESC-MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MR-MC-01"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04610359"
                        ]
                  },
                  {
                        "Rank": 598,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention Group1(n=20). Patients will receive two doses of MSCs 100\u00d710e6 (\u00b110%) intravenously plus Conventional treatment.",
                              "Intervention Group 2 (n=20). Patients will receive two doses of MSCs 100\u00d710e6 (\u00b110%), intravenously plus two doses of EVs plus Conventional treatment",
                              "Control (n=20). Patients will conventional therapy for virus treatment and supportive care for ARDS will be used as control."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cell therapy protocol 1",
                              "Biological: Cell therapy protocol 2"
                        ],
                        "ArmGroupLabel": [
                              "Two MSC infusion",
                              "Two MSC infusion Plus two EVs infusion",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04366063"
                        ]
                  },
                  {
                        "Rank": 599,
                        "Acronym": [
                              "ARTHROSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: arthroplasty"
                        ],
                        "ArmGroupLabel": [
                              "Surgical intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01879046"
                        ]
                  },
                  {
                        "Rank": 600,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.\n\nWJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: WJ-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04313322"
                        ]
                  },
                  {
                        "Rank": 601,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment and aerosol inhalation of MSCs-derived exosomes treatment participants will receive conventional treatment and 5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs-derived exosomes"
                        ],
                        "ArmGroupLabel": [
                              "MSCs-derived Exosomes Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04276987"
                        ]
                  },
                  {
                        "Rank": 602,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transendocardial injection of placebo solution",
                              "transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: placebo intervention",
                              "Other: bone marrow-derived MSCs injection"
                        ],
                        "ArmGroupLabel": [
                              "placebo comparator",
                              "bone marrow-derived MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01957826"
                        ]
                  },
                  {
                        "Rank": 603,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Normal Saline 100 mL",
                              "Normal saline 85 mL and ExoFlo 15 mL, which is 10.5 x 10^8 EV"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Saline",
                              "Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm 1",
                              "Treatment Arm 2"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05116761"
                        ]
                  },
                  {
                        "Rank": 604,
                        "Acronym": [
                              "TEAM-AMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Atorvastatin routine dose + placebo transplantation",
                              "Atorvastatin routine dose + low dose BMMSC Transplantation",
                              "Atorvastatin routine dose + middle dose BMMSC Transplantation",
                              "Atorvastatin routine dose + high dose BMMSC Transplantation",
                              "Atorvastatin routine dose + placebo transplantation",
                              "Atorvastatin routine dose+ Optimal dose BMMSC Transplantation",
                              "Atorvastatin Intensive dose + placebo transplantation",
                              "Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Atorvastatin",
                              "Drug: Atorvastatin",
                              "Drug: Low dose BMMSC",
                              "Drug: Atorvastatin",
                              "Drug: Middle dose BMMSC",
                              "Drug: Atorvastatin",
                              "Drug: High dose BMMSC",
                              "Drug: Atorvastatin",
                              "Drug: Atorvastatin",
                              "Drug: Transplantation",
                              "Drug: Intensive Atorvastatin",
                              "Drug: Intensive Atorvastatin",
                              "Drug: Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Phase A: Atorvastatin",
                              "Phase A: Low dose BMMSC",
                              "Phase A: Middle dose BMMSC",
                              "Phase A: High dose BMMSC",
                              "Phase B: Atorvastatin",
                              "Phase B: Atorvastatin+Transplantation",
                              "Phase B: Intensive Atorvastatin",
                              "Phase B: Intensive Atorvastatin+Transplantation"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator",
                              "Active Comparator",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03047772"
                        ]
                  },
                  {
                        "Rank": 605,
                        "Acronym": [
                              "CIS/MSC08"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "Cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01275612"
                        ]
                  },
                  {
                        "Rank": 606,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with spinal cord injury that will undergo laminectomy and autologous mesenchymal cells intralesional injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Single group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02574572"
                        ]
                  },
                  {
                        "Rank": 607,
                        "Acronym": [
                              "S-CURE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in CSWT+BMMSCs group will receive a 3-month cardiac shock wave therapy and then a total of 1 million/kg BMMSCs will be infused using the stop-flow technique through an over-the-wire balloon catheter positioned in a coronary artery or bypass graft supplying the targeting viable myocardium.",
                              "Placebo group will receive a 3-month CSWT and a sham procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: CSWT+BMMSCs",
                              "Device: CSWT+Sham operation"
                        ],
                        "ArmGroupLabel": [
                              "CSWT+BMMSCs",
                              "CSWT+Sham operation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03397095"
                        ]
                  },
                  {
                        "Rank": 608,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of cultured autologous bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous BMSCs",
                              "Drug: bone marrow-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous BMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02327832"
                        ]
                  },
                  {
                        "Rank": 609,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose Tissue Derived MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue derived MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02474342"
                        ]
                  },
                  {
                        "Rank": 610,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of WJMSC",
                              "Intraarticular injection of WJMSC",
                              "Intraarticular injection of WJMSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intraarticular injection of WJMSC",
                              "Biological: Intraarticular injection of WJMSC",
                              "Biological: Intraarticular injection of WJMSC"
                        ],
                        "ArmGroupLabel": [
                              "osteoarthritis of the knee",
                              "osteoarthritis of the hip",
                              "osteoarthritis of the glenohumeral joint"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03866330"
                        ]
                  },
                  {
                        "Rank": 611,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSC infusion by intravenus, 1*10^8 cells/dose, 2 doses (apart from 24weeks)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UC-MSC infusion"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05106972"
                        ]
                  },
                  {
                        "Rank": 612,
                        "Acronym": [
                              "MESHT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02472002"
                        ]
                  },
                  {
                        "Rank": 613,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Five IV infusions of autologous, adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety lab follow ups at weeks 6, 14, 26; inflammatory marker follow ups at weeks 6, 14, 26; SF-36 and PHQ-9 Questionnaires at weeks 2,6,10, 14, 18, 22, 26."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04349631"
                        ]
                  },
                  {
                        "Rank": 614,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in Group A will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive standard regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF.",
                              "Patients in Group B will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive 80% less of calcineurin inhibitor than in Group A. Other immunosuppressive agents such as glucocorticoid and MMF remained the same doses as in Group A.",
                              "Patients in Group C will receive anti-interleukin 2 receptor antibody (Basiliximab)for induction therapy. Patients will receive the same doses of regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF as in Group A."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Kidney transplantation with MSCs infusion",
                              "Procedure: Kidney transplantation with MSCs infusion",
                              "Procedure: kidney transplantation without MSC infusion"
                        ],
                        "ArmGroupLabel": [
                              "A",
                              "B",
                              "C"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00658073"
                        ]
                  },
                  {
                        "Rank": 615,
                        "Acronym": [
                              "CLOSE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells obtained from autogenous deciduous dental pulp associated with biomaterials. The stem cells will be obtained by enzimatic digestion in GMP laboratory and will be seed into the biomaterial (hydroxyapatite/collagen).",
                              "Autogenous bone will be obtained from iliac crest. The prepare of the receptor area will be the same in both arms and will follow current recommendations."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: Mesenchymal stem cells associated with biomaterials",
                              "Combination Product: Iliac crest autogenous bone graft"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells associated with biomaterials",
                              "Iliac crest autogenous bone graft"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03766217"
                        ]
                  },
                  {
                        "Rank": 616,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive standardized treatment, consisting of Oseltamivir and Azithromycin",
                              "Patients receive intravenous infusion of 1x10^6 unit of umbilical-cord derived mesenchymal stem cells (UC-MSCs)/kgBW in 100 cc of 0.9% NaCl for 1 hour, in addition to standardized treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Oseltamivir",
                              "Drug: Azithromycin",
                              "Drug: Oseltamivir",
                              "Drug: Azithromycin",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Control Group",
                              "Experiment Group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04457609"
                        ]
                  },
                  {
                        "Rank": 617,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intraarticular injection of Hyaluronic acid (Hyal One)",
                              "Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells",
                              "Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Hyaluronic acid",
                              "Drug: Hyaluronic acid",
                              "Biological: 10 million Bone marrow mesenchimal stem cells",
                              "Drug: Hyaluronic acid",
                              "Biological: 100 million Bone marrow mesenchimal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Hialuronic acid",
                              "Hyaluronic acid and MSC 10",
                              "Hyaluronic acid AND MSC 100"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02123368"
                        ]
                  },
                  {
                        "Rank": 618,
                        "Acronym": [
                              "AMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dosage of intravenous route is 2 million MSCs/kg for each subject.",
                              "Dosage of intracoronary route is \u00b150 million MSCs for each subject.",
                              "Standard treatment of acute myocardia infarction"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous Group",
                              "Intracoronary Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04340609"
                        ]
                  },
                  {
                        "Rank": 619,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "5\u00d7106/0.5ml MSC was injected subconjunctival at the inferior fornix.If persistent epithelial defect was noted thereafter, a second AMT and MSC injection was performed."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: human bone marrow MSC"
                        ],
                        "ArmGroupLabel": [
                              "human bone marrow MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02325843"
                        ]
                  },
                  {
                        "Rank": 620,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by UMSC-exo intervention for 2 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Mesenchymal Stem Cells derived Exosomes"
                        ],
                        "ArmGroupLabel": [
                              "UMSC-exo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04213248"
                        ]
                  },
                  {
                        "Rank": 621,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle and CsA 5mg/kg po for 12 months",
                              "cyclosporine A at a dose of 5 mg CsA/kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Human umbilical cord-derived MSCs and cyclosporin A",
                              "Other: cyclosporin A"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord-derived MSCs and cyclosporin",
                              "cyclosporine A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01182662"
                        ]
                  },
                  {
                        "Rank": 622,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months",
                              "DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord-derived MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord-derived MSCs and DMARDs",
                              "DMARDs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01420432"
                        ]
                  },
                  {
                        "Rank": 623,
                        "Acronym": [
                              "CLI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: allogeneic umbilical cord-derived mesenchymal stem cells",
                              "Biological: allogeneic umbilical cord-derived mesenchymal stem cells",
                              "Biological: Placebo (NaCl)"
                        ],
                        "ArmGroupLabel": [
                              "simple dose",
                              "double dose",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03994666"
                        ]
                  },
                  {
                        "Rank": 624,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous BM MSC"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05080465"
                        ]
                  },
                  {
                        "Rank": 625,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue",
                              "Intravenous infusion of 4 doses of Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Infusion of MSC",
                              "Drug: Infusion of placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02290041"
                        ]
                  },
                  {
                        "Rank": 626,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2\u00d710 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.\n\nPSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs.",
                              "Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2\u00d710 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.\n\nGu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: PSORI-CM01 formula",
                              "Biological: adipose-derived multipotent mesenchymal stem cells",
                              "Drug: Gu Ben Hua Yu formula",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "PSORI-CM01 group",
                              "Gu Ben Hua Yu group"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04785027"
                        ]
                  },
                  {
                        "Rank": 627,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle",
                              "CsA at a dose of 5 mg CsA/kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Human umbilical cord-derived MSCs",
                              "Other: cyclosporine A (CsA)"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord-derived MSCs",
                              "cyclosporine A (CsA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01129739"
                        ]
                  },
                  {
                        "Rank": 628,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "IPF patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03187431"
                        ]
                  },
                  {
                        "Rank": 629,
                        "Acronym": [
                              "KNEEXO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The left knee will receive 1 million cells/kg SF-MSC-EX (Synovial fluid mesenchymal stem cell-derived exosome) by intra-articular injection method.",
                              "The right knee will receive 1 million cells/kg SF-MSC (Synovial fluid-derived mesenchymal stem cell) by intra-articular injection method.",
                              "Participants who received no treatment were defined as the control group."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: SF-MSC-EX",
                              "Drug: SF-MSC"
                        ],
                        "ArmGroupLabel": [
                              "SF-MSC-EX Treatment Group (Experimental group's left knees)",
                              "SF-MSC Treatment Group (Experimental group's right knees)",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05261360"
                        ]
                  },
                  {
                        "Rank": 630,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSCs by peripheral intravenous infusion",
                              "received hormone maintenance therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: UC-MSCs by peripheral intravenous infusion",
                              "Drug: received hormone maintenance therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02445547"
                        ]
                  },
                  {
                        "Rank": 631,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Arterial infusion of autologous mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "infusion of autologous mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01840540"
                        ]
                  },
                  {
                        "Rank": 632,
                        "Acronym": [
                              "SIRONA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.",
                              "10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.",
                              "10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.",
                              "10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs",
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs",
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs",
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs"
                        ],
                        "ArmGroupLabel": [
                              "LMSCs 10 million IV",
                              "Placebo (Plasmalyte A,HSA) IV",
                              "LMSCs 20 million IV",
                              "LMSCs100 million IV"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02587572"
                        ]
                  },
                  {
                        "Rank": 633,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100ml normal saline",
                              "10ml ExoFlo + 90ml normal saline",
                              "15ml ExoFlo + 85ml normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ExoFlo",
                              "Drug: ExoFlo",
                              "Drug: ExoFlo"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "10ml ExoFlo",
                              "15ml ExoFlo"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05125562"
                        ]
                  },
                  {
                        "Rank": 634,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Routine treatment + Intravenous injection of human dental pulp stem cells",
                              "Routine treatment + Intravenous saline injection (Placebo)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)",
                              "Other: Intravenous saline injection (Placebo)"
                        ],
                        "ArmGroupLabel": [
                              "hDPSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04336254"
                        ]
                  },
                  {
                        "Rank": 635,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Exosome of MSC at a dose of 150mg will be given intravenously to Patients in the exosome of MSC arm once a day for 14 times.",
                              "Patients in the control arm will not be given exosome of MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Exosome of MSC"
                        ],
                        "ArmGroupLabel": [
                              "The exosome of MSC arm",
                              "The control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04356300"
                        ]
                  },
                  {
                        "Rank": 636,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "historic cohort of patients with ABMR treated with standard of care therapy",
                              "patients with ABMR treated with MSC transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: MSC transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Historic control",
                              "MSC transplantation"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03585855"
                        ]
                  },
                  {
                        "Rank": 637,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.",
                              "Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.",
                              "Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.",
                              "Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: 50 Adipose Derived Stem Cell Infusion",
                              "Drug: 150 Adipose Derived Stem Cell Infusion",
                              "Drug: 300 Adipose Derived Stem Cell Infusion",
                              "Drug: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "50 million cell infusion",
                              "150 million cell infusion",
                              "300 million cell infusion",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04744051"
                        ]
                  },
                  {
                        "Rank": 638,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "human umbilical cord derived MSC transplantation for SLE"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord derived MSC transplantation for SLE"
                        ],
                        "ArmGroupLabel": [
                              "human umbilical cord derived MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01741857"
                        ]
                  },
                  {
                        "Rank": 639,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologue bone marrow mononuclear cell",
                              "Umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC",
                              "Biological: Intravenous Infusion of UC-MSC"
                        ],
                        "ArmGroupLabel": [
                              "BM-MNC experimental",
                              "UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04501341"
                        ]
                  },
                  {
                        "Rank": 640,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conserved Therapy",
                              "Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Conserved Therapy",
                              "Procedure: Hepatic artery infusion"
                        ],
                        "ArmGroupLabel": [
                              "Conserved Therapy",
                              "Interventional Therapy"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00976287"
                        ]
                  },
                  {
                        "Rank": 641,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02055625"
                        ]
                  },
                  {
                        "Rank": 642,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01494480"
                        ]
                  },
                  {
                        "Rank": 643,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: UC-MSCs therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03592849"
                        ]
                  },
                  {
                        "Rank": 644,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.\nADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ADSTEM Inj. (Adult human mesenchymal stem cells)"
                        ],
                        "ArmGroupLabel": [
                              "intervention: Biological: ADSTEM Inj."
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02888704"
                        ]
                  },
                  {
                        "Rank": 645,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "the participants will receive the single-dose UC-MSCs (1\u00d710^6 cells/kg ) in combined with the present treatment.",
                              "the participants will receive the placebo in combined with the present treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs treatment",
                              "no UC-MSCs treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03798028"
                        ]
                  },
                  {
                        "Rank": 646,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.",
                              "Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.",
                              "Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human allogeneic mesenchymal bone marrow derived stem cells",
                              "Biological: Human allogeneic mesenchymal bone marrow derived stem cells",
                              "Biological: Human allogeneic mesenchymal bone marrow derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2",
                              "Group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03602872"
                        ]
                  },
                  {
                        "Rank": 647,
                        "Acronym": [
                              "PRIME"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05210309"
                        ]
                  },
                  {
                        "Rank": 648,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "one randomly assigned maxillary sinus grafted internally defined as control (bone substitute + saline solution) per subject.",
                              "one randomly assigned maxillary sinus grafted internally defined as test (bone substitute + concentrated culture medium) per subject."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Maxillary sinus floor elevation grafting with synthetic bone substitute.",
                              "Procedure: Maxillary sinus floor elevation grafting with synthetic bone substitute."
                        ],
                        "ArmGroupLabel": [
                              "Control (conventional graft procedure), bone substitute and saline solution.",
                              "Test (modified graft), bone substitute and concentrated culture medium (CM)"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04998058"
                        ]
                  },
                  {
                        "Rank": 649,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells",
                              "Other: Liberation therapy"
                        ],
                        "ArmGroupLabel": [
                              "AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02587715"
                        ]
                  },
                  {
                        "Rank": 650,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells",
                              "Other: Liberation therapy"
                        ],
                        "ArmGroupLabel": [
                              "AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02418325"
                        ]
                  },
                  {
                        "Rank": 651,
                        "Acronym": [
                              "COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants in this group will receive the 2 intravenous (IV) UCMSCs intervention on day 0 and day 3.",
                              "Participants in this group will receive the placebo, a solution of 1% human serum albumin in Plasmalyte A, on day 0 and day 3."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group 1: (UCMSCs)",
                              "Group 2: (Placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04490486"
                        ]
                  },
                  {
                        "Rank": 652,
                        "Acronym": [
                              "PREVENT-TAHA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the experimental group, 3-7 days after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive a single intracoronary infusion of 10^7 umbilical cord-derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs) alongside conventional treatment.",
                              "In the control group, after an acute anterior myocardial infarction treated successfully with primary percutaneous coronary intervention, 120 patients will receive only conventional treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)",
                              "Other: Conventional Treatment",
                              "Other: Conventional Treatment"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2 (Control Group)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05043610"
                        ]
                  },
                  {
                        "Rank": 653,
                        "Acronym": [
                              "SCA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.",
                              "10 patients in the group accept stem cell transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01489267"
                        ]
                  },
                  {
                        "Rank": 654,
                        "Acronym": [
                              "CMM-PRGF/ART"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.",
                              "Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Platelet Rich plasma (PRGF)",
                              "Biological: 100 million Bone marrow mesenchimal stem cells",
                              "Biological: Platelet Rich plasma (PRGF)"
                        ],
                        "ArmGroupLabel": [
                              "Platelet Rich Plasma (PRGF)",
                              "BMMSC with Platelet Rich Plasma (PRGF)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02365142"
                        ]
                  },
                  {
                        "Rank": 655,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03460223"
                        ]
                  },
                  {
                        "Rank": 656,
                        "Acronym": [
                              "msctendonrep"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells with a collagen type I membrane (OrthoADAPT)",
                              "Membrane of collagen type I (OrthoADAPT)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSCs)",
                              "Biological: OrthADAPT"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells (MSCs)",
                              "OrthADAPT"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01687777"
                        ]
                  },
                  {
                        "Rank": 657,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cell Therapy"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03078621"
                        ]
                  },
                  {
                        "Rank": 658,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01143168"
                        ]
                  },
                  {
                        "Rank": 659,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04029896"
                        ]
                  },
                  {
                        "Rank": 660,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.",
                              "Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: HAM and HUMCWJ Injections"
                        ],
                        "ArmGroupLabel": [
                              "HAM and HUMCWJ Injections (Group 1)",
                              "Control (Group 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03337243"
                        ]
                  },
                  {
                        "Rank": 661,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with nonunion fracture of long bones"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: cell injection"
                        ],
                        "ArmGroupLabel": [
                              "non union"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01206179"
                        ]
                  },
                  {
                        "Rank": 662,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment plus UC-MSCs:\n\nParticipants will receive conventional treatment plus 4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1\uff0cDay 3\uff0cDay 5\uff0cDay7).",
                              "Conventional treatment plus Placebo:\n\nWithout UC-MSCs Therapy but conventional treatment should be received. Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day 1\uff0cDay 3\uff0cDay 5\uff0cDay7)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs Treatment Group",
                              "Conventional Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04273646"
                        ]
                  },
                  {
                        "Rank": 663,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UCMSC: umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSC"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02961725"
                        ]
                  },
                  {
                        "Rank": 664,
                        "Acronym": [
                              "UwmWjmscAls"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Biological: Cell-based therapy"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic WJ-MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02881476"
                        ]
                  },
                  {
                        "Rank": 665,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 \u00b5g teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.",
                              "subcutaneous injection of 20 \u00b5g teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: WJ-MSC",
                              "Drug: Teriparatide",
                              "Drug: Teriparatide"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC group",
                              "Teriparatide group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018637"
                        ]
                  },
                  {
                        "Rank": 666,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "with 2cc saline/NaCl 0,9% solution once at baseline",
                              "with umbilical cord stem cells 15x10^6 cells in 2 cc saline/NaCl 0,9% solution once at baseline"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: placebo",
                              "Biological: stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Stem Cell Group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04972890"
                        ]
                  },
                  {
                        "Rank": 667,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplantation of mesenchymal stem cell will be given to the infants with BPD.",
                              "transplantation of mesenchymal stem cell will be not given to the infants with BPD."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: transplantation of mesenchymal stem cell",
                              "Drug: no transplantation of mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "transplantation of mesenchymal stem cell",
                              "no transplantation of mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03378063"
                        ]
                  },
                  {
                        "Rank": 668,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects in this arm will receive 6 times UC-MSCs infusions (each time 1\u00d710^6/kg) within 8 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Treat Psoriasis Vulgaris with UC-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02491658"
                        ]
                  },
                  {
                        "Rank": 669,
                        "Acronym": [
                              "CONCERT-HF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Target dose of 150 million MSCs",
                              "Target dose of 5 million c-kit+ cells",
                              "Target dose of 150 million MSCs and 5 million c-kit+ cells",
                              "Plasmalyte A"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSC)",
                              "Biological: c-kit+ cells",
                              "Biological: Mesenchymal Stem Cells (MSC)",
                              "Biological: c-kit+ cells",
                              "Biological: Placebo (Plasmalyte A)"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells (MSC)",
                              "c-kit+ cells",
                              "Combination Cells (MSC and c-kit+ cells)",
                              "Placebo (Plasmalyte A)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG004"
                        ],
                        "NCTId": [
                              "NCT02501811"
                        ]
                  },
                  {
                        "Rank": 670,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMSC01"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04434768"
                        ]
                  },
                  {
                        "Rank": 671,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.\n\nPatients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.\n\nMSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor.",
                              "Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.\n\nIsotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Other: Isotonic solution"
                        ],
                        "ArmGroupLabel": [
                              "Mensenchymal Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01045382"
                        ]
                  },
                  {
                        "Rank": 672,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic Bone Marrow mesenchymal stem cell in amniotic membrane transplant",
                              "Stem Cell with Amniotic Membrane Transplant"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Stem Cell with Amniotic Membrane Transplant",
                              "Procedure: Stem Cell with Amniotic Membrane Transplant"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow mesenchymal stem cell",
                              "Allogenic limbal stem cell Transplant"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01562002"
                        ]
                  },
                  {
                        "Rank": 673,
                        "Acronym": [
                              "AdMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion",
                              "50 subjects receive two doses of 2.0-2.86 x 10^6 cells/kg on days 0 and 6 via intravenous infusion.\n\nOn day 3, each subject will receive a single dose of 1.0-2.86 x 10^6 cells/kg via intra-articular injection into the injured joint.",
                              "Control group- 50 subjects receive three doses of 2.0-2.86 x 10^6 cells/kg on day 0, 3, and 6 via intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs",
                              "Biological: Celltex- AdMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Phase 2 Arm 1 - OA Knee",
                              "Phase 2 Arm 2 OA Knee",
                              "Phase 2 Arm 3 - OA Hip",
                              "Phase 2 Arm 4 - OA Hip",
                              "Phase 2 Arm 5 - OA Shoulder",
                              "Phase 2 Arm 6 - OA Shoulder"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04448106"
                        ]
                  },
                  {
                        "Rank": 674,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (one vial, ~18.5 million cells) on Day 0, Day 2, and Day 4.",
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials, ~37 million cells) on Day 0, Day 2, and Day 4."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Biological: COVI-MSC"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC 1 vial",
                              "COVI-MSC 2 vials"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04909892"
                        ]
                  },
                  {
                        "Rank": 675,
                        "Acronym": [
                              "CuRe"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One-time administration of PMSC-ECM during the course of in utero fetal myelomeningocele surgery will be administered",
                              "Contemporaneous cohort of patients undergoing routine fetal or postnatal MMC repair without PMSC-ECM (non-PMSC untreated contemporaneous cohort)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix",
                              "Other: Untreated contemporaneous cohort"
                        ],
                        "ArmGroupLabel": [
                              "Treatment with PMSC-ECM",
                              "non-PMSC untreated contemporaneous cohort"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04652908"
                        ]
                  },
                  {
                        "Rank": 676,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Triamcinolone acetonide (10mg / mL) via intra-articular, 5 cc, one dose (zero time).",
                              "CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution, one dose (zero time)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Triamcinolone acetonide",
                              "Biological: CELLISTEM-OA"
                        ],
                        "ArmGroupLabel": [
                              "Group 1 (control-Triamcinolone acetonide)",
                              "Group 2 (experimental- CELLISTEM-OA)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04863183"
                        ]
                  },
                  {
                        "Rank": 677,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSC and Tregs"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus MSC and Tregs treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03460795"
                        ]
                  },
                  {
                        "Rank": 678,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: umbilical cord mesenchymal stem cells combined with collagen scaffold"
                        ],
                        "ArmGroupLabel": [
                              "stem cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03724617"
                        ]
                  },
                  {
                        "Rank": 679,
                        "Acronym": [
                              "MSCGVHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00749164"
                        ]
                  },
                  {
                        "Rank": 680,
                        "Acronym": [
                              "MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose tisse derrived MSCs",
                              "Fat graft withiut enrichment with MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC",
                              "Drug: MSC"
                        ],
                        "ArmGroupLabel": [
                              "Fat graft enriched with MSCs",
                              "Fat graft only"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03564808"
                        ]
                  },
                  {
                        "Rank": 681,
                        "Acronym": [
                              "ELPIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.",
                              "Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allo-hMSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group A - Allo-hMSCs",
                              "Group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02398604"
                        ]
                  },
                  {
                        "Rank": 682,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03069209"
                        ]
                  },
                  {
                        "Rank": 683,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Target dose of 2 times 106 MSC/kg for up to 12 doses"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02379442"
                        ]
                  },
                  {
                        "Rank": 684,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will include 20 patients with liver cirrhosis, autologous bone marrow derived mesenchymal stem cells will be transplanted to them. Every patient will receive 2 million cells per Kg via portal vein once.",
                              "This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell transplantation",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02943889"
                        ]
                  },
                  {
                        "Rank": 685,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous MitoCell Transplantation in Subjects with Idiopathic Parkinson's Disease"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Aadipose-Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Single Arm Study"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05094011"
                        ]
                  },
                  {
                        "Rank": 686,
                        "Acronym": [
                              "HAPI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.",
                              "2 subjects will receive a single administration of allogeneic MSCs: 100 x 10^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.",
                              "Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10^6 MSCs (20 million cells) will be administered to each subject.",
                              "Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10^6 MSCs (100 million cells) will be administered to each subject.",
                              "Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allo-hMSCs",
                              "Biological: Allo-hMSCs",
                              "Biological: Allo-hMSCs",
                              "Biological: Allo-hMSCs",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Safety Run-In: Treatment 1 Allo-hMSCs",
                              "Safety Run-In: Treatment 2 Allo-hMSCs",
                              "Randomized: Cohort 1 Allo-hMSCs",
                              "Randomized: Cohort 2 Allo-hMSCs",
                              "Randomized: Cohort 3 Allo-hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03058068"
                        ]
                  },
                  {
                        "Rank": 687,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 \u03bcg/kg/day of Filgrastim will be given subcutaneously for 4 days"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Filgrastim"
                        ],
                        "ArmGroupLabel": [
                              "Melanoma, head and neck"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02331134"
                        ]
                  },
                  {
                        "Rank": 688,
                        "Acronym": [
                              "SENECA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Target dose of 100 million allo-MSCs",
                              "Buminate solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allo-MSCs",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allo-MSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT02509156"
                        ]
                  },
                  {
                        "Rank": 689,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HB-adMSCs will be infused three times over a six week period, spaced 14 days apart"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04063215"
                        ]
                  },
                  {
                        "Rank": 690,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01301664"
                        ]
                  },
                  {
                        "Rank": 691,
                        "Acronym": [
                              "Cellgram-LC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Best Supportive care",
                              "Within 1 month after extracting bone marrow, directly inject 7X10^7 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cellgram-LC"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Injection group: Cellgram-LC"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04689152"
                        ]
                  },
                  {
                        "Rank": 692,
                        "Acronym": [
                              "HB-adMSCs"
                        ],
                        "AgreementOtherDetails": [
                              "In the protocol signature page, the investigator agreed to the following: \"I further agree to treat the results of this Study as confidential information and will not submit the results of the Study for publication without prior written authorization from Hope Biosciences. \""
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03691909"
                        ]
                  },
                  {
                        "Rank": 693,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs will be given at a median dose of 1\u00d710^6 cells/kg once weekly for 4 dose (as 1 cycle) or until CR. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given. Besides, CD25 monoclonal antibody (20mg/kg) will be administered at day 1,4,8,15, 21 and calcineurin inhibitors will also be used.",
                              "CD25 monoclonal antibody (20mg/kg, day 1,4,8,15,21) will be administered combined with calcineurin inhibitors. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: CD25 monoclonal antibody",
                              "Drug: calcineurin inhibitors",
                              "Biological: MSCs",
                              "Drug: CD25 monoclonal antibody",
                              "Drug: calcineurin inhibitors"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "CD25 Mc Ab & calcineurin inhibitors"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02241018"
                        ]
                  },
                  {
                        "Rank": 694,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Arm 1: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).",
                              "Arm 2: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate",
                              "Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate"
                        ],
                        "ArmGroupLabel": [
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46",
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05130983"
                        ]
                  },
                  {
                        "Rank": 695,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Phase 1 Dose escalation : low Mid High Single administalation of ADR-001\n\nPhase 2 The recommended dose of ADR-001"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03254758"
                        ]
                  },
                  {
                        "Rank": 696,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous MSCs transplantation were performed plus medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin)",
                              "only medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin) were performed without autologous MSCs transplantation."
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "group A",
                              "group B"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00956891"
                        ]
                  },
                  {
                        "Rank": 697,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to unilateral procurement of bone marrow.",
                              "Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to bilateral procurement of bone marrow."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Unilateral Bone Marrow Procurement",
                              "Procedure: Bilateral Bone Marrow Procurement"
                        ],
                        "ArmGroupLabel": [
                              "Unilateral Procurement of Bone Marrow",
                              "Bilateral Bone Marrow Procurement"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03014037"
                        ]
                  },
                  {
                        "Rank": 698,
                        "Acronym": [
                              "Trident"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.",
                              "Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic hMSCs",
                              "Biological: Allogeneic hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Group 1: 20 million Allogeneic hMSCs",
                              "Group 2: 100 million Allogeneic hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02013674"
                        ]
                  },
                  {
                        "Rank": 699,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.",
                              "Patients were treated with routine drug therapy\uff0cdo not inject stem cell to the facial nerve of patient"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose stem cell therapy",
                              "Drug: Mecobalamin",
                              "Drug: Mecobalamin"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell therapy group",
                              "Neurotrophic drugs treatment group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02853942"
                        ]
                  },
                  {
                        "Rank": 700,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic bone marrow-derived mesenchymal stem cells (10^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.\n\nThe third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx.",
                              "Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: bone marrow-derived mesenchymal stem cells",
                              "Drug: Induction therapy (ATG or Basiliximab)",
                              "Drug: Maintenance therapy (Low-dose CNI + MPA + steroids)",
                              "Other: Saline",
                              "Drug: Induction therapy (ATG or Basiliximab)",
                              "Drug: Maintenance therapy (Low-dose CNI + MPA + steroids)"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02561767"
                        ]
                  },
                  {
                        "Rank": 701,
                        "Acronym": [
                              "Cartistem"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem\u00ae) is added on the lesion after above mentioned procedure.",
                              "standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cartistem",
                              "Biological: Cartistem"
                        ],
                        "ArmGroupLabel": [
                              "Cartistem",
                              "standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02338375"
                        ]
                  },
                  {
                        "Rank": 702,
                        "Acronym": [
                              "MSCLCTWPOI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The low dosage will inject 2 million MSC-like cells (in 100ul suspension) for each ovary.",
                              "The medium dosage will inject 5 million MSC-like cells (in 100ul suspension) for each ovary.",
                              "The high dosage will inject 10 million MSC-like cells (in 100ul suspension) for each ovary."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Cell therapy",
                              "Genetic: Cell therapy",
                              "Genetic: Cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Low dosage",
                              "Medium dosage",
                              "High dosage"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03877471"
                        ]
                  },
                  {
                        "Rank": 703,
                        "Acronym": [
                              "COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "4 times dose of Mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04522986"
                        ]
                  },
                  {
                        "Rank": 704,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placenta Derived Mesenchymal Stem Cell administered into the knee joint once",
                              "Sodium hyaluronate administered into the knee joint once"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta Derived Mesenchymal Stem Cell",
                              "Drug: Sodium Hyaluronate"
                        ],
                        "ArmGroupLabel": [
                              "Placenta Derived Mesenchymal Stem Cell",
                              "sodium hyaluronate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03028428"
                        ]
                  },
                  {
                        "Rank": 705,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of \u2248 30 million cells) on Day 0, Day 2, and Day 4",
                              "Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04905836"
                        ]
                  },
                  {
                        "Rank": 706,
                        "Acronym": [
                              "BR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)",
                              "Excipient"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04992247"
                        ]
                  },
                  {
                        "Rank": 707,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of \u2248 30 million cells) on Day 0, Day 2, and Day 4",
                              "Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04909879"
                        ]
                  },
                  {
                        "Rank": 708,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)",
                              "Excipient"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04728698"
                        ]
                  },
                  {
                        "Rank": 709,
                        "Acronym": [
                              "ASTEC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion",
                              "3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hMSCs",
                              "Biological: hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Group receiving 20 million hMSCs",
                              "Group receiving 100 million hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03137199"
                        ]
                  },
                  {
                        "Rank": 710,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Best Supportive care",
                              "Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.",
                              "Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Livercellgram",
                              "Biological: Livercellgram"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "1-time injection group: Livercellgram",
                              "2-time injection group: Livercellgram"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01875081"
                        ]
                  },
                  {
                        "Rank": 711,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients",
                              "Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection of Umbilical cord derived MSCs",
                              "Biological: Injection of Umbilical cord derived MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Injection of Umbilical cord derived MSCs",
                              "Injection of MSCs differentiated into neural stem cells NSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03684122"
                        ]
                  },
                  {
                        "Rank": 712,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants with moderate to severe acute respiratory distress syndrome (6 patients)",
                              "Participants with moderate to severe acute respiratory distress syndrome (10 patients)",
                              "Participants with moderate to severe acute respiratory distress syndrome (10 patients)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: HCR040 (Phase 1)",
                              "Drug: Placebo (Phase 2)",
                              "Drug: HCR040 (Phase 2)"
                        ],
                        "ArmGroupLabel": [
                              "HCR040 (Phase 1)",
                              "Control group (Phase 2)",
                              "HCR040 (Phase 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04289194"
                        ]
                  },
                  {
                        "Rank": 713,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.9% physiological saline",
                              "Low dose allogeneic mesenchymal stem cells derived from adipose tissue",
                              "High dose allogeneic mesenchymal stem cells derived from adipose tissue"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebos",
                              "Drug: Low dose allogeneic mesenchymal stromal cells",
                              "Drug: High dose allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Control arm",
                              "Low dose treatment arm",
                              "High dose treatment arm"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04466007"
                        ]
                  },
                  {
                        "Rank": 714,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allogenic bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "CS20AT04"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03174587"
                        ]
                  },
                  {
                        "Rank": 715,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.",
                              "Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.",
                              "Other: Vehicle + Heparin along with best supportive care"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Positive PRA",
                              "Negative PRA",
                              "Positive PRA",
                              "Negative PRA",
                              "Positive",
                              "Negative",
                              "Borderline",
                              "Positive",
                              "Negative",
                              "Borderline"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT04355728"
                        ]
                  },
                  {
                        "Rank": 716,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "safety with received beta-tricalcium phosphate (\u03b2 TCP) bone substitute only. (Bioresorb, Sybron, implant solutions GmbH Bremen, Germany)",
                              "safety with surgical augmentation of GF+GMSCs carried on \u03b2 TCP in intrabony periodontal defect and covered by collagen membrane and received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of \u03b2 TCP covered by a resorbable collagen membrane.\n\n(Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Jersey, USA)."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: \u03b2 TCP bone substitute only",
                              "Procedure: GF+GMSCs carried on \u03b2 TCP"
                        ],
                        "ArmGroupLabel": [
                              "GroupI",
                              "GroupII"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03638154"
                        ]
                  },
                  {
                        "Rank": 717,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One time infusion of islets plus BM-MSCs at 20x10^6/patient, n=14",
                              "One time infusion of islets plus BM-MSCs at 50x10^6/patient, n=14",
                              "One time infusion of islets only."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone marrow-derived mesenchymal stem cells",
                              "Biological: Bone marrow-derived mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSCs at 20x10^6",
                              "BM-MSCs at 50x10^6",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05095532"
                        ]
                  },
                  {
                        "Rank": 718,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.",
                              "Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Auto-hMSCs",
                              "Biological: Allo-hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Auto-hMSCs",
                              "Allo-hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01087996"
                        ]
                  },
                  {
                        "Rank": 719,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with CKD who underwent intravenous injection of MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "MSC recipient"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02195323"
                        ]
                  },
                  {
                        "Rank": 720,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.",
                              "Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.",
                              "Patients receive standard of care treatment for heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis"
                        ],
                        "ArmGroupLabel": [
                              "Arm I (hMSCs IV)",
                              "Arm II (hMSCs transendocardially)",
                              "Arm III (standard of care)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02962661"
                        ]
                  },
                  {
                        "Rank": 721,
                        "Acronym": [
                              "ROBUST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800\u00ae cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;",
                              "open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Cellularized composite graft augmentation",
                              "Procedure: Acellular composite graft augmentation"
                        ],
                        "ArmGroupLabel": [
                              "cellularized composite graft augmentation",
                              "Control acellular composite graft augmentation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01532076"
                        ]
                  },
                  {
                        "Rank": 722,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cord blood transplantation performed on day 0. Busulfan 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4.\n\nFludarabine 10 mg/m2 by vein on Days -7 to -4, 40 mg/m2 by vein on Days -6 to -3 or on Days -5 to -2.\n\nRituximab 375 mg/m2 by vein on Day -9. ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3, 1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2.\n\nCyclophosphamide 50 mg/kg by vein on Day -6. Clofarabine 30 mg/m2 by vein on Days -7 to -4. Total body irradiation (TBI) 200 cGy at 25 cGy/minute delivered on Day -3. Melphalan 140 mg/m2 by vein on Day -2. Tacrolimus 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Cord Blood Infusion",
                              "Drug: Busulfan",
                              "Drug: Fludarabine",
                              "Drug: Rituximab",
                              "Other: ATG",
                              "Drug: Cyclophosphamide",
                              "Drug: Clofarabine",
                              "Radiation: Total Body Irradiation (TBI)",
                              "Drug: Melphalan",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil",
                              "Drug: G-CSF"
                        ],
                        "ArmGroupLabel": [
                              "Cord Blood Infusion"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00498316"
                        ]
                  },
                  {
                        "Rank": 723,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "NEUROSTEM\u00ae-AD"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01297218"
                        ]
                  },
                  {
                        "Rank": 724,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients presenting to the Ohio State University Emergency Department or directly admitted to the Ohio State University Burn Unit following thermal burn.",
                              "Healthy volunteers"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "1",
                              "2"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00609661"
                        ]
                  },
                  {
                        "Rank": 725,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in the test group received autologous peripheral blood mesenchymal stem cell therapy",
                              "Patients in the control group 1 received microfracture surgical treatment",
                              "Patients in the control group 2 received microfracture combined with surgical treatment of collagen membrane",
                              "Patients in the control group 3 received autologous osteochondral transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: autologous peripheral blood mesenchymal stem cell",
                              "Procedure: Microfracture",
                              "Combination Product: Microfracture + collagen membrane",
                              "Procedure: Autologous osteochondral transplantation"
                        ],
                        "ArmGroupLabel": [
                              "test group",
                              "control group 1",
                              "control group 2",
                              "control group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04953572"
                        ]
                  },
                  {
                        "Rank": 726,
                        "Acronym": [
                              "ACESO-IHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).",
                              "Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: 100 million Allogeneic Mesenchymal Human Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group",
                              "Group 2: Placebo Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04776239"
                        ]
                  },
                  {
                        "Rank": 727,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After implementing PCI, contemporary drug treatment is conducted.\n\n*Contemporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotein llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, \u03b2-blocker, CCB, Diuretics, Statin, etc.)",
                              "Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1\u00d710^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Hearticellgram-AMI"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Single dose of Hearticellgram-AMI"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01652209"
                        ]
                  },
                  {
                        "Rank": 728,
                        "Acronym": [
                              "CERES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.",
                              "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
                              "Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.",
                              "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.",
                              "Participants randomized to receive a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
                              "Participants randomized to receive a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.",
                              "Participants randomized to receive a single administration of placebo via peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Biological: UCMSCs",
                              "Biological: BMMSCs",
                              "Biological: BMMSCs",
                              "Biological: UCMSCs",
                              "Biological: BMMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Pilot Phase: Group 1 (UCMSCs - 20 million)",
                              "Pilot Phase: Group 3 (UCMSCs - 100 million)",
                              "Pilot Phase: Group 2 (BMMSCs - 20 million)",
                              "Pilot Phase: Group 4 (BMMSCs -100 million)",
                              "Group A (UCMSCs - 100 million)",
                              "Group B (BMMSCs - 100 million)",
                              "Group C (Placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03059355"
                        ]
                  },
                  {
                        "Rank": 729,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous BM MSC"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03626090"
                        ]
                  },
                  {
                        "Rank": 730,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01159899"
                        ]
                  },
                  {
                        "Rank": 731,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                              "13 COVID-19 infected subjects (Patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                              "7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention.",
                              "7 healthy subjects (healthcare providers following patients admitted to hospital suffering complications from COVID-19) will be randomized and equally distributed between placebo and experimental intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PrimePro",
                              "Other: Placebo",
                              "Biological: PrimePro",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVID-19 Patients Experimental",
                              "COVID-19 Patients Placebo",
                              "Healthcare Providers Experimental",
                              "Healthcare Providers Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04573270"
                        ]
                  },
                  {
                        "Rank": 732,
                        "Acronym": [
                              "T2DM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.",
                              "30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MNC and UC-MSC",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "BM-MNC and UC-MSC",
                              "Stand medicines"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03943940"
                        ]
                  },
                  {
                        "Rank": 733,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placebo",
                              "Low dose (total of 600 million cells)",
                              "High dose (total of 1200 cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebo",
                              "Drug: PROCHYMAL adult human mesenchymal stem cells",
                              "Drug: PROCHYMAL adult human mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "PROCHYMAL Low dose",
                              "PROCHYMAL High dose"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00543374"
                        ]
                  },
                  {
                        "Rank": 734,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Isolation and \"Ex-Vivo\" expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-Divisi\u00f3n de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Autologous MSC knee implantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous MSC knee implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01227694"
                        ]
                  },
                  {
                        "Rank": 735,
                        "Acronym": [
                              "ASCAT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02064062"
                        ]
                  },
                  {
                        "Rank": 736,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03822858"
                        ]
                  },
                  {
                        "Rank": 737,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)",
                              "Normal Saline with Autologous Serum"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: JointStem",
                              "Other: Placebo Control"
                        ],
                        "ArmGroupLabel": [
                              "JointStem",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04368806"
                        ]
                  },
                  {
                        "Rank": 738,
                        "Acronym": [
                              "ASCROD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with autologous ASC",
                              "Treatment with autologous chondrocytes"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Implantation of autologous cells",
                              "Other: Implantation of autologous cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologous ASC implantation",
                              "Autologous Chondrocytes implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01399749"
                        ]
                  },
                  {
                        "Rank": 739,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Stem cell",
                              "Drug: Plasmalyte A"
                        ],
                        "ArmGroupLabel": [
                              "stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00883727"
                        ]
                  },
                  {
                        "Rank": 740,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 200 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.",
                              "Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 100 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.",
                              "Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 50 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.",
                              "Subjects assigned to this arm will receive 5 intravenous infusions of placebo intervention (saline). Infusions will occur at weeks 0, 2, 6, 10, and 14."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs",
                              "Biological: HB-adMSCs",
                              "Biological: HB-adMSCs",
                              "Other: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic HB-adMSCs 200MM",
                              "Allogeneic HB-adMSCs 100MM",
                              "Allogeneic HB-adMSCs 50MM",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04348435"
                        ]
                  },
                  {
                        "Rank": 741,
                        "Acronym": [
                              "MSCTPHSCT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients treated with mesenchymal stromal cell",
                              "Patients treated without mesenchymal stromal cell"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "mesenchymal stromal cell",
                              "non-mesenchymal stromal cell"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05131412"
                        ]
                  },
                  {
                        "Rank": 742,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PROCHYMAL\u00ae",
                              "Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: PROCHYMAL\u00ae",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Prochymal",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00690066"
                        ]
                  },
                  {
                        "Rank": 743,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intracoronary infusion of umbilical cord mesenchymal stem cells (UCMSCs)",
                              "Standard medical treatment without umbilical cord mesenchymal stem cells (UCMSCs) infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs",
                              "controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02666391"
                        ]
                  },
                  {
                        "Rank": 744,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hAMSCs were injected via venous in the dorsum of hand."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hAMSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04706312"
                        ]
                  },
                  {
                        "Rank": 745,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stem Cell Preparation and Injection:\n\nStem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared and suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .\n\nStem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cell Preparation and Injection"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cell Preparation and Injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02062931"
                        ]
                  },
                  {
                        "Rank": 746,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose A: PNEUMOSTEM\u00ae 10 million cells per kg Dose B: PNEUMOSTEM\u00ae 20 million cells per kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "PNEUMOSTEM\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02381366"
                        ]
                  },
                  {
                        "Rank": 747,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC Treatment",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04377334"
                        ]
                  },
                  {
                        "Rank": 748,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.",
                              "To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation",
                              "Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation"
                        ],
                        "ArmGroupLabel": [
                              "Adipose tissue-derived stem/stromal cells",
                              "Daily 2000 UI of daily oral cholecalciferol"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03920397"
                        ]
                  },
                  {
                        "Rank": 749,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.",
                              "Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly."
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Control group",
                              "Preeclampsia group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03562715"
                        ]
                  },
                  {
                        "Rank": 750,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.",
                              "This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Linagliptin",
                              "Drug: Linagliptin"
                        ],
                        "ArmGroupLabel": [
                              "Linagliptin patients with schizophrenia",
                              "Linagliptin control group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02442817"
                        ]
                  },
                  {
                        "Rank": 751,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMC119-06-05"
                        ],
                        "ArmGroupLabel": [
                              "UMC119-06-05"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04914403"
                        ]
                  },
                  {
                        "Rank": 752,
                        "Acronym": [
                              "GVHD Cyto-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment",
                              "Placebo (normal saline) and standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord derived mesenchymal stem cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group A",
                              "Group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03847844"
                        ]
                  },
                  {
                        "Rank": 753,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Derived-Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "UMC119-01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03631420"
                        ]
                  },
                  {
                        "Rank": 754,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous Bone marrow derived stem cells transplant"
                        ],
                        "ArmGroupLabel": [
                              "Therapy for Parkinson's disease"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00976430"
                        ]
                  },
                  {
                        "Rank": 755,
                        "Acronym": [
                              "UCMSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group receiving standard COVID-19 treatment and UCMSC infusion",
                              "Group receiving standard COVID-19 treatment and normal saline infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Normoxic Allogenic UCMSC",
                              "Other: Normal saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05132972"
                        ]
                  },
                  {
                        "Rank": 756,
                        "Acronym": [
                              "DCMII"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.",
                              "Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.",
                              "Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.",
                              "Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.",
                              "Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.",
                              "Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Placebo",
                              "Biological: allogeneic human mesenchymal stem cells (hMSCs)",
                              "Other: Placebo",
                              "Biological: allogeneic human mesenchymal stem cells (hMSCs)",
                              "Other: Placebo",
                              "Biological: allogeneic human mesenchymal stem cells (hMSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Genotype A administered with placebo Group",
                              "Genotype A administered with hMSC Group",
                              "Genotype B administered with placebo Group",
                              "Genotype B administered with hMSC Group",
                              "Genotype C administered with placebo Group",
                              "Genotype C administered with hMSC Group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04476901"
                        ]
                  },
                  {
                        "Rank": 757,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMC119-06"
                        ],
                        "ArmGroupLabel": [
                              "UMC119-06"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04206007"
                        ]
                  },
                  {
                        "Rank": 758,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow",
                              "Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03522545"
                        ]
                  },
                  {
                        "Rank": 759,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01663376"
                        ]
                  },
                  {
                        "Rank": 760,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.",
                              "Patients will be given tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.",
                              "Patients will be given tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.",
                              "Patients will be given Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Biological: Secretomes",
                              "Biological: UC-MSCs and Secretomes",
                              "Biological: Control"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSCs",
                              "Secretomes",
                              "WJ-MSCs and Secretomes",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05279768"
                        ]
                  },
                  {
                        "Rank": 761,
                        "Acronym": [
                              "FTD_ET-STEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "injected with 3x10^7 cells/2mL of ET-STEM to intraventricular space via an Ommaya reservoir. repeated 3 times at 4 week intervals"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ET-STEM"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05315661"
                        ]
                  },
                  {
                        "Rank": 762,
                        "Acronym": [
                              "MSCforGVHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00827398"
                        ]
                  },
                  {
                        "Rank": 763,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Observational Only",
                              "The drugs dasatinib and quercetin will be used in this arm"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Group 2: Dasatinib",
                              "Drug: Group 2: Quercetin"
                        ],
                        "ArmGroupLabel": [
                              "Group 1: Observational",
                              "Group 2: Dasatinib & Quercetin"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02848131"
                        ]
                  },
                  {
                        "Rank": 764,
                        "Acronym": [
                              "ESTIMATION"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Endocardial Stem cells implantation with Noga system",
                              "Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: PCI and Stem Cells or Placebo injections",
                              "Procedure: PCI and Stem Cells or Placebo injections"
                        ],
                        "ArmGroupLabel": [
                              "Group 1 (PCI+SC implantation)",
                              "Group 2 (PCI+Placebo)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01394432"
                        ]
                  },
                  {
                        "Rank": 765,
                        "Acronym": [
                              "HERA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.",
                              "Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.",
                              "2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine"
                        ],
                        "ArmGroupLabel": [
                              "Pilot Phase- Cohort A",
                              "Pilot Phase Cohort B & C",
                              "Double-Blind,Randomized,Placebo Phase"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02982915"
                        ]
                  },
                  {
                        "Rank": 766,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived-Mesenchymal Stem Cells. Subjects will receive a single-dose intra-articular (IA) injection of UMC119-06-05 followed by an IA injection of hyaluronic acid."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMC119-06-05",
                              "Device: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "UMC119-06-05"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04893174"
                        ]
                  },
                  {
                        "Rank": 767,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.",
                              "Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells",
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular knee injection of MTF",
                              "Subcutaneous injection of MTF"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02003131"
                        ]
                  },
                  {
                        "Rank": 768,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will received weekly (n=6) IV infusion of Celyvir."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CELYVIR"
                        ],
                        "ArmGroupLabel": [
                              "CELYVIR"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01844661"
                        ]
                  },
                  {
                        "Rank": 769,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "cfMSCs treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: clonal fetal MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Single arm, cfMSC to treat immune disorders"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03123458"
                        ]
                  },
                  {
                        "Rank": 770,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSCs treated"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03631589"
                        ]
                  },
                  {
                        "Rank": 771,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-nasal infusion of MTF"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02192736"
                        ]
                  },
                  {
                        "Rank": 772,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "infusion of aUCMSC and Ursodeoxycholic acid therapy",
                              "Ursodeoxycholic acid therapy 15mg/kg/d"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UCMSC",
                              "Drug: UDCA",
                              "Drug: UDCA"
                        ],
                        "ArmGroupLabel": [
                              "UCMSC",
                              "UDCA"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03516006"
                        ]
                  },
                  {
                        "Rank": 773,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs will be used to treat refractory CMV infection or CMV-associated diseases. MSCs will be intravenously infused at a dose of 1\u00d710^6 cells/kg. If anticipates do not attain the complete remission standards within 14d, a second course of the same treatment will be given."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02083731"
                        ]
                  },
                  {
                        "Rank": 774,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: aMSC",
                              "Biological: aMSC+hyaluronan gel"
                        ],
                        "ArmGroupLabel": [
                              "aMSC with and without hyaluronan gel"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01981330"
                        ]
                  },
                  {
                        "Rank": 775,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Two intrathecal MSC injections"
                        ],
                        "ArmGroupLabel": [
                              "MSC injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02917681"
                        ]
                  },
                  {
                        "Rank": 776,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "xerostomy using mesenchymal stem cells adult autologous bone marrow"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "treatment with mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03743155"
                        ]
                  },
                  {
                        "Rank": 777,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.",
                              "Gel-One\u00ae is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BMAC injection",
                              "Biological: PRP injection",
                              "Device: Gel-One\u00ae hyaluronate injection"
                        ],
                        "ArmGroupLabel": [
                              "BMAC injection and PRP injection",
                              "Gel-One\u00ae hyaluronate injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT02958267"
                        ]
                  },
                  {
                        "Rank": 778,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The treatment period consists of a single, 28-day cycle. Participants will be treated with ECP 2 to 3 times per week per the discretion of the treating physician. Participants will receive IV infusions of MSCs on days 1 (+ 2 days) and 8 (+/- 2 days). A third dose may be given on day 15 (+/- 2 days) if the principal investigator (PI) and treating physician determine the MSC infusions have benefited the participant.\n\nParticipants will be followed for up to 1 year for assessment of endpoints."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic mesenchymal stromal cells (MSCs)",
                              "Biological: Extracorporeal photopheresis (ECP)"
                        ],
                        "ArmGroupLabel": [
                              "MSCs + ECP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05333029"
                        ]
                  },
                  {
                        "Rank": 779,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: TH-SC01"
                        ],
                        "ArmGroupLabel": [
                              "TH-SC01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04939337"
                        ]
                  },
                  {
                        "Rank": 780,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.",
                              "Participants will receive conventional treatment and Placebo intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04339660"
                        ]
                  },
                  {
                        "Rank": 781,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152368"
                        ]
                  },
                  {
                        "Rank": 782,
                        "Acronym": [
                              "STEM-VAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.",
                              "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03925324"
                        ]
                  },
                  {
                        "Rank": 783,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Hormone replacement therapy, placebo transplantation.",
                              "Hormone replacement therapy,HUC-MSCs transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placebo transplantation",
                              "Biological: HUC-MSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03033277"
                        ]
                  },
                  {
                        "Rank": 784,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05167188"
                        ]
                  },
                  {
                        "Rank": 785,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will undergo a bone marrow aspirate procedure. Participants will receive a single intra-articular injection of NGRM-001 on treatment day.",
                              "Participants will undergo a bone marrow aspirate procedure. Participants will receive a single subchondral injection of NGRM-001 on treatment day.",
                              "Participants will undergo a bone marrow aspirate procedure. Participants will receive a single combined intra-articular and subchondral injection of NGRM-001 on treatment day.",
                              "Subjects in the corticosteroid group will undergo a mock bone marrow aspirate procedure. Participants will receive a single intra-articular injection of corticosteroid on treatment day."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Derived MSCs",
                              "Device: Bone Marrow Aspirate",
                              "Biological: Bone Marrow Derived MSCs",
                              "Device: Bone Marrow Aspirate",
                              "Biological: Bone Marrow Derived MSCs",
                              "Device: Bone Marrow Aspirate",
                              "Drug: Corticosteroid",
                              "Device: Bone Marrow Aspirate"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular injection with Bone Marrow Derived Mesenchymal Stem Cells (MSCs)",
                              "Subchondral injection with Bone Marrow Derived MSCs",
                              "Combined Intra-articular and Subchondral injection with Bone Marrow Derived MSCs",
                              "Corticosteroid injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05288725"
                        ]
                  },
                  {
                        "Rank": 786,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous and intracavernosal or interstitial delivery (total dose of 100 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147779"
                        ]
                  },
                  {
                        "Rank": 787,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.",
                              "patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: stem cell therapy",
                              "Biological: stem cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "immediate stem cell therapy",
                              "delayed stem cell therapy"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01824121"
                        ]
                  },
                  {
                        "Rank": 788,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.\n\nCohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCTC-0010 Dose Escalation"
                        ],
                        "ArmGroupLabel": [
                              "MSCTC-0010 Dose Escalation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03158896"
                        ]
                  },
                  {
                        "Rank": 789,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells"
                        ],
                        "ArmGroupLabel": [
                              "IV and IT UC-MSC and BMMC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02237547"
                        ]
                  },
                  {
                        "Rank": 790,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Jointstem"
                        ],
                        "ArmGroupLabel": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03509025"
                        ]
                  },
                  {
                        "Rank": 791,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.",
                              "50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Chondrogen",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Active Participant of Phase 2B Clinical Study Chondrogen",
                              "Placebo Participant of Phase 2B Clinical Study Chondrogen"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04520945"
                        ]
                  },
                  {
                        "Rank": 792,
                        "Acronym": [
                              "Homeo-GH"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01318330"
                        ]
                  },
                  {
                        "Rank": 793,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs Participants will received i. m. HUC-MSCs both lower extremities",
                              "The control group will receive i.v Lipoic Acid Injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HUC-MSCs",
                              "Biological: Lipoic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Comparator"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05507697"
                        ]
                  },
                  {
                        "Rank": 794,
                        "Acronym": [
                              "SEESCMMSCTSD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Applications of medical collagen membrane with umbilical cord derived mesenchymal stem cells (MSC).",
                              "Application of medical collagen membrane only."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Medical Collagen Membrane with MSC",
                              "Device: Medical Collagen Membrane"
                        ],
                        "ArmGroupLabel": [
                              "Medical Collagen Membrane with MSC",
                              "Medical Collagen Membrane"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02672280"
                        ]
                  },
                  {
                        "Rank": 795,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cell injection"
                        ],
                        "ArmGroupLabel": [
                              "Cirrhotic Patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01454336"
                        ]
                  },
                  {
                        "Rank": 796,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PLACEBO Normal saline 100 mL",
                              "IP (ExoFlo) 15ml dose in Normal saline 85 mL, which is approximately 1.2 trillion EVs."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: EXOFLO",
                              "Drug: EXOFLO"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm 1",
                              "Treatment Arm 2"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05354141"
                        ]
                  },
                  {
                        "Rank": 797,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants received Prochymal\u2122 a total of 400\u00d710^6 cells, intravenous (IV) infusions on Days 0, 30, 60, and 90.",
                              "Participants received placebo-matching IV infusions on Days 0, 30, 60 and 90."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Prochymal\u2122",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Prochymal\u2122",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00683722"
                        ]
                  },
                  {
                        "Rank": 798,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: NeuroRegen scaffold with BMMCs or MSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "NeuroRegen Scaffold with BMMCs or MSCs transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02352077"
                        ]
                  },
                  {
                        "Rank": 799,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.",
                              "Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.",
                              "Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.",
                              "Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Biological: hUCMSCs and hCBMNCs",
                              "Biological: human cord blood mononuclear cells",
                              "Drug: Hormone Replacement Therapy"
                        ],
                        "ArmGroupLabel": [
                              "Group1 : HRT plus hUCMSCs treatment:",
                              "Group 2: HRT plus hCBMNCs and hUCMSCs therapy",
                              "Group3 : HRT plus hCBMNCs treatment:",
                              "Group 4:Hormone Replacement Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01742533"
                        ]
                  },
                  {
                        "Rank": 800,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human bone marrow-derived MSCs at a dose of 1.0E+6 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. total for 12 weeks.",
                              "50mg,hypodermic injection,once per week, for 12 weeks"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous infusion of MSCs",
                              "Drug: Etanercept"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous infusion of MSCs",
                              "Etanercept"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02809781"
                        ]
                  },
                  {
                        "Rank": 801,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection\n\nOther Names:\n\nADSC, mesenchymal cells, stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose derived mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "Adipose derived mesenchymal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02326935"
                        ]
                  },
                  {
                        "Rank": 802,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)\n\nPharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Bone Marrow Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02570932"
                        ]
                  },
                  {
                        "Rank": 803,
                        "Acronym": [
                              "hUC-MSC-SLE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord derived MSCs",
                              "Drug: Cyclophosphamide"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord derived MSCs",
                              "Cyclophosphamide"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01539902"
                        ]
                  },
                  {
                        "Rank": 804,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery\n\nDOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain",
                              "A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM\u00ae-AD-treated group, but did not receive the treatment with NEUROSTEM\u00ae-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows:\n\nPatients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia.\n\nFor drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NEUROSTEM\u00ae-AD"
                        ],
                        "ArmGroupLabel": [
                              "NEUROSTEM\u00ae-AD",
                              "Control Group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01696591"
                        ]
                  },
                  {
                        "Rank": 805,
                        "Acronym": [
                              "MESRIX-III"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "60 patients will be randomized to receive adipose-derived allogeneic stem cells",
                              "60 patients will receive placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell group",
                              "Placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04776538"
                        ]
                  },
                  {
                        "Rank": 806,
                        "Acronym": [
                              "BOOST2B"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database",
                              "Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BOOST cells"
                        ],
                        "ArmGroupLabel": [
                              "Prospective Control (Untreated) and historical controls",
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04623606"
                        ]
                  },
                  {
                        "Rank": 807,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Prochymal\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "Prochymal\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00284986"
                        ]
                  },
                  {
                        "Rank": 808,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: HYNR-CS inj.\n\nTreatment group with HYNR-CS inj."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HYNR-CS inj."
                        ],
                        "ArmGroupLabel": [
                              "Single arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02210624"
                        ]
                  },
                  {
                        "Rank": 809,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).",
                              "IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ExoFlo",
                              "Drug: ExoFlo"
                        ],
                        "ArmGroupLabel": [
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46",
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05176366"
                        ]
                  },
                  {
                        "Rank": 810,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive matching placebo administered as intravenous (IV) infusions.",
                              "Participants will receive a total dose of Prochymal\u00ae 600 x 10^6 cells, IV infusion, on four days, once daily.",
                              "Participants will receive a total dose of Prochymal\u00ae 1200 x 10^6 cells, IV infusion, on four days, once daily."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebo",
                              "Drug: Prochymal\u00ae",
                              "Drug: Prochymal\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "Prochymal\u00ae - Low dose",
                              "Prochymal\u00ae - High dose"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00482092"
                        ]
                  },
                  {
                        "Rank": 811,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AstroStem-V which consists of three syringes and each syringe contains 1.0 x 10^8 cells / 3mL of saline with 30% human serum"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AstroStem-V"
                        ],
                        "ArmGroupLabel": [
                              "AstroStem-V"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04527224"
                        ]
                  },
                  {
                        "Rank": 812,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ambulatory patients receiving stem cell therapy",
                              "non-ambulatory patients receiving stem cell therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell",
                              "Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Ambulatory Patients",
                              "Non-Ambulatory Patients"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02484560"
                        ]
                  },
                  {
                        "Rank": 813,
                        "Acronym": [
                              "2ABC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous ADSC injection combined with laser therapy of the skin.",
                              "Normal sline injection combined with laser therapy of the skin."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Laser therapy",
                              "Biological: Autologous ADSC injection",
                              "Procedure: Laser therapy",
                              "Procedure: Normal saline injection"
                        ],
                        "ArmGroupLabel": [
                              "Autologous adipose derived stem cells",
                              "Placebo - Normal saline injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03887208"
                        ]
                  },
                  {
                        "Rank": 814,
                        "Acronym": [
                              "CELOPHIN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells",
                              "Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells at day 0 and 12,5 million cells at day 14"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Single Dose",
                              "Drug: Double Dose"
                        ],
                        "ArmGroupLabel": [
                              "Single dose Allogenic Adiposse derived mesenchimal stem cells",
                              "Double dose Allogenic Adiposse derived mesenchimal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05520086"
                        ]
                  },
                  {
                        "Rank": 815,
                        "Acronym": [
                              "BOOSTB4"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 participants.\n\nAdministration of four postnatal doses of BOOST cells with the first dose as soon as possible after birth and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.",
                              "15 participants.\n\nAdministration of one prenatal dose of BOOST cells followed by three postnatal doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.",
                              "1-30 participants.\n\nSubjects eligible for the trial but not willing/able to participate in any of the experimental arms.",
                              "30-150 participants.\n\nMatched historical controls. Subjects will be identified in historical registries and data will be retrieved from national OI registers and the OI Variant Database (Dalgleish 2018)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BOOST cells",
                              "Biological: BOOST cells"
                        ],
                        "ArmGroupLabel": [
                              "Postnatal",
                              "Prenatal",
                              "Prospective control (untreated)",
                              "Historic control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03706482"
                        ]
                  },
                  {
                        "Rank": 816,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At this stage, 3 patients with knee OA will be treated by the cell products of this dose.",
                              "At this stage, 3 patients with knee OA will be treated by the cell products of this dose.",
                              "At this stage, 3 patients with knee OA will be treated by the cell products of this dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Chondrochymal\u00ae",
                              "Biological: Chondrochymal\u00ae",
                              "Biological: Chondrochymal\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "Chondrochymal\u00ae 1 x 10^7 cells",
                              "Chondrochymal\u00ae 5 x 10^7 cells",
                              "Chondrochymal\u00ae 10 x 10^7 cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03589287"
                        ]
                  },
                  {
                        "Rank": 817,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "TENS , Open chain knee flexion and extension, Calf stretch , Quad set",
                              "MET ( isometric contraction with 6-10 sec )"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: CONVENTIONAL PHYSICAL THERAPY",
                              "Other: MUSCLE ENERGY TECHNIQUE"
                        ],
                        "ArmGroupLabel": [
                              "CONVENTIONAL PHYSICAL THERAPY",
                              "MUSCLE ENERGY TECHNIQUE"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05349565"
                        ]
                  },
                  {
                        "Rank": 818,
                        "Acronym": [
                              "ELPIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.",
                              "Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.",
                              "Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Longeveron Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Cohort A - Phase 1 (Open Label)",
                              "Cohort B - Phase 2 Treatment Group",
                              "Cohort C - Phase 2 Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 819,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "PNEUMOSTEM\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01297205"
                        ]
                  },
                  {
                        "Rank": 820,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NurOwn (MSC-NTF cells)"
                        ],
                        "ArmGroupLabel": [
                              "NurOwn (MSC-NTF cells)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03799718"
                        ]
                  },
                  {
                        "Rank": 821,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: EV-Pure\u2122 and WJ-Pure\u2122",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Experimental/treatment arm",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05387278"
                        ]
                  },
                  {
                        "Rank": 822,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Outpatient in hospital",
                              "interventions: rehabilitation",
                              "interventions: stem cell transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: rehabilitation of limb function",
                              "Procedure: Stem Cells Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "control",
                              "rehabilitation",
                              "Stem Cell Transplantation"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01393977"
                        ]
                  },
                  {
                        "Rank": 823,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "ALLO-ASC-SHEET Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells",
                              "Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-SHEET",
                              "Biological: ALLO-ASC-SHEET"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-SHEET",
                              "Hydrogel SHEET(Vehicle control)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04497805"
                        ]
                  },
                  {
                        "Rank": 824,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: physiological saline",
                              "Biological: MSCs Derived Pleiotropic Factors"
                        ],
                        "ArmGroupLabel": [
                              "control group",
                              "experimental group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04536233"
                        ]
                  },
                  {
                        "Rank": 825,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)",
                              "Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymoangioblast-derived mesenchymal stem cells",
                              "Biological: Mesenchymoangioblast-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Cohort A",
                              "Cohort B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02923375"
                        ]
                  },
                  {
                        "Rank": 826,
                        "Acronym": [
                              "SCI-III"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.",
                              "Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.",
                              "Patients receive no professional treatment in hospital or rehabilitation centre."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: rehabilitation",
                              "Biological: cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "rehabilitation",
                              "cell therapy",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01873547"
                        ]
                  },
                  {
                        "Rank": 827,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "infusion of BMMSC+BMMNC and insulin injection",
                              "infusion of BMMNC and insulin injection",
                              "insulin injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: infusion of BMMSCs",
                              "Drug: infusion BMMNCs",
                              "Drug: insulin",
                              "Drug: infusion BMMNCs",
                              "Drug: insulin",
                              "Drug: insulin"
                        ],
                        "ArmGroupLabel": [
                              "BMMSC+BMMNC",
                              "BMMNC",
                              "Insulin"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01719640"
                        ]
                  },
                  {
                        "Rank": 828,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.",
                              "Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ARM 1: AdMSC: adipose stem cells",
                              "Other: ARM 2: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "ARM 1: AdMSC: adipose stem cells",
                              "ARM 2 Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02107118"
                        ]
                  },
                  {
                        "Rank": 829,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.",
                              "participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: conventional plus MSC treatment",
                              "Drug: conventional plus placebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "conventional plus MSC treatment",
                              "conventional plus placebo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01220492"
                        ]
                  },
                  {
                        "Rank": 830,
                        "Acronym": [
                              "CISS2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells",
                              "Intravenous infusion of Placebo, with excipients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03369275"
                        ]
                  },
                  {
                        "Rank": 831,
                        "Acronym": [
                              "ORTHOUNION"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Cultured Mesenchymal Stem Cells +Biomaterial (Low Dose): 100x106 cells",
                              "Autologous Cultured Mesenchymal Stem Cells+Biomaterial (High Dose): 200x106 cells",
                              "Autologous Iliac Crest Grafting"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cultured Mesenchymal Stem Cells",
                              "Biological: Cultured Mesenchymal Stem Cells",
                              "Procedure: Autologous iliac crest graft"
                        ],
                        "ArmGroupLabel": [
                              "hBM-MSCs-Low Dose",
                              "hBM-MSCs-High Dose",
                              "Autologous iliac crest graft"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03325504"
                        ]
                  },
                  {
                        "Rank": 832,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00826046"
                        ]
                  },
                  {
                        "Rank": 833,
                        "Acronym": [
                              "1ABC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Application of allogeneic ADSC stem cells in fibrin gel, to cover wound surface with thin cells layer.\n\nTherapy is based on standard procedure of diabetic foot ulcer treatment combined with application of allogeneic ADSC stem cells in fibrin solution onto the wound surface.",
                              "Application of fibrin gel to cover wound surface."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Application of allogeneic ADSC stem cells in fibrin gel",
                              "Procedure: Standard care in diabetic foot ulcer"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic ADSC cells in fibrin solution",
                              "Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface."
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03865394"
                        ]
                  },
                  {
                        "Rank": 834,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5\u00d710^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.",
                              "The control arm will be given placebo which contains the same cell suspension solution but without cells. Placebo will be given the same way as BX-U001 via a single IV infusion using a blood transfusion kit."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hUC-MSC suspension",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment",
                              "Placebo control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03828344"
                        ]
                  },
                  {
                        "Rank": 835,
                        "Acronym": [
                              "PASSIoN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All (near-)term newborns \u226536 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03356821"
                        ]
                  },
                  {
                        "Rank": 836,
                        "Acronym": [
                              "MESRIX"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the MSC-suspension , the surgeon will identify the submandibular glands and inject the suspension MSCs into the submandibular gland. Calculation of injected number of MSCs pr. participant rests on the following calculation: 2.8 x 10^6 MSC / Cm^3 X volume , where volume is the volume of the submandibular gland, and a gland-volume of app. 7-8cm3 is the norm. Therefore the amount of cells given to each participant will be app. 4.6 x 10^7 MSC in total. Afterwards the participant will be given a band-aid and over the counter analgesics.",
                              "The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the placebo-suspension , the surgeon will identify the submandibular glands and inject the suspension. Placebo will be 2ml of Isotonic NaCl (0,9mg/ml) and HA 1%."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cell",
                              "Drug: Isotonic NaCl"
                        ],
                        "ArmGroupLabel": [
                              "Stemcells injected into submandibularis",
                              "Saltwater injected into submandibularis"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02513238"
                        ]
                  },
                  {
                        "Rank": 837,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals",
                              "human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals",
                              "normal saline 2mL, doses separated by 4 weeks for a total of 3 doses"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord blood derived mesenchymal stem cells",
                              "Biological: human umbilical cord blood derived mesenchymal stem cells",
                              "Other: Normal saline 2mL"
                        ],
                        "ArmGroupLabel": [
                              "NEUROSTEM (hUCB-MSCs)- low dose",
                              "NEUROSTEM (hUCB-MSCs) - high dose",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02054208"
                        ]
                  },
                  {
                        "Rank": 838,
                        "Acronym": [
                              "Maxibone"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The gold standard; Bone block from the ramus of the nation will be transplanted to the alveolar ridge.",
                              "Expanded, autologous mesenchymal stem cells in combination with biphasic calcium phosphate"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous bone graft",
                              "Combination Product: Advanced medicinal Therapy (MSC combined with biomaterial)"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Test"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04297813"
                        ]
                  },
                  {
                        "Rank": 839,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Cellular transplantation"
                        ],
                        "ArmGroupLabel": [
                              "A"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00515307"
                        ]
                  },
                  {
                        "Rank": 840,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous administration of placebo",
                              "Intravenous administration of 1 million of MSC/ kg",
                              "Intravenous administration of 2 million of MSC/ kg",
                              "Intravenous administration of 4 million of MSC/ kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Intravenous administration of placebo",
                              "Drug: Intravenous administration of 1 million of MSC",
                              "Drug: Intravenous administration of 2 million of MSC",
                              "Drug: Intravenous administration of 4 million of MSC"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "1 million of MSC",
                              "2 million of MSC",
                              "4 million of MSC"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02290886"
                        ]
                  },
                  {
                        "Rank": 841,
                        "Acronym": [
                              "DISCUSS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with sepsis, Patients with inflammatory disease without sepsis, Patients without inflammatory disease without sepsis.\n\nHuman biological samples collected for research :\n\nBlood sample\nMuscle biopsy\nBone marrow sample (mesenchymal stem cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Human biological samples"
                        ],
                        "ArmGroupLabel": [
                              "Patients with and without sepsis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02789995"
                        ]
                  },
                  {
                        "Rank": 842,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Fisetin 20 mg/kg/day, orally for 2 consecutive days",
                              "Placebo capsules orally for 2 consecutive days"
                        ],
                        "ArmGroupInterventionName": [
                              "Dietary Supplement: Fisetin",
                              "Drug: Placebo oral capsule"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03325322"
                        ]
                  },
                  {
                        "Rank": 843,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived MSC:\n\nPatients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01754454"
                        ]
                  },
                  {
                        "Rank": 844,
                        "Acronym": [
                              "WAIAMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Standard therapy+Intravenous infusion PBS in patients with AMI",
                              "Standard therapy+Intravenous infusion WJMSCs in patients with AMI"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous infusion placebo",
                              "Biological: Intravenous infusion WJMSCs",
                              "Biological: Intravenous infusion placebo",
                              "Biological: Intravenous infusion WJMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Placebo PBS",
                              "WJMScs"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04551443"
                        ]
                  },
                  {
                        "Rank": 845,
                        "Acronym": [
                              "Epi-KAB"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention on primary cultured cells from 4 patients with KS and sex match parents"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Intervention on primary cultured cells"
                        ],
                        "ArmGroupLabel": [
                              "Kabuki syndrome/ unaffected parents"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03855631"
                        ]
                  },
                  {
                        "Rank": 846,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Conventional therapy plus low dose UCMSCs treatment",
                              "Biological: Conventional therapy plus medium dose UCMSCs treatment",
                              "Biological: Conventional therapy plus high dose UCMSCs treatment"
                        ],
                        "ArmGroupLabel": [
                              "Low dose umbilical cord mesenchymal stem cells (UCMSCs)",
                              "Medium dose UCMSCs",
                              "High dose UCMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05155657"
                        ]
                  },
                  {
                        "Rank": 847,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group of patients with complete transection of the spinal cord group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive AutoBM-MSCs by a specialized spine surgeon into the spinal medulla.",
                              "This group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI. All patients will receive WJ-MSCs by a specialized spine surgeon into the spinal medulla."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Collection and expansion of BM-MSC",
                              "Diagnostic Test: VI-SCI evaluation and patients' follow up",
                              "Biological: Collection and expansion of BM-MSC",
                              "Diagnostic Test: VI-SCI evaluation and patients' follow up"
                        ],
                        "ArmGroupLabel": [
                              "patients with complete transection of the spinal cord",
                              "patients with SCI without total transaction."
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04288934"
                        ]
                  },
                  {
                        "Rank": 848,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.",
                              "Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.",
                              "Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Rabbit antithymoglobulin (ATG)",
                              "Drug: Rabbit antithymoglobulin (ATG)",
                              "Procedure: Adipose derived mesenchymal stem cells ( AD-MSCs)",
                              "Drug: Rabbit antithymoglobulin (ATG)",
                              "Procedure: AD-MSC transdifferentiated HSCs (AD-HSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Rabbit antithymoglobulin \uff08ATG\uff09",
                              "Rabbit ATG & AD-MSCs",
                              "Rabbit ATG & AD-HSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02407470"
                        ]
                  },
                  {
                        "Rank": 849,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year",
                              "400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Other: Reference therapy: 400 mL of 0.9% NaCl solution"
                        ],
                        "ArmGroupLabel": [
                              "MSC group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01849159"
                        ]
                  },
                  {
                        "Rank": 850,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Low dose UCMSCs",
                              "Biological: Moderate dose UCMSCs",
                              "Biological: High dose UCMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Low dose UCMSCs",
                              "Moderate dose UCMSCs",
                              "High dose UCMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05151133"
                        ]
                  },
                  {
                        "Rank": 851,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) in patients with fracture and bone nonunion.",
                              "The patients with fracture and bone nonunion who underwent percutaneous injection of placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Biological: Percutaneous"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02815423"
                        ]
                  },
                  {
                        "Rank": 852,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each subject receives three doses of 200 million autologous adipose derived mesenchymal stem cells via intravenously infusion every three days\n\nOther Names: Celltex-AdMSCs Celltex-AdMSCs",
                              "The control group- receive three doses of placebo via intravenously infusion every three days."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose-derived stem cells",
                              "Biological: autologous adipose-derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Phase 2 AdMSC group",
                              "Phase 2 Placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04428801"
                        ]
                  },
                  {
                        "Rank": 853,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PBSC will be intravenously infused at a dose of 2\u00d710^8/kg. MSCs will be intravenously infused at a dose of 1\u00d710^6 cells/kg once per week or until complete response(CR) . If the patients do not achieve CR or partial remission (PR) within 4 weeks, they will swithed to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.",
                              "MSCs will be intravenously infused at a dose of 1\u00d710^6 cells/kg once per week or until CR. If the patients have no response (NR) within 4 weeks, they will switch to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PBSC",
                              "Biological: MSCs",
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSCs&PBSC",
                              "MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02240992"
                        ]
                  },
                  {
                        "Rank": 854,
                        "Acronym": [
                              "MSC11FCD-GBM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The investigational drug in the amount of 1x10^7, 3x10^7cells per dose into the tumor or the tumor removal site using a syringe during surgery"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC11FCD"
                        ],
                        "ArmGroupLabel": [
                              "The investigational drug into the Intratumoral administration"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04657315"
                        ]
                  },
                  {
                        "Rank": 855,
                        "Acronym": [
                              "ASC-OA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04223622"
                        ]
                  },
                  {
                        "Rank": 856,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "4 times dose of Mesenchymal stem cell",
                              "Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04888949"
                        ]
                  },
                  {
                        "Rank": 857,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem Cell-Derived Exosomes",
                              "conventional treatment"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "trial group",
                              "control group"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04850469"
                        ]
                  },
                  {
                        "Rank": 858,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive Prochymal\u00ae single intravenous (IV) infusion at a dose of 200 x 10^6 human mesenchymal stem cells (hMSC), reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months.",
                              "Participants will receive Prochymal\u00ae placebo-matching single IV infusion at a dose of of 200 x 10^6 hMSC, reconstituted in 80 mL, delivered at a rate of 2 mL/min, with a maximum rate of 5.0 x 10^6 hMSC/minute, and the participants will be followed for 24 months and remain in the study for up to 60 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Prochymal\u00ae",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Prochymal\u00ae",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00877903"
                        ]
                  },
                  {
                        "Rank": 859,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: sampling mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Children with cleft"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02900014"
                        ]
                  },
                  {
                        "Rank": 860,
                        "Acronym": [
                              "ADASCs-CT-CD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "5 patients, who will receive adipose tissue mesenchymal stem cells in a single dose as study treatment",
                              "5 patients, who will receive decellularized corneal laminas as treatment medication",
                              "5 patients, who will receive adipose tissue mesenchymal cells combined with decellularized corneal laminas as study treatment in a single intervention"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Implantation",
                              "Procedure: Lipoaspiration",
                              "Procedure: Implantation",
                              "Procedure: Implantation",
                              "Procedure: Lipoaspiration"
                        ],
                        "ArmGroupLabel": [
                              "ADASCs Group",
                              "Acellular laminas group",
                              "ADASCs recellularized laminas group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05279157"
                        ]
                  },
                  {
                        "Rank": 861,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1 (10 subjects) Target dose 20 million Longeveron Mesenchymal Stem Cells (LMSCs) via peripheral intravenous infusion.",
                              "Cohort 2 (10 subjects) Target dose 100 million Longeveron Mesenchymal Stem Cells (LMSCs)via peripheral intravenous infusion.",
                              "Cohort 3 (5 subjects) Placebo (Plasmalyte A and 1% human serum albumin (HSA)) via peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02600130"
                        ]
                  },
                  {
                        "Rank": 862,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs: adipose-derived multipotent mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg of body weight at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks.\n\nThe basic treatment is oral PSORI-CM01 Granule plus calcipotriol ointment (Dovonex;LEO Laboratories Ltd, Ireland) for topical use twice daily for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Calcipotriol ointment",
                              "Drug: PSORI-CM01 Granule",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04275024"
                        ]
                  },
                  {
                        "Rank": 863,
                        "Acronym": [
                              "MILES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants randomized to this arm will undergo bone marrow aspiration and then will be further randomized to receive a standard orthobiologic injection into the knee joint of autologous bone marrow concentrate (BMAC).",
                              "Participants randomized to this arm will undergo small volume lipoplasty, and then will be further randomized to receive an injection into the knee joint of adipose-derived stromal vascular fraction (SVF).",
                              "Participants randomized to this arm will receive an injection into the knee joint of cryopreserved doses of umbilical cord tissue MSCs.",
                              "Participants randomized to the bone marrow derived MSC, adipose-derived MSC, or umbilical cord tissue MSC study arms will be further randomized within the arm in a 3:1 ratio to receive either MSCs derived from the study arm of the initial randomization or a corticosteroid (CS) injection. Participants randomized to the control group will receive an injection of corticosteroid into the knee joint."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone Marrow Derived MSCs",
                              "Biological: Adipose-derived MSCs",
                              "Biological: Umbilical Cord Tissue (UCT) MSCs",
                              "Drug: Corticosteroid injection"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow Derived MSCs",
                              "Adipose-derived MSCs",
                              "Umbilical Cord Tissue (UCT) MSCs",
                              "Corticosteroid Injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03818737"
                        ]
                  },
                  {
                        "Rank": 864,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "stem cells + hydroxy apatite"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: stem cells + hydroxy apatite",
                              "Other: autograft taken from iliac crest"
                        ],
                        "ArmGroupLabel": [
                              "stem cells",
                              "autograft"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01626625"
                        ]
                  },
                  {
                        "Rank": 865,
                        "Acronym": [
                              "EISMO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation"
                        ],
                        "ArmGroupInterventionName": [
                              "Dietary Supplement: Antioxidative supplementation"
                        ],
                        "ArmGroupLabel": [
                              "Antioxidative Supplementation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03747913"
                        ]
                  },
                  {
                        "Rank": 866,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving regular respiratory distress treatment",
                              "Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04348461"
                        ]
                  },
                  {
                        "Rank": 867,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Spinal decompression with an instrumented posterolateral fusion"
                        ],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [
                              "Spinal decompression"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01409954"
                        ]
                  },
                  {
                        "Rank": 868,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients received kidney transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.",
                              "Patients received hematopoietic stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.",
                              "Patients received mesenchymal stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.",
                              "Patients received liver transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed."
                        ],
                        "ArmGroupInterventionName": [
                              "Diagnostic Test: Intestinal microbiome new generation sequencing",
                              "Diagnostic Test: Intestinal microbiome new generation sequencing",
                              "Diagnostic Test: Intestinal microbiome new generation sequencing",
                              "Diagnostic Test: Intestinal microbiome new generation sequencing"
                        ],
                        "ArmGroupLabel": [
                              "Kidney transplant recipients",
                              "HSCT-recipients",
                              "MSCT-recipients",
                              "Liver transplant recipients"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04281797"
                        ]
                  },
                  {
                        "Rank": 869,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intrathecal at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "standard stroke treatment and rehabilitation therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC infusion via intravenous route",
                              "Other: standard stroke treatment and rehabilitation therapy",
                              "Biological: UC-MSC infusion via intrathecal route",
                              "Other: standard stroke treatment and rehabilitation therapy",
                              "Other: standard stroke treatment and rehabilitation therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC infusion via intravenous route",
                              "UC-MSC infusion via intrathecal route",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05292625"
                        ]
                  },
                  {
                        "Rank": 870,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Control group receives placebo medication (normal saline)",
                              "MSC group receives mesenchymal stem cells transplantation (Pneumostem)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Normal saline",
                              "Drug: Pneumostem"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "MSC group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02890953"
                        ]
                  },
                  {
                        "Rank": 871,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This clinical study uses a 4-fold concentrate of ADMSCs secretome developed by PT. Kimia Farma (Persero), Tbk. The secretome is extracted from stem cell line filtered through syringe with pore size of 0.22 \u00b5m to eliminate the debris, then concentrated with Corning\u24c7 Spin-X\u24c7 UF 500 \u00b5L centrifugator. Stabilization analysis is performed before utilization. As for fractional CO\u2082 laser, AMI\u24c7 device is used with this following settings: 24 mJ energy, 1.2 ms pulse duration, and density level 15.",
                              "This clinical study uses a 4-fold concentrate of ADMSCs secretome developed by PT. Kimia Farma (Persero), Tbk. The secretome is extracted from stem cell line filtered through syringe with pore size of 0.22 \u00b5m to eliminate the debris, then concentrated with Corning\u24c7 Spin-X\u24c7 UF 500 \u00b5L centrifugator. Stabilization analysis is performed before utilization. As for microneedle, DrPen\u24c7 dermapen is used in this following direction and order: vertical, horizontal, and diagonal, with the depth of 1.5 mm."
                        ],
                        "ArmGroupInterventionName": [
                              "Device: Fractional CO\u2082 Laser",
                              "Device: Microneedle"
                        ],
                        "ArmGroupLabel": [
                              "Secretome + Fractional CO\u2082 Laser",
                              "Secretome + Microneedle"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05508191"
                        ]
                  },
                  {
                        "Rank": 872,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient will receive a combination of mesenchymal and Hematopoetic stem cell through hepatic artery under fluroscopic guidance",
                              "Diuretics, Hepatoprotective agents and Lactulose"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: CD 34 and MSC infusion",
                              "Drug: Standard of care for Cirrhosis management"
                        ],
                        "ArmGroupLabel": [
                              "Combination MSC and HSC",
                              "Standard of care for Cirrhosis management"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04243681"
                        ]
                  },
                  {
                        "Rank": 873,
                        "Acronym": [],
                        "AgreementOtherDetails": [
                              "Institution and/or Principal Investigator agree not to publish or publicly present any interim results of the study without the prior written consent of Sponsor, not to be unreasonably withheld or delayed. Institution and/or Principal Investigator further agree to provide Sponsor with drafts of any such publication or presentation for review and approval no less than 30 days prior to submission for publication or the date of public presentation."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "UNEX-42 administered at 20 pmol phospholipid/kg body weight",
                              "UNEX-42 administered at 60 pmol phospholipid/kg body weight",
                              "UNEX-42 administered at 200 pmol phospholipid/kg body weight",
                              "Phosphate-buffered saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UNEX-42",
                              "Biological: UNEX-42",
                              "Biological: UNEX-42",
                              "Biological: Phosphate-buffered saline"
                        ],
                        "ArmGroupLabel": [
                              "20 pmol phospholipid/kg body weight",
                              "60 pmol phospholipid/kg body weight",
                              "200 pmol phospholipid/kg body weight",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03857841"
                        ]
                  },
                  {
                        "Rank": 874,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will be IA injected at the target knee with 3 mL of Chondrochymal\u00ae containing 5.0 x 107 BM-MSCs in lactated Ringer's solution at Day 1.",
                              "Hya-Joint Plus Synovial Fluid Supplement containing 60 mg/3 mL of hyaluronic acid will be IA administrated into the subject's target knee at Day 1."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone marrow mesenchymal stem cells",
                              "Drug: hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Chondrochymal\u00ae group",
                              "Hya-Joint Plus Synovial Fluid Supplement"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05027581"
                        ]
                  },
                  {
                        "Rank": 875,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)",
                              "only has intracytoplasmic sperm injection (ICSI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: autologous mitochondria transplantation",
                              "Combination Product: autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)",
                              "Drug: intracytoplasmic sperm injection (ICSI)"
                        ],
                        "ArmGroupLabel": [
                              "autologous mitochondria transplantation",
                              "ICSI"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03639506"
                        ]
                  },
                  {
                        "Rank": 876,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 million human MSC (hMSC)/kg infusion versus placebo infusion",
                              "4 million hMSC/kg infusion versus placebo infusion",
                              "6 million hMSC/kg infusion versus placebo infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: 2 million hMSC/kg",
                              "Biological: placebo",
                              "Biological: 4 million hMSC/kg",
                              "Biological: placebo",
                              "Biological: 6 million hMSC/kg",
                              "Biological: placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03186417"
                        ]
                  },
                  {
                        "Rank": 877,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Periurethral injection of autologous bone-marrow derived stem cells.",
                              "Tension-free vaginal tape operation: a midurethral sling operation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cells,Mesenchymal",
                              "Procedure: surgery (TVT)"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells,Mesenchymal",
                              "surgery (TVT)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02334878"
                        ]
                  },
                  {
                        "Rank": 878,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous Adipose Tissue derived MSCs",
                              "saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM",
                              "Drug: saline"
                        ],
                        "ArmGroupLabel": [
                              "JOINTSTEM",
                              "saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03990805"
                        ]
                  },
                  {
                        "Rank": 879,
                        "Acronym": [
                              "DREAM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Two procedures:\n\nBone marrow harvesting from the posterior superior iliac crest region\nSingle injections of a dose of 15 million of autologous BM-MSC for each disc affected by IDD (up to 3 discs) via imaging control",
                              "Two sham procedures:\n\nSimulated bone marrow harvesting without insertion into the posterior iliac crest region\nSimulated injection under only local anaesthesia without disc injection and without placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous BM-MSC",
                              "Procedure: Sham"
                        ],
                        "ArmGroupLabel": [
                              "Active Arm",
                              "Sham Procedure"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05066334"
                        ]
                  },
                  {
                        "Rank": 880,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: exogenous indulin injection daily",
                              "Biological: MenSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Traditional therapy control",
                              "Stem cell infusion"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01496339"
                        ]
                  },
                  {
                        "Rank": 881,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive no interventions after rectal cancer treatment.",
                              "Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.",
                              "Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.",
                              "Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Laparoscopic surgery",
                              "Device: NeuroRegen scaffold transplantation",
                              "Biological: NeuroRegen scaffold/BMMCs transplantation",
                              "Biological: NeuroRegen scaffold/HUC-MSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Laparoscopic surgery",
                              "NeuroRegen scaffold transplantation",
                              "NeuroRegen scaffold/BMMCs transplantation",
                              "NeuroRegen scaffold/HUC-MSCs transplantation"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02648386"
                        ]
                  },
                  {
                        "Rank": 882,
                        "Acronym": [
                              "RegenHeart"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients of the main group will undergo cardiac catheterization with intracoronary administration of 1\u00d710 (7) umbilical cord-derived mesenchymal stromal cells and and will continue to receive optimal pharmacological therapy",
                              "Patients in the control group will only have cardiac catheterization and will continue to receive optimal pharmacological therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Cardiac catheterization",
                              "Biological: Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells",
                              "Procedure: Cardiac catheterization"
                        ],
                        "ArmGroupLabel": [
                              "Main Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04325594"
                        ]
                  },
                  {
                        "Rank": 883,
                        "Acronym": [
                              "MSC-OA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of Catholic MASTER cell, 1 time, 1 x 10^8 cells/DMEM 5cc, into knee joint of patients with osteoarthritis",
                              "Intraarticular injection of saline, 1 time, 5cc, into knee joint of patients with osteoarthritis"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Catholic MASTER cell",
                              "Other: Saline"
                        ],
                        "ArmGroupLabel": [
                              "MASTER cell",
                              "Saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04240873"
                        ]
                  },
                  {
                        "Rank": 884,
                        "Acronym": [
                              "Magnovision"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "WJ-MSC was applied first to the patients after necessary preparations. rEMS application was started 10 days after WJ-MSC application.",
                              "rEMS applications were repeated 10 times with a 1-week interval.",
                              "WJ-MSC was applied only one time for both eyes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton jelly derived mesenchymal stem cell",
                              "Device: Repetitive electromagnetic stimulation",
                              "Device: Repetitive electromagnetic stimulation",
                              "Biological: Wharton jelly derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "WJ-MSC combine witf rEMS",
                              "Only rEMS",
                              "Only WJ-MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04877067"
                        ]
                  },
                  {
                        "Rank": 885,
                        "Acronym": [
                              "SEMAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01547689"
                        ]
                  },
                  {
                        "Rank": 886,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00759018"
                        ]
                  },
                  {
                        "Rank": 887,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.",
                              "Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human cord blood mononuclear cells",
                              "Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Rehabilitation plus hCB-MNCs treatment",
                              "Rehabilitation plus hCB-MNCs and hUC-MSCs therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01343511"
                        ]
                  },
                  {
                        "Rank": 888,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.",
                              "cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BM-MSCs",
                              "Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)",
                              "Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02563340"
                        ]
                  },
                  {
                        "Rank": 889,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03925649"
                        ]
                  },
                  {
                        "Rank": 890,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly",
                              "One dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Stromal Vascular Fraction (SVF)",
                              "Biological: Autologous Adipose Derieved MSCs",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Stromal Vascular Fraction",
                              "Autologous Adipose Derived MSCs",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02145897"
                        ]
                  },
                  {
                        "Rank": 891,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Application of IMP into peripheral vein (arm) by use of a perfusor."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allo-APZ2-ACLF"
                        ],
                        "ArmGroupLabel": [
                              "allo-APZ2-ACLF"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03860155"
                        ]
                  },
                  {
                        "Rank": 892,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMC119-06"
                        ],
                        "ArmGroupLabel": [
                              "UMC119-06"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04097652"
                        ]
                  },
                  {
                        "Rank": 893,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)",
                              "No treatment (after high tibial osteotomy)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose Tissue derived MSCs",
                              "No treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03000712"
                        ]
                  },
                  {
                        "Rank": 894,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMC119-06"
                        ],
                        "ArmGroupLabel": [
                              "UMC119-06"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04347967"
                        ]
                  },
                  {
                        "Rank": 895,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A bone marrow aspiration will be performed from the iliac crest. The bone marrow aspirate will be processed using a bone marrow aspirate concentrate (BMAC) harvesting system. The osteochondral allograft plug will then be soaked in the BMAC for a minimum 2 minutes prior to implantation. The remaining BMAC will be placed in the defect site prior to plug implantation.",
                              "The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed. The osteochondral allograft plug will not be soaked in BMAC prior to implantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation",
                              "Procedure: Control group incision"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow Aspiration Group",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04739930"
                        ]
                  },
                  {
                        "Rank": 896,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with early poor graft function receive allogeneic BM-MSCs at the dose of 1*10^6/kg every week for four consecutive doses.",
                              "Patients with early poor graft function receive placebo of MSCs, i.e. saline every week for four consecutive doses."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BM-MSCs",
                              "Other: Saline"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02563366"
                        ]
                  },
                  {
                        "Rank": 897,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with cytopenia after allo-HSCT"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Sequential infusion of allogeneic mesenchymal stem cells expanded \"in vitro\""
                        ],
                        "ArmGroupLabel": [
                              "Patients with cytopenia after allo-HSCT"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02104440"
                        ]
                  },
                  {
                        "Rank": 898,
                        "Acronym": [
                              "DW-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low-dose group (5 x 10^7cells):\n\nDrug substance and the amount: 2.5 \u00d7 107 cells/1 mL/vial, 2 vials for low-dose group",
                              "High-dose group (1 x 10^8 cells):\n\nDrug substance and the amount: 2.5 \u00d7 107 cells/1 mL/vial, 4 vials for High-dose group",
                              "Control group (placebo):\n\nNo Drug substance: 4 vials for Place group"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: allogeneic mesenchymal stem cell",
                              "Drug: allogeneic mesenchymal stem cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Low-dose group",
                              "High-dose group",
                              "Control group (placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04535856"
                        ]
                  },
                  {
                        "Rank": 899,
                        "Acronym": [
                              "SEESUPAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with Alzheimer's Disease Intervention: UCMSCs",
                              "Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02672306"
                        ]
                  },
                  {
                        "Rank": 900,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.",
                              "Participants will receive a low dose of MSC treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.",
                              "Participants will receive a saline placebo treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: high dose of MSC",
                              "Drug: low dose of MSC treatment"
                        ],
                        "ArmGroupLabel": [
                              "Drug: high dose of MSC treatment",
                              "low dose of MSC treatment",
                              "low dose of MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01213186"
                        ]
                  },
                  {
                        "Rank": 901,
                        "Acronym": [
                              "CSM/FAP/2012"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with prolonged postoperative air leaks"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Implantation of autologous mesenchymal stem cells (CSM) expanded \"in vitro\" and administered directly into the lung suture line"
                        ],
                        "ArmGroupLabel": [
                              "Prolonged postoperative air leaks in risk patients."
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02045745"
                        ]
                  },
                  {
                        "Rank": 902,
                        "Acronym": [
                              "ORTHO-2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.\n\n20x106 cells per cc in a single administration of 7cc"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cultured autologous Mesenchymal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Cultured autologous Mesenchymal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02065167"
                        ]
                  },
                  {
                        "Rank": 903,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hESC Derived MSC Like Cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hESC derived MSC like cell"
                        ],
                        "ArmGroupLabel": [
                              "Meniscus Injured patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03839238"
                        ]
                  },
                  {
                        "Rank": 904,
                        "Acronym": [
                              "FISPAC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.",
                              "Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: \u25e6Drug: ASCs. + fibrin glue",
                              "Drug: fibrin glue"
                        ],
                        "ArmGroupLabel": [
                              "ASC + fibrin glue",
                              "Fibrin glue"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01803347"
                        ]
                  },
                  {
                        "Rank": 905,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01309061"
                        ]
                  },
                  {
                        "Rank": 906,
                        "Acronym": [
                              "SPINE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with acute traumatic spinal cord injury grading AIS A (8 patients)",
                              "Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)",
                              "Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: FAB117-HC",
                              "Other: Control group",
                              "Drug: FAB117-HC"
                        ],
                        "ArmGroupLabel": [
                              "FAB117-HC (Ph 1)",
                              "Control group (Ph 2)",
                              "FAB117-HC (Ph 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02917291"
                        ]
                  },
                  {
                        "Rank": 907,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CARTISTEM\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "CARTISTEM\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01733186"
                        ]
                  },
                  {
                        "Rank": 908,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Cyclophosphamide",
                              "Drug: Fludarabine",
                              "Drug: Anti-thymocyte globulin",
                              "Drug: Cyclosporine A",
                              "Drug: Mycophenolate mofetil",
                              "Procedure: Mesenchymal stem cell transplantation",
                              "Radiation: Total body irradiation",
                              "Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Transplant in Epidermolysis Bullosa"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01033552"
                        ]
                  },
                  {
                        "Rank": 909,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Ex vivo cultured adult allogenic MSCs",
                              "Other: Plasmalyte-A"
                        ],
                        "ArmGroupLabel": [
                              "Ex vivo cultured adult allogenic MSCs",
                              "Plasmalyte-A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01091701"
                        ]
                  },
                  {
                        "Rank": 910,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Stereotactic Hematoma Evacuation",
                              "Biological: MSCs Transplantation",
                              "Biological: Injectable Collagen Scaffold with MSCs Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stereotactic Hematoma Evacuation",
                              "MSCs Transplantation",
                              "Injectable Collagen Scaffold with MSCs Transplantation"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02767817"
                        ]
                  },
                  {
                        "Rank": 911,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: JOINTSTEM"
                        ],
                        "ArmGroupLabel": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04825730"
                        ]
                  },
                  {
                        "Rank": 912,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants in the hMSC treatment group will receive a total of 4 doses of the hMSC intervention. Each dose will be administered once about every 13 weeks within a year period."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Approximately 100 million cells allogeneic hMSC"
                        ],
                        "ArmGroupLabel": [
                              "hMSC Treatment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04040348"
                        ]
                  },
                  {
                        "Rank": 913,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by recurrent intrauterine adhesions"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: UC-MSCs therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02313415"
                        ]
                  },
                  {
                        "Rank": 914,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSC transplantation",
                              "Routine treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC",
                              "Biological: Control Group"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03902067"
                        ]
                  },
                  {
                        "Rank": 915,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "On the basis conventional symptomatic treatment and supportive therapy, P-MMSCs were given at 1 million cells/kg body weight/ time, once every 3 days for a total of 3 times: Day \"1\", Day \"4\", Day \"7\".",
                              "Conventional symptomatic treatments such as antibacterial (ceftriaxone, azithromycin), anticoagulants, hormones, oxygen therapy, mechanical ventilation and other supportive therapies"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells",
                              "Drug: Antibiotics",
                              "Drug: Hormones",
                              "Drug: Anticoagulant Therapy",
                              "Device: \u041exygen therapy",
                              "Drug: Antibiotics",
                              "Drug: Hormones",
                              "Drug: Anticoagulant Therapy",
                              "Device: \u041exygen therapy"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04461925"
                        ]
                  },
                  {
                        "Rank": 916,
                        "Acronym": [
                              "MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02669199"
                        ]
                  },
                  {
                        "Rank": 917,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.",
                              "AZM and glucocorticoid will be given for the patients in Non-MSCs group."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs",
                              "Drug: AZM",
                              "Drug: Glucocorticoid",
                              "Drug: AZM",
                              "Drug: Glucocorticoid"
                        ],
                        "ArmGroupLabel": [
                              "MSCs",
                              "Non-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02543073"
                        ]
                  },
                  {
                        "Rank": 918,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: JOINTSTEM"
                        ],
                        "ArmGroupLabel": [
                              "JOINTSTEM"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04427930"
                        ]
                  },
                  {
                        "Rank": 919,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs-Exos. low-dose group",
                              "MSCs-Exos mid-dose group",
                              "MSCs-Exos high-dose group"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: low dosage MSCs-Exos administrated for nasal drip",
                              "Biological: mild dosage MSCs-Exos administrated for nasal drip",
                              "Biological: high dosage MSCs-Exos administrated for nasal drip"
                        ],
                        "ArmGroupLabel": [
                              "MSCs-Exos Dosage 1",
                              "MSCs-Exos Dosage 2",
                              "MSCs-Exos Dosage 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04388982"
                        ]
                  },
                  {
                        "Rank": 920,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Collagen membrane + HUC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Collagen membrane + HUC-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02947191"
                        ]
                  },
                  {
                        "Rank": 921,
                        "Acronym": [
                              "ACE_CARD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: Cohort 1 Low dose, 20M cells, 3 patients",
                              "Experimental: Cohort 2 Med dose, 100M cells, 3 patients",
                              "Experimental: Cohort 3 High dose, 200M cells, 3 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: intravenous delivery of allogeneic bone marrow-derived MSCs",
                              "Biological: intravenous delivery of allogeneic bone marrow-derived MSCs",
                              "Biological: intravenous delivery of allogeneic bone marrow-derived MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Low dose",
                              "Medium dose",
                              "High dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05491681"
                        ]
                  },
                  {
                        "Rank": 922,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Conventional therapy",
                              "Biological: Injectable Collagen Scaffold + HUC-MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Conventional therapy",
                              "Injectable Collagen Scaffold + HUC-MSCs"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02786017"
                        ]
                  },
                  {
                        "Rank": 923,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: REcycled CartiLage Auto/Allo IMplantation"
                        ],
                        "ArmGroupLabel": [
                              "RECLAIM"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03672825"
                        ]
                  },
                  {
                        "Rank": 924,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single injection of mesenchymal stem cells at dose of 100M",
                              "Single injection of mesenchymal stem cells at dose of 300M",
                              "Single injection of normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: OSSM-001",
                              "Biological: OSSM-001",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "100M of OSSM-001",
                              "300M of OSSM-001",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05407766"
                        ]
                  },
                  {
                        "Rank": 925,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.5 \u00d7 10 ^ 6 / kg (body weight) of it-hMSC per person",
                              "1 \u00d7 10 ^ 6 / kg (body weight) of it-hMSC per person",
                              "2 \u00d7 10 ^ 6 / kg (body weight) of it-hMSC per person",
                              "Highest dose of it-hMSC",
                              "Sub high dose of it-hMSC",
                              "placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: it-hMSC",
                              "Biological: it-hMSC",
                              "Biological: it-hMSC",
                              "Biological: it-hMSC",
                              "Biological: it-hMSC",
                              "Biological: it-hMSC"
                        ],
                        "ArmGroupLabel": [
                              "Low dose group",
                              "Middle dose group",
                              "High dose group",
                              "Highest dose cell group",
                              "Sub high dose cell group",
                              "placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04953663"
                        ]
                  },
                  {
                        "Rank": 926,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The single injection of CS10BR05 Inj. in the carotid artery"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CS10BR05"
                        ],
                        "ArmGroupLabel": [
                              "CS10BR05"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03265444"
                        ]
                  },
                  {
                        "Rank": 927,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic mesenchymal stem cells",
                              "Standard therapy for patients with diabetic foot ulcer"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU",
                              "Other: Standard therapy"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Standard therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02619877"
                        ]
                  },
                  {
                        "Rank": 928,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic mesenchymal stem cells",
                              "Typical therapy conducted for burn injury patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU",
                              "Device: Conventional Therapy"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Conventional Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02619851"
                        ]
                  },
                  {
                        "Rank": 929,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In forty cases, the posterolateral fusion was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone allogaft with bone marrow concentrate"
                        ],
                        "ArmGroupLabel": [
                              "bone marrow concentrate"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01603836"
                        ]
                  },
                  {
                        "Rank": 930,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with bone cyst defect are injected with mesenchymal cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: cell injection"
                        ],
                        "ArmGroupLabel": [
                              "bone cyst"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01207193"
                        ]
                  },
                  {
                        "Rank": 931,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "low dose hUMSCs or high dose hUMSCs",
                              "best dose of hUMSCs (from cohort 1) or placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: stereotactic surgery",
                              "Biological: hUMSCs",
                              "Procedure: stereotactic surgery",
                              "Biological: hUMSCs",
                              "Biological: placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04074408"
                        ]
                  },
                  {
                        "Rank": 932,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of ADR-001 (Mesenchymal stem cell)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: infusion of ADR-001 (Mesenchymal stem cell)"
                        ],
                        "ArmGroupLabel": [
                              "ADR-001"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04342325"
                        ]
                  },
                  {
                        "Rank": 933,
                        "Acronym": [
                              "ULSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous (IV) infusion of ULSC in 20 patients with COVID-19 ARDS:\n\nIn Phase 1, two separate cohorts per group will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The first cohort enrolled will receive the single dose; the next cohort enrolled will be administered the repeat dose regimen.",
                              "Intravenous (IV) infusion of ULSC in 30 patients with COVID-19 ARDS:\n\nIn Phase 2a, 30 patients assigned ULSC will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The ULSC dosing regimen will be chosen based on Phase 1 data of safety and tolerability.",
                              "Intravenous (IV) infusion of carrier control in 10 patients with COVID-19 ARDS:\n\nIn Phase 2a, 10 patients assigned Placebo will receive either single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval) of carrier control; the dosing regimen will correspond to that of the experimental arm."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Lining Stem Cells (ULSC)",
                              "Biological: Umbilical Cord Lining Stem Cells (ULSC)",
                              "Other: Placebo (carrier control)"
                        ],
                        "ArmGroupLabel": [
                              "ULSC in Phase 1 Open Label",
                              "ULSC in Phase 2a Randomized",
                              "Placebo in Phase 2a Randomized"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04494386"
                        ]
                  },
                  {
                        "Rank": 934,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intervention with transplantation of autologous purified stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cell Transplantation"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02641769"
                        ]
                  },
                  {
                        "Rank": 935,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "prednisolone 20 mg tablet by mouth taken once daily for 10 days each month for 2 years",
                              "sildenafil 25 mg tablet by mouth once daily for 2 years",
                              "The cells can be injected intramuscular in several points in the muscle alternatively they can be injected in the motor point of the muscle. A motor point is the point at which the motor branch of the innervating nerve enters the muscle). This injection is repeated every 6 month up to 2 years."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Prednisolone (Steroids)",
                              "Drug: Sildenafil (Phosphodiesterase inhibitors)",
                              "Procedure: Mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Steroid",
                              "Phosphodiestrase inhibitors",
                              "Mesenchymal stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03633565"
                        ]
                  },
                  {
                        "Rank": 936,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "taking umbilical cord derived mesenchymal stem cells",
                              "taking stromal vascular fraction cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem Cells",
                              "Biological: Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord derived mesenchymal stem cells transplantation group",
                              "stromal vascular fraction cells application group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05305833"
                        ]
                  },
                  {
                        "Rank": 937,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.",
                              "Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human derived umbilical cord derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSCs treatment",
                              "non-cell therapy"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04951882"
                        ]
                  },
                  {
                        "Rank": 938,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "only ACL reconstruction without any injection",
                              "ACL reconstruction and concomitant Cartistem(TM) injection which is human cord blood derived mesenchymal stem cell under arthroscopy.",
                              "ACL reconstruction and concomitant hyaluronic acid injection under arthroscopy"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: ACL reconstruction only",
                              "Biological: Cartistem(TM)",
                              "Procedure: ACL reconstruction only",
                              "Biological: hyaluronic acid",
                              "Procedure: ACL reconstruction only"
                        ],
                        "ArmGroupLabel": [
                              "ACL reconstruction only",
                              "ACL reconstruction + Cartistem(TM)",
                              "ACL reconstruction + Hyaluronic acid"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02755376"
                        ]
                  },
                  {
                        "Rank": 939,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: Stem Cells ALLOGENEIC LOW OXYGEN MESENCHYMAL BONE MARROW CELLS Intervention: Biological: Stem cells",
                              "Lactated Ringer's Solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02672267"
                        ]
                  },
                  {
                        "Rank": 940,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SMUP-IA-01(low-dose)",
                              "Biological: SMUP-IA-01(mid-dose)",
                              "Biological: SMUP-IA-01(high-dose)"
                        ],
                        "ArmGroupLabel": [
                              "SMUP-IA-01(low-dose)",
                              "SMUP-IA-01(mid-dose)",
                              "SMUP-IA-01(high-dose)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04339504"
                        ]
                  },
                  {
                        "Rank": 941,
                        "Acronym": [
                              "CME-LEM1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01909154"
                        ]
                  },
                  {
                        "Rank": 942,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "(Autologous Adipose-derived Mesenchymal Stem Cells)",
                              "Standard comparator"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ASC",
                              "Drug: Fibringlue"
                        ],
                        "ArmGroupLabel": [
                              "ASC (test arm)",
                              "Fibringlue"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04612465"
                        ]
                  },
                  {
                        "Rank": 943,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with spinal cord injury that will undergo autologous bone marrow stem cell transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cell Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01325103"
                        ]
                  },
                  {
                        "Rank": 944,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus 4 times of 0.5*10E6 UC-MSCs /kg body weight intravenously at Day1, Day3, Day5, Day7).",
                              "Participants will receive conventional treatment plus 4 times of Placebo intravenously at Day1, Day3, Day5, Day7."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04293692"
                        ]
                  },
                  {
                        "Rank": 945,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal cells and plasma reach protein are injected to the callus center of short limb"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: cell and RPR injection"
                        ],
                        "ArmGroupLabel": [
                              "cell and RPR recepients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01210950"
                        ]
                  },
                  {
                        "Rank": 946,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.\n\nSubjects with uremia in the intervention group will undergo puncture to collect SVF\nSVF will be cultured to abstain MSC\nThe abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD.",
                              "induction with Basiliximab during kidney transplantation from DCD"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: SVFderived MSC transplantations",
                              "Drug: Basiliximab"
                        ],
                        "ArmGroupLabel": [
                              "SVF(Stromal Vascular Fraction) derived MSC transprlantation",
                              "Basiliximab"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02492490"
                        ]
                  },
                  {
                        "Rank": 947,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment arm"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AGLE 102"
                        ],
                        "ArmGroupLabel": [
                              "AGLE 102"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04173650"
                        ]
                  },
                  {
                        "Rank": 948,
                        "Acronym": [
                              "UC-MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment plus UC-MSCs:\n\nParticipants will receive conventional treatment plus 3 times of UC-MSCs (1*10E6 UC-MSCs/kg body weight/100mL intravenously at week 1, week 2\uff0cweek3).",
                              "Conventional treatment plus Placebo:\n\nWithout UC-MSCs therapy but conventional treatment should be received. Participants will receive conventional treatment plus 3 times of Placebo intravenously at week 1, week 2\uff0cweek3."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UC-MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs treatment group",
                              "Placebo control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04562025"
                        ]
                  },
                  {
                        "Rank": 949,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1",
                              "30 subjects receive three doses of 2.0-2.86\u00d710^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a",
                              "15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: autologous adipose derived stem cells",
                              "Biological: autologous adipose derived stem cells",
                              "Biological: autologous adipose derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1 ARM 0",
                              "Phase 2 ARM 1",
                              "Phase 2 ARM 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04170426"
                        ]
                  },
                  {
                        "Rank": 950,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites .",
                              "Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SUPERCELL GLUE",
                              "Biological: PRFM ALONE"
                        ],
                        "ArmGroupLabel": [
                              "SUPERCELL GLUE(STEM CELLS AND PRFM)",
                              "PRFM ALONE"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03766139"
                        ]
                  },
                  {
                        "Rank": 951,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "human umbilical cord blood-derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord blood derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "NEUROSTEM (hUCB-MSCs) - high dose"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04954534"
                        ]
                  },
                  {
                        "Rank": 952,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00221130"
                        ]
                  },
                  {
                        "Rank": 953,
                        "Acronym": [
                              "AURA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.",
                              "Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Microfracture",
                              "Device: Arthroscopic synovial brushing"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Intervention group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02696876"
                        ]
                  },
                  {
                        "Rank": 954,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with ultra filtration failure (UFF) underwent AD-MSC injection.",
                              "The patients with ultra filtration failure (UFF) underwent Placebo injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection",
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02801890"
                        ]
                  },
                  {
                        "Rank": 955,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In total twenty five subjects will be treated by injecting UMSCs in sub-tenon space of eye.",
                              "A total of twenty five subjects will be treated by suprachoroidal injection of UMSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa",
                              "Biological: Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa"
                        ],
                        "ArmGroupLabel": [
                              "Sub-tenon injection group",
                              "Suprachoroidal injection group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04763369"
                        ]
                  },
                  {
                        "Rank": 956,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "once intracavernous injection of 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells",
                              "once intracavernous injection of collagen scaffolds loaded with 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HUCMSC injection",
                              "Biological: collagen scaffolds/HUCMSC injection"
                        ],
                        "ArmGroupLabel": [
                              "HUCMSC injection",
                              "collagen scaffolds/HUCMSC injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02579148"
                        ]
                  },
                  {
                        "Rank": 957,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells",
                              "Hydrogel sheet without Allogenic mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU",
                              "Procedure: Vehicle sheet"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Vehicle Sheet"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03370874"
                        ]
                  },
                  {
                        "Rank": 958,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells",
                              "Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU",
                              "Procedure: Hydrogel SHEET(Vehicle control)"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Hydrogel SHEET(Vehicle control)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03754465"
                        ]
                  },
                  {
                        "Rank": 959,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stempeucel(R)"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03056742"
                        ]
                  },
                  {
                        "Rank": 960,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.\n\nParticipants will then be followed until the week 48 study visit.",
                              "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: conventional plus UC-MSC treatment",
                              "Other: Conventional plus placebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus UC-MSC treatment",
                              "Conventional plus placebo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01662973"
                        ]
                  },
                  {
                        "Rank": 961,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU treatment"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03183726"
                        ]
                  },
                  {
                        "Rank": 962,
                        "Acronym": [
                              "EXOMSC-COV19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group participants who receive injection of EXOSOME-MSC as adjuvant",
                              "Group participants who receive injection of Placebo (NaCL) as adjuvant"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Exosome-MSC Intravenous injection",
                              "Drug: COVID-19 Standard Treatment",
                              "Drug: Placebo Intravenous Injection",
                              "Drug: COVID-19 Standard Treatment"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05216562"
                        ]
                  },
                  {
                        "Rank": 963,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-CD"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-CD injection"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03183661"
                        ]
                  },
                  {
                        "Rank": 964,
                        "Acronym": [
                              "TENDO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: mesenchymal stem cells",
                              "Procedure: Pure platelet-rich plasma"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Pure platelet-rich plasma"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03454737"
                        ]
                  },
                  {
                        "Rank": 965,
                        "Acronym": [
                              "PoseidonDCM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.",
                              "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous hMSCs",
                              "Biological: Allogeneic hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Autologous hMSCs",
                              "Allogeneic hMSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Class I - no limitation",
                              "Class II - Slight Limitation of Physical Activity",
                              "Class III - Marked Limitation of Physical Activity",
                              "Class IV -Inability to carry on physical activity"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT01392625"
                        ]
                  },
                  {
                        "Rank": 966,
                        "Acronym": [
                              "UB-OVF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04675970"
                        ]
                  },
                  {
                        "Rank": 967,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The intervention examined is the extraction method by liposuction.",
                              "Control group"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Liposuction"
                        ],
                        "ArmGroupLabel": [
                              "Liposuction of fat",
                              "Excision of fat"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03105284"
                        ]
                  },
                  {
                        "Rank": 968,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 500\u3395/\u33a0 of cartilage defect"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cartistem",
                              "Procedure: Microfracture treatment"
                        ],
                        "ArmGroupLabel": [
                              "Cartistem",
                              "Microfracture treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01041001"
                        ]
                  },
                  {
                        "Rank": 969,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intra-articular injection of XSTEM-OA"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XSTEM-OA"
                        ],
                        "ArmGroupLabel": [
                              "XSTEM-OA"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05344157"
                        ]
                  },
                  {
                        "Rank": 970,
                        "Acronym": [
                              "SAMCIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset",
                              "Infusion of normal saline placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC Infusion",
                              "Biological: Placebo Comparator"
                        ],
                        "ArmGroupLabel": [
                              "MSC infusion",
                              "SHAM infusion"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01922908"
                        ]
                  },
                  {
                        "Rank": 971,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0",
                              "Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0 and day 7"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cordstem-ST",
                              "Biological: Placebo",
                              "Biological: Cordstem-ST",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02378974"
                        ]
                  },
                  {
                        "Rank": 972,
                        "Acronym": [
                              "ANTG-ASC-210"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low dose group",
                              "high dose group"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous cultured adipose derived stem cells(low dose group)",
                              "Biological: Autologous cultured adipose derived stem cells(high dose group)"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01314092"
                        ]
                  },
                  {
                        "Rank": 973,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.",
                              "Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSC",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04362189"
                        ]
                  },
                  {
                        "Rank": 974,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intratracheal administration of Pneumostem\u00ae (10.0 x 10^6 cells/kg)",
                              "A single intratracheal administration of normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PNEUMOSTEM\u00ae",
                              "Biological: normal saline"
                        ],
                        "ArmGroupLabel": [
                              "PNEUMOSTEM\u00ae",
                              "normal saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04003857"
                        ]
                  },
                  {
                        "Rank": 975,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intratracheal administration of Pneumostem\u00ae (1.0 x 10^7 cells/kg)",
                              "A single intratracheal administration of normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Pneumostem\u00ae",
                              "Biological: normal saline"
                        ],
                        "ArmGroupLabel": [
                              "Pneumostem\u00ae",
                              "normal saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01897987"
                        ]
                  },
                  {
                        "Rank": 976,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intratracheal administration of Pneumostem\u00ae (1.0 x 10^7 cells/kg)",
                              "A single intratracheal administration of normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Pneumostem\u00ae",
                              "Other: Normal Saline"
                        ],
                        "ArmGroupLabel": [
                              "Pneumostem\u00ae",
                              "normal saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01828957"
                        ]
                  },
                  {
                        "Rank": 977,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03389919"
                        ]
                  },
                  {
                        "Rank": 978,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSC, iv, 1\u00d710^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg\uff0ctwice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.",
                              "Anti-CD25 mAb, iv, 20mg\uff0ctwice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UC-MSC",
                              "Drug: Anti-CD25 mAb",
                              "Drug: Anti-CD25 mAb"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC and anti-CD25 mAb",
                              "Anti-CD25 mAb"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04738981"
                        ]
                  },
                  {
                        "Rank": 979,
                        "Acronym": [
                              "EXIT-COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Normal saline 100 mL",
                              "Normal saline 90 mL and ExoFlo 10 mL, which is 800 Billion Extracellular Vesicles.",
                              "Normal saline 85 mL and ExoFlo 15 mL, which is 1.2 Trillion Extracellular Vesicles."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Intravenous normal saline",
                              "Biological: DB-001",
                              "Biological: DB-001"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "Experimental Dose 1",
                              "Experimental Dose 2"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04493242"
                        ]
                  },
                  {
                        "Rank": 980,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.\n\nParticipants will then be followed until the week 96 study visit.",
                              "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: conventional plus UC-MSC treatment",
                              "Other: Conventional plus placebo treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional plus UC-MSC treatment",
                              "Conventional plus placebo treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01661842"
                        ]
                  },
                  {
                        "Rank": 981,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of \u2248 30 million cells) on Day 0, Day 2, and Day 4",
                              "Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04903327"
                        ]
                  },
                  {
                        "Rank": 982,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells derived from bone marrow infusion",
                              "saline injections"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells",
                              "Biological: saline"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Bone Marrow Stem Cell",
                              "saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02796079"
                        ]
                  },
                  {
                        "Rank": 983,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "autologous adipose tissue derived mesenchymal stem cells (AdMSC)",
                              "hyaluronic acid"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: JointStem",
                              "Drug: Synvisc-One"
                        ],
                        "ArmGroupLabel": [
                              "JointStem",
                              "Synvisc-One"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02674399"
                        ]
                  },
                  {
                        "Rank": 984,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: AstroStem",
                              "Other: Placebo-Control"
                        ],
                        "ArmGroupLabel": [
                              "AstroStem",
                              "Placebo-Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03117738"
                        ]
                  },
                  {
                        "Rank": 985,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10^6 cells/kg in normal saline injection",
                              "Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10^6 cells/kg in normal saline injection",
                              "5-25mg Methotrexate orally"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low-dose UC-MSCs",
                              "Biological: High-dose UC-MSCs",
                              "Drug: Methotrexate"
                        ],
                        "ArmGroupLabel": [
                              "Low-Dose UC-MSCs",
                              "High-Dose UC-MSCs",
                              "Methotrexate"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03424629"
                        ]
                  },
                  {
                        "Rank": 986,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment group will be administered via intravenously AstroStem which consists of two syringes and each syringe contains 2.0 x 10^8 cells / 20 mL of saline with 30% auto-serum.",
                              "Placebo control group will receive AstroStem Placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AstroStem",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04482413"
                        ]
                  },
                  {
                        "Rank": 987,
                        "Acronym": [
                              "HBMS01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose derived Mesenchymal stem cells (Autologous)",
                              "Normal Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05116540"
                        ]
                  },
                  {
                        "Rank": 988,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection to IT (Group 1). After 6 months, 8 patients (group 1A) will be treated with MSC once again in IT, and 8 additional patients (group 1B) will receive a placebo.",
                              "Injection to IV (Group 2). After 6 months, 8 patients (group 2A) will be treated with MSC once again in IV, and 8 additional patients (group 2B) will receive a placebo.",
                              "Placebo at the first injection (group 3). After 6 months, 8 patients (group 3A) will be treated with MSC in IT, and 8 additional patients (group 3B) will be treated with MSC in IV."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "IT- Treated",
                              "IV - Treated",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02166021"
                        ]
                  },
                  {
                        "Rank": 989,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient: Intravenous infusion of single-dose of Mesenchymal stem cells (MSCs)",
                              "Intravenous infusion of single-dose of Ringer's lactate, albumin and heparin solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05433298"
                        ]
                  },
                  {
                        "Rank": 990,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "human mesenchymal stem cells:1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment, plus non-steroid anti-inflammatory drugs (NSAID: \"celecoxib\", \"Celebrex\u00ae\" 0.2g Bid(twice a day),PO (Per Os).\n\nDuration of treatment:24 weeks for follow up. collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent.",
                              "non-steroid anti-inflammatory drugs (NSAID: \"celecoxib\", \"Celebrex\u00ae\" 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up;collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC",
                              "Drug: \"celecoxib\", \"Celebrex\u00ae\"",
                              "Drug: \"celecoxib\", \"Celebrex\u00ae\""
                        ],
                        "ArmGroupLabel": [
                              "MSC plus NSAID",
                              "NSAID"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01709656"
                        ]
                  },
                  {
                        "Rank": 991,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10^7 cells/2mL) ( 2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "A single knee administration of SMUP-IA-01 (high-dose, 2.0 x 10^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SMUP-IA-01(low-dose)",
                              "Biological: SMUP-IA-01(mid-dose)",
                              "Biological: SMUP-IA-01(high-dose)"
                        ],
                        "ArmGroupLabel": [
                              "SMUP-IA-01(low-dose)",
                              "SMUP-IA-01(mid-dose)",
                              "SMUP-IA-01(high-dose)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04037345"
                        ]
                  },
                  {
                        "Rank": 992,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single topical dose of XSTEM-VLU",
                              "Single topical dose of CryoStor CS10"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XSTEM-VLU",
                              "Other: Vehicle"
                        ],
                        "ArmGroupLabel": [
                              "XSTEM-VLU",
                              "Vehicle"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05549609"
                        ]
                  },
                  {
                        "Rank": 993,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for autoimmune conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for cardiovascular disorders and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for diabetes complications. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for integumentary diseases and conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for orthopedic and musculoskeletal conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for neurologic and neurodegenerative disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for pulmonary disorders. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for sexual dysfunction conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for urologic conditions. Outcomes will be compared to results in peer-reviewed literature for several conditions.",
                              "Purpose is to evaluate an amniotic and umbilical cord stem cell rich tissue substance for viral illnesses. Outcomes will be compared to results in peer-reviewed literature for several conditions."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122",
                              "Biological: PrimePro\u2122/ PrimeMSK\u2122"
                        ],
                        "ArmGroupLabel": [
                              "Arm 1: Autoimmune Diseases",
                              "Arm 2: Cardiovascular Disorders",
                              "Arm 3: Diabetes Complications",
                              "Arm 4: Integumentary Disease",
                              "Arm 5: Musculoskeletal Disorders",
                              "Arm 6: Neurodegenerative Disorders",
                              "Arm 7: Pulmonary Disorders",
                              "Arm 8: Sexual Dysfunction",
                              "Arm 9: Urologic Disorders",
                              "Arm 10: Viral Illnesses"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04684602"
                        ]
                  },
                  {
                        "Rank": 994,
                        "Acronym": [
                              "Mito Moms"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Physically active will be defined by self-report and confirmed by step counts >8,000 per day from activity monitoring.",
                              "Sedentary lifestyle will be defined by self-report and confirmed by step counts <5,000 per day from activity monitoring."
                        ],
                        "ArmGroupInterventionName": [
                              "Behavioral: Active",
                              "Behavioral: Sedentary"
                        ],
                        "ArmGroupLabel": [
                              "Active",
                              "Sedentary"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03489564"
                        ]
                  },
                  {
                        "Rank": 995,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 0.5 million cells/kg in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1 million cells/kg in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the dose of 1.5 million cells/kg in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of hUC-MCS product at the selected dose from phase 1 in addition to standard of care treatment.",
                              "Eligible subjects will receive a single infusion of placebo control and standard of care treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Biological: Human umbilical cord mesenchymal stem cells + best supportive care",
                              "Other: Placebo control + best supportive care"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1 Low-dose Group",
                              "Phase 1 Middle-dose Group",
                              "Phase 1 High-dose Group",
                              "Phase 2a Treatment Group",
                              "Phase 2a Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04452097"
                        ]
                  },
                  {
                        "Rank": 996,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg\n\nIntervention: Biological: Pneumostem\u00ae"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PNEUMOSTEM"
                        ],
                        "ArmGroupLabel": [
                              "Pneumostem\u00ae"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02023788"
                        ]
                  },
                  {
                        "Rank": 997,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 patients with sepsis and septic shock and received MSCs&standart therapy",
                              "20 patients with sepsis and septic shock and not received MSCs, only received standart therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Patients received MSCs",
                              "Patients not received MSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05283317"
                        ]
                  },
                  {
                        "Rank": 998,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "As per Institutional COVID-19 Management Guidelines all patients of moderate, severe and critical COVID-19 received standard protocol of aspirin, anticoagulation, ulcer prophylaxis, awake Proning (if PaO2 < 80mmHg) and corticosteroids. All patients of Cytokine release storm (CRS) received either Methylprednisolone 1 mg/kg or Dexamethasone 6-12mg/day irrespective of disease severity.",
                              "addition to standard care TPE will be performed once daily using COBE Spectra Apheresis machine version 7 (Manufacturer TERUMO BCT, Lakewood, CO, USA INC) having continuous flow centrifugation. Venous access will be achieved using an ultrasound guided double lumen catheter (Arrow - 12 FR) via femoral vein. Patient's total blood volume will be calculated as per Nadler's formula. Anticoagulant acid dextrose ratio will be 1:10 and flow rate 30-40 ml/minutes (Adjusted as per hemodynamic status). Patients' blood pressure, pulse, oxygen saturation will be monitored throughout procedure. Duration of procedure varied from 2-4 hours and 1-1.5 times total plasma volume will be removed during each procedure. Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively. All procedures will be performed in intensive care or high dependency unit by Apheresis Department of PEMH. TPE will be continued till recovery.",
                              "During TPE, Replacement fluid will be fresh frozen plasma (FFP) and normal saline in 2:1 respectively plus 200-400 ml of convalescent plasma. A predefined number of patients will also receive mesenchymal stem cell therapy and/or Remdesivir",
                              "A predefined number of patients will receive either alone Tocilizumab, Remdesivir and Mesenchymal stem cell therapy or their combination"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Therapeutic Plasma exchange",
                              "Procedure: Therapeutic Plasma exchange",
                              "Biological: Convalescent Plasma",
                              "Drug: Tocilizumab",
                              "Drug: Remdesivir",
                              "Biological: Mesenchymal stem cell therapy",
                              "Procedure: Therapeutic Plasma exchange",
                              "Biological: Convalescent Plasma",
                              "Drug: Tocilizumab",
                              "Drug: Remdesivir",
                              "Biological: Mesenchymal stem cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Supportive Arm",
                              "TPE arm",
                              "TPE in combination with other investigational treatments",
                              "Either alone or combination of MSC, Remdesivir and Tocilizumab"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04492501"
                        ]
                  },
                  {
                        "Rank": 999,
                        "Acronym": [
                              "EB-CMF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subject receiving EB-CMF implant"
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: EB-CMF"
                        ],
                        "ArmGroupLabel": [
                              "EB-CMF Implant"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03678467"
                        ]
                  },
                  {
                        "Rank": 1000,
                        "Acronym": [
                              "IMECOV19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05191381"
                        ]
                  }
            ]
      }
}